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Abstract 
The need for prosthetic joint implants continues to grow, but many implants fail and require revision 
surgery, mainly due to non-bonding to bone. Currently many metal prostheses are coated with 
hydroxyapatite (HA), often giving rise to ceramic particles leading to wear of the prosthesis surface. 
This thesis describes the development of bioactive glass (BG) coatings for metallic implants to 
improve the bone-implant bond, enable better osseointegration, and improve implant lifespan.  
Strontium was substituted for calcium in two series of melt-derived BG based on the SiO2-MgO-
Na2O-K2O-ZnO-P2O5-CaO system. In the first series, 0, 10, 25, 50, 75 and 100% of the CaO was 
replaced by SrO; and in the second series 10% of the CaO was replaced by SrO and the P2O5 content 
was varied between 1.07 and 6.42 mol%. Ti alloy coupons were surface coated with BG by 
enamelling technique. 
The structural and physical properties of the glasses and glass coatings were investigated by 
differential scanning calorimetry (DSC), X-ray diffraction (XRD), nuclear magnetic resonance 
(NMR), Fourier-transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). 
Amorphous coatings showed good adhesion to the Ti alloy with the exception of the 100% Sr-
substituted coating. The mixed calcium/strontium glasses exhibited a larger processing window; 
temperature difference between glass transition and onset of crystallization temperature; favouring the 
production of amorphous well sintered coatings.  
Dissolution profiles and bioactivity of the produced glasses were investigated by inductively coupled 
plasma-optical emission spectroscopy (ICP-OES), XRD, NMR and FTIR. Increasing the P2O5 content 
of the Sr-substituted glasses aided the formation of the hydroxycarbonate apatite (HCA) layer in SBF. 
31P and 29Si NMR showed that the glasses were phase separated with a predominantly Q2 silicate 
structure co-existing with phosphorus in a predominantly Q0 orthophosphate environment. The Q2 
silicate structure in the network did not change with substitution of SrO for CaO. LIVE/DEAD 
staining of human osteosarcoma cells (Saos-2) seeded onto BG coatings indicated that the coatings 
were not cytotoxic. SEM imaging showed that the cells attached and spread over the coating surface.  
The degree of osseointegration of the high-phosphate Sr-contatining (50% of the CaO replaced by 
SrO) BG-coated implants were compared with HA-coated implants up to 24 weeks which were 
inserted into lapine long bones (distal femur, proximal tibia). High-phosphate Sr-containing BG-
coated implants demonstrated superior mechanical fixation and increased peri-implant bone formation 
compared to HA-coated implants. The results presented in this thesis demonstrate the potential of Sr-
substituted BGs with high-phosphate content for the coating of metallic joint implants. 
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The main goal of this thesis was to further develop bioactive glass (BG) coatings on Ti6Al4V (Ti 
alloy) with thermal expansion coefficients (TEC) that matched that of Ti alloy. Matching the TEC 
between the metal prosthesis and the bioactive glass coating is important in order to obtain the 
satisfactory adhesion between them. For instance, TEC of 45S5 Bioglass® is higher than Ti alloy 
which causes cracks and delimitation of the coatings while it cools. The coatings should have the 
ability to stimulate bone mineralisation to form a strong bond between the bone and implant surface. 
BGs promote the formation of a strong bond with living bone tissue and have the added benefit that 
their dissolution ions stimulate cell activity. We chose strontium ions to incorporate into the bioactive 
glass structure, since the dual effects of formation of new bone and prevention of osteoclast-mediated 
resorption with strontium have been reported in the literature (1;2). The strontium-substituted BG 
coatings degrade as they are exposed to body fluids, releasing ions from the glass structure including 
strontium ions which can affect bone cells. By designing and producing a BG coating for metallic 
implants that forms strong bond with bone, as well as exploiting the beneficial effect of strontium 
especially in osteoporotic patients, the outcome of this project may provide a platform to improve 
implant fixation and avoid implant failure and necessity for revision surgery. 
To achieve this overall goal, the specific aims of this thesis are to: 
1. Design strontium-substituted BG coatings with TEC matched with that of the metallic implant 
and characterise the effect of strontium substitution on the structural and physical properties, 
sintering behaviour and apatite formation of the BG and its coating.  
 
2. Investigate the effect of increasing phosphate (P2O5) content of the strontium-containing BGs 
on the structure, physical properties and bioactivity of the glasses. 
 
3. Evaluate the biological response of the produced BG coatings and study the interaction of 
cells with the coatings. 
 
4. Investigate the degree of osseointegration and implant fixation of a high-phosphate strontium-
containing BG coating on Ti alloy implants. 
 
Chapter 2 provides a comprehensive review on the use of biomaterials in bone tissue engineering, 
bone biology, tissue response to implants, structure of BGs, and a summary of the current knowledge 
on BG coatings. Chapters 3-5 explain and discuss the main experimental results of the thesis as well 
as experimental methodologies, including related literature reviews. Chapter 6 provides the final 
conclusions and suggestions for future work. 
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The thesis is divided into three main parts. The first part describes the design and characterisation of 
two BG coatings: (a) a series of strontium-substituted BG coatings and (b) a series of 10% strontium-
substituted with varying P2O5 content (referred to as phosphate series I) BG coatings (Chapter 3), the 
second consists of the biological assessment of the produced BGs (Chapter 4) and the third consists 
of a comparison of the plasma-sprayed high-phosphate strontium-containing BG-coated implant with 
a plasma-sprayed hydroxyapatite-coated implant after implantation in an animal model (Chapter 5). 
The following sections highlight the scope of each chapter. 
 
1.1 Development and characterisation of the strontium-substituted and 
phosphate series I BG coatings 
A series of silica-based multicomponent strontium-substituted BGs with TEC that closely matched 
with that of Ti alloy were designed and synthesised by a melt-quench route. Glasses were coated onto 
the surface of Ti alloy using an enamelling technique. Sintering behaviour was characterised by 
differential scanning calorimetry, X-ray diffraction and scanning electron microscopy. Glass 
transition and crystallisation temperatures and their respective activation energies were determined; 
and extrapolated onset values for these parameters were determined in order to optimise the sintering 
temperature for production of amorphous coatings. The glasses and their coatings were characterised 
to determine the role of the strontium on the BG’s structure and physical properties. Ion release 
profile and hydroxycarbonated apatite-forming ability were also assessed. 
With the aim of promoting apatite formation of the glasses, a second series of strontium-substituted 
BGs with varying phosphate content and a TEC closely matched with Ti alloy was produced by a 
melt-quench route. Since it has been shown that the presence of phosphate in the glass leads to the 
deposition of a greater HCA layer which results in a strong bond with bone (3;4). The same studies 
were carried out on this series as described for strontium-substituted BGs, to investigate the effect of 
increasing phosphate content on the structure, physical properties, and bioactivity of the glasses. 
 
1.2 Assessment of biological activity of the strontium-substituted and 
phosphate series I BGs 
Cellular response to the produced BGs was studied using a human osteosarcoma cell line. The toxicity 
of the BGs on the cells was assessed indirectly, via culture in dissolution ions and directly, via culture 
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on BG coatings. Several techniques were used to evaluate the effect of the dissolution ions from BGs 
on cell viability and metabolic activity of the cells. Additionally, the interaction between cells and 
coatings was observed using scanning electron microscopy. 
 
1.3 Implant study of high-phosphate strontium-containing BG coating in an 
animal model 
The aim of this part of the thesis is to determine the degree of osseointegration of the high-phosphate 
strontium-containing BG-coated implant and compare this with that of hydroxyapatite-coated implant 
in a lapine model. Implants were coated using the plasma-spray technique and inserted in the distal 
area of the femur and proximal part of the tibia. Osseointegration of implants and the impact of the 
high-phosphate strontium-containing BG on the surrounding bone were evaluated using histological 
and mechanical studies as well as scanning electron microscopy studies. The extent of 
osseointegration was assessed by measuring bone-implant contact, peri-implant bone volume and 
push-out testing. 
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2.1 Bone Tissue Engineering 
Tissue engineering (TE), a bridge between the science of the living organism and engineering, has 
appeared as a potential approach for the repair and regeneration of tissues and organs lost or damaged 
due to trauma, injury, congenital abnormalities, disease or aging (5;6). TE aims to use materials to 
promote new tissue formation and it involves interaction of cells with the material (7). The incredible 
ability of living tissues to regenerate after injury has been the leading point for the researcher in this 
field. There has been  remarkable growth in the field of TE in the last two decades (8). The outcomes 
of these attempts have been generation of tissues such as bone (9-11), cartilage (12) and skin (13;14).  
Bone repair may be one of the first foremost applications of tissue engineering (15). TE as a 
promising approach for bone regeneration and repair has aimed to create multipurpose implantable 
biomaterials that result in tissue regeneration, while providing structural support and preserving the 
tissues in a functional form.  
Bone has a high capacity for regeneration, predominantly in younger people, which allows this tissue 
to heal without external intervention. However, a major increase in human survival and the 
consequent increasingly aging population has resulted in people outliving the quality of their bone 
tissue (16). This issue has resulted in complications such as osteoporosis, fractures and decreasing 
long-term survival of many prostheses (17;18). Additionally, the demand for implants with long-term 
survival is even more essential due to the increasing numbers of young and highly active patients 
undergoing orthopaedic surgeries due to road accidents and sport-related injuries. One more issue 
which currently available therapies have found it difficult to deal with is large bone defects after bone 
tumour resections and severe non-union fractures (19;20). 
In summary, the clinical reasons for developing bone tissue engineering alternatives include first the 
requirement for orthopaedic implants that are mechanically more desirable to their physiological 
surrounded environment and second the need for filler materials that can be used in the large 
orthopaedic defects. Bone tissue engineering can provide promising alternative materials with better 
mechanical properties than those used at present (21). Bone tissue engineered materials need to meet a 
set of criteria that are either necessary or desirable for better tissue formation (22). The mechanical 
properties of a bone tissue engineered material should be adjusted in order to avoid stress shielding 
which can decrease the incidence of implant-related osteopenia and subsequent fracture (23). A tissue 
engineered implant surface that has been coated with cells and/or bioactive materials is able to 
stabilise the implant and therefore has extremely useful application in reconstructive orthopaedic 
surgeries, which have potentially high incidences of failure due to poor bone quality in the elderly for 
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example as a result of osteoporosis and micromotion at the interface between the prosthesis and tissue 
(18;24).  
The achieved successes in TE would not have been possible without the novel design and fabrication 
of biomaterials. The development and use of bioactive glasses for tissue engineering applications, 
despite their brittleness, has introduced several attractive characteristics in their use as a coating, 
scaffold, and bone-defect filling material for bone tissue engineering purposes (21;25-27). Over the 
last decades, the use of bioactive glasses in bone tissue engineering has been approached by 
investigating the biochemical interaction between glass and cell/tissue or by using the effect of 
dissolution ions on genes (20;28-30). The aim of all these approaches is to produce bioactive glass 
materials that mimic the properties of bone and enhance bone growth factors (31-33). The in vivo and 
in vitro outcomes of specific bioactive glasses suitable for TE approaches will be discussed in detail 
in section 2.4.4.4. Before discussing the materials in use for bone repair applications in more detail, it 
is necessary to understand bone structure and function. 
 
2.2 Principles of Bone Biology 
2.2.1 Bone Function 
Bone is a highly specialised form of connective tissue that forms the framework of the endoskeleton 
of vertebrates (34). Skeletal system is necessary for body movement and has a supportive role for 
internal organs. Bone is a major source of calcium and phosphorus in the body and is important for 
mineral homeostasis. Bone buffers the blood against extreme pH changes by releasing or absorbing 
alkaline mineral salt (35). Furthermore, formation of blood cells including most cells of the immune 
system happens in red bone marrow (36).  
2.2.2 Bone Structure 
The structural properties of bone tissue are unique because of its composite structure. Calcified bone 
consists of about 25% organic matrix, including cells (2–5%), water (5%), and inorganic minerals 
(70%) (37;38). Approximately 90% of the organic matrix is made of type I collagen, proteoglycans 
and glycoproteins (39). The inorganic component is mainly composed of calcium and phosphate. 
Bone minerial is similar to hydroxyapatite with the formula of Ca10(PO4)6(OH)2 but also contains 
substitutions, e.g. CO3- for PO4+ (39;40). 
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Bone tissue is non-homogeneous and porous and its porosity varies from 5 to 95%. At the 
macroscopic level, based on porosities of bone tissue is categorised in two types of bone. Briefly, the 
first one is trabecular bone, also called cancellous or spongy bone, which has 50-95% porosity and is 
found in flat, cuboidal bones and at the end of long bones (36). The second type of bone is called 
cortical or compact bone and this has between 5 to 10% porosity. The location of this type of bone is 
the shafts of long bones. It can also be found in the surrounding of the trabecular bone which forms 
the external shell of flat bones. Indeed, the combination of trabecular and cortical bone builds a 
structure known as “sandwich-type” structure in engineering, which is well known because of its 
excellent structural properties (41). 
2.2.3 Bone Cells 
Bone consists of four different cell types which are classified according to their function (34;36;42): 
• Osteoblasts are differentiated mesenchymal cells with a size of 10-20 µm; they can produce 
new bone and regulate mineralisation of the bone matrix. 
• Osteoclasts originate from the bone marrow and they are large (20-100 µm) multinucleate 
cells which contain many mitochondria and vacuoles. They are responsible for bone 
resorption by producing weak acids, which solubilise the mineral crystals. 
• Osteocytes are mature osteoblasts within the bone matrix and are responsible for its 
maintenance. They are located in lacunae and communicate with the rest of the cells via 
canaliculi. It has been suggested that osteocytes are the mechanosensor cells that control bone 
remodelling (43;44). 
• Bone lining cells are flat, inactive osteoblasts that stay on the bone surface. These cells can 
be precursors for osteoblast cells, when activated by chemical or mechanical stimuli (45). 
2.2.4 Mechanical Properties of Bone 
As described earlier, bone consists of inorganic and organic components. The bone components which 
may have an effect on the mechanical properties of bone can be summarised as shown in the 
diagram/flowchart below: 
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Inorganic phase Organic phase
Crystalline
e.g. hydroxyapatite
Components which can affect  
bone mechanical properties 
Amorphous
e.g. amorphous 
calcium phosphate
Amorphous
e.g. protein molecules in the 
form of gels 
Crystalline
e.g. collagen 
Liquid
e.g. water
 
Figure 2.1:  Diagram showing the components which have an effect on bone mechanical properties.  
Figure 2.1 shows and emphasises that bone is a composite material, of which the inorganic part is 
responsible for the compressive strength and stiffness of bone, while the organic components help 
provide good mechanical properties in tension (36;46). The water component plays a role in bone 
viscoelasticity. There are several factors that can affect the amounts of organic and inorganic 
components of bone, e.g., age, sex, bone disease and the location of the bone (47). Landis et al. 
indicate that the mechanical properties of bone depend in part upon the molecular structure and 
arrangement of inorganic crystals within the organic matrix of the bone (48). Crystal size, crystal 
structure and hormonal changes may alter the inorganic components and can affect the modulus of 
elasticity and the ultimate strength of the bone (34). Consequently, dependent on the position in the 
skeleton the mechanical properties may vary, e.g., the compressive strength of cortical bone is 100-
230 MPa while for cancellous bone it is 2-12 MPa (23). Furthermore, the hierarchical structure of 
bone is another important parameter with influence on the mechanical properties of the bone (49).  
 
2.2.5 Bone Remodeling Cycle 
A complex process of bone remodeling occurs in the bone constantly, which is defined by Frost (50) 
as the resorption of bone on a particular surface followed by a bone-formation phase. The main reason 
for bone remodeling is to aid bone to adjust its mechanical load and strain. It is likely that remodelling 
occurs as a result of the interaction between different cell phenotypes including osteoblasts and 
osteoclasts (51), which give the bone the ability to adapt its microstructure according to the 
mechanical and physiological environment. In healthy adults the amount of bone formed by 
osteoblastic cells and the amount of bone resorbed by osteoclastic cells are in balance (52). In some of 
the most common skeletal diseases such as osteoporosis there is an imbalance between formation and 
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resorption of the bone, where resorption is significantly higher than formation and causes 
considerable suffering. 
The remodelling cycle can be described in terms of the following steps:  
• Resorptive phase: activated osteoclasts resorb mineralised bone matrix to form erosion 
cavity. 
• Reversal phase: preosteoblast cells, which can proliferate and differentiate into osteoblasts, 
migrate to the resorption cavity and disclose the osteoclastic activity.  
• Formative phase: new matrix is secreted from osteoblasts; this phase takes three months. 
• Resting phase: osteoblasts that have embedded in osteoid convert into differentiated 
osteocytes and those remaining on the surface suppress the lining cells until activated. 
 
 
2.2.6 Influence of inorganic ions on bone metabolism 
Inorganic ions are known to be involved in bone metabolism and their essential role in angiogenesis, 
growth and mineralisation of bone tissue is understood. It is important to study the biological 
responses to inorganic ions, particularly metal ions. These ions play roles as enzyme co-factors and 
consequently affect metabolic activities that occur during bone tissue formation (53;54). The 
simulative effect of metallic ions can be applied in therapeutic applications in hard and soft tissue 
engineering (55). Furthmoere, the does-dependency affects of the ions need to be considred since high 
concentration of the ions can be toxic for cells. The effect of selected metallic ions on human bone 
metabolism will be discussed in the following section; strontium will be elaborated further since this 
ion is an interest of this study. This knowledge should give insight to enable us to engineer 
biomaterials with tailored ion-release kinetics, in order to control biological response in the relevant 
physiological situation. 
Calcium (Ca) and phosphorous (P) are the main components of the mineral phase of bone and have 
an essential role in bone metabolism. It has been shown that Ca in low concentrations (2-4 mmol) can 
enhance osteoblast proliferation and differentiation, while in culture media of concentration (6-8 
mmol) it stimulates extracellular matrix mineralization (56). Furthermore, Ca can activate Ca-sensing 
receptors in osteoblastic cells which results in bone remodelling (57). This effect of Ca on the 
receptors in bone cells may allow us to develop drugs that are helpful for the treatment of 
osteoporosis. Inorganic phosphate plays a role in the expression of matrix Gala protein (MGP), which 
is the regulator factor in bone formation, when added to the cell culture medium (58). 
Strontium ions (Sr) can replace with Ca in the crystal lattice of hydroxyapatite in bone because of 
the similar chemical properties of this ion with Ca (59). At the cellular level Sr increases the 
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osteoblast cells’ activation and decreases the osteoclasts’ activation (60;61). Sr demonstrates 
beneficial effects on bone cells and bone formation in vivo and has a potential therapeutic role in bone 
metabolism (1;2). The mechanism of action of Sr on osteoblast cells has not yet been fully 
understood, however, it is likely that there is more than one mechanism. Some studies have confirmed 
that the calcium-sensing receptors situated in the membrane of osteoblasts and osteoclasts are 
stimulated by Sr (62;63). Mitogenic signals can be triggered by stimulation of the calcium-sensing 
receptor located in the osteoblast cells and this results in proliferation, differentiation, and activation 
of the osteoblastic cells and inhibition of bone resorption (62;64). Another mechanism of action has 
been described based on the greater increase of bone formation than resorption due to the release of 
autocrine growth factor by Sr-inducing osteoblastic cell replication (62;65). Therefore, the effect of 
this latest mechanism is a rise in bone mass. Furthermore, Sr inhibits osteoclast maturation through an 
increase in osteoprotegerin (OPG), an inhibitor to RANKL (66), and induces apoptosis of osteoclasts 
via the calcium-sensing receptor (67). 
Sr is incorporated in the surface of old bone by an ion-exchange mechanism, whereas during the bone 
formation it is incorporated by ion substitution. This does not have an adverse effect on bone 
mineralisation provided there is sufficient Ca (68;69). Experimental studies on rats showed that a high 
Sr dosage caused hypomineralisation (70;71). However, in another study it has been shown that low 
Sr concentration increased bone formation in rats fed with a normal calcium-containing diet, without 
hypomineralisation arising (72).  
Sr-based drugs such as strontium ranelate, in which strontium is combined with ranelic acid, have a 
dual mechanism of action; they prevent resorption of bone through action on osteoclasts, in a similar 
manner to the anti-resorptive bisphosphonates. They also have anabolic effects, promoting new bone 
formation through stimulation of osteoblasts (73;74). Strontium ranelate has been investigated 
clinically and is promising in reducing the risk of non-vertebral fracture in osteoporotic patients 
(75;76). To the best of our knowledge, toxic effects from strontium have not been reported in humans.  
There has been increasing interest in the use of anti-osteoporotic agents such as strontium and 
bisphosphonates due to their potential to enhance osseointegration and prevent peri-prosthetic 
fracture, which can reduce the chances of an implant loosening. Numerous experimental studies have 
evaluated the local and systematic effects of bisphosphonates on implant fixation in both healthy and 
osteoporotic bone and the majority of these studies have shown enhanced implant fixation (77-81). 
However, number of case reports have suggested that long-term treatment with bisphosphonates is 
related to the occurrence of complications such as osteonecrosis of the mandible (82) and atypical 
femoral fractures (82;83). Therefore, the administration of bisphosphonates should be carried out with 
caution, which has made researchers to turn to alternative candidates such as Sr, particularly in 
osteoporotic patients. Early efforts at developing Sr-based drugs focused on incorporation into bone 
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cements for arthroplasty or kyphoplasty and, and studies have reported that using Sr caused increased 
local bone formation (84;85). 
Successive studies have shown an enhancing effect of Sr in bone formation and osseointegration 
using SrTiO
 
nano-tube arrays (86), Sr-substituted hydroxyapatite (80), oral strontium ranelate (87) 
and Sr-incorporated into Ti oxide surfaces (88). 
Silicon (Si) is known to play an essential role in bone metabolism processes related to bone tissue 
formation and calcification (89;90). Carlisle has shown that Si is involved in calcification at an early 
stage of bone matrix (90), whereas in the presence of aqueous Si, the precipitation of hydroxyapatite 
induced (91). In vitro study has shown that orthosilicilic acid (Si(OH)4) stimulates collagen I 
formation in human osteoblastic cells and induces their differentiation (92). Moreover, the bone 
mineral density in men and premenopausal women was shown to be increased through dietary intake 
of Si (93). 
Zinc (Zn) is important for bone metabolism and stimulates bone formation in vitro by increasing bone 
protein synthesis and ATPase activity (94). It has anti-inflammatory effects as well as (95) and 
antibacterial effects on the bacterial strains relevant to orthopaedic surgery (96). It has been reported 
that Zn enhances bone fracture healing in rats (97) and increases bone density in premenopausal 
women (98). There is a relation between Zn deficiency and retardation in skeletal growth (99). 
Additionally, Eberle et al. showed that growth of bone mass in humans may be affected by Zn 
deficiency and from this they suggested that Zn deficiency may be considered as a risk factor for 
osteoporosis (100).  
Magnesium (Mg) is another element that has an essential role in bone metabolism and can stimulate 
new bone formation (101). An in vivo study in mice demonstrated that Mg reduction results in 
impaired bone growth, resulting in bone resorption and a decrease in cancellous bone with stimulation 
of cytokine activity in bone (102;103).  
 
2.3 The Need for Materials in Medicine 
A revolution in public health and a combination of factors, including nutrition and discovery of 
antiseptics and antibiotics, has resulted in a major increase in human survival rates. As a consequence, 
maintaining the quality of life in an aging population is a new challenge for society. In 2030 more 
than 70 million people aged between 65 to 80 years old will be alive in the U.S. alone (104). This 
increase in the elderly population results in people outliving the useful function of their connective 
tissues and organs. Also, people desire a high quality of life and achieving this desire seems 
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challenging. The routine approach toward these goals is the replacement of aged, diseased or injured 
tissues with reliable and affordable biomaterials by surgical intervention, to implant prostheses with 
the aim of treating the patients (17;105). A variety of ceramic (23), metal, and polymeric (106) 
materials have been used to replace and repair different parts of the body (106). However, reliable 
long-term implant fixation for bone repair applications is an ongoing surgical challenge. Hip 
replacement surgery is increasingly being performed on a large part of the population. According to 
the National Joint Registry, the numbers of total hip replacements performed in England and Wales in 
2005 was 66,151 compared to 79,413 in 2009, whereas almost 9% of the 2005 hip replacement 
patients underwent a revision procedure and this rate increased to 11% in 2009 (107). Another report 
from the National Centre for Health Statistics reports that almost 15% of the hip replacement 
surgeries performed in 2002 were to revise and this rate is likely to rise as younger people undergo 
these procedures (108). Therefore even ten year survival rates of 90-95% will result in a significant 
number of high risk and costly revision procedures each year. With the increasing numbers of young 
and highly active patients undergoing orthopaedic procedures due to road accident or sport injuries, 
the clinical demand for long-term survival implants is critical.  
2.3.1 Metallic Implants 
Metals and metal alloys have traditionally been used due to their reasonable biocompatibility and 
excellent mechanical properties. Materials such as 316L stainless steel, cobalt-chromium (Co-Cr) 
alloy, and titanium (Ti) or titanium alloy (Ti6Al4V: titanium-6 wt % aluminium-4 wt % vanadium) 
are commonly used in fracture fixation, joint replacement and dental prostheses and have been used 
for decades as load-bearing devices because of their mechanical properties and nontoxic behaviour 
(109). 
Wolff’s law states that “Bone in a healthy person or animal remodels in response to the loads it is 
placed under. If loading on a particular bone increases, the bone remodels itself over time to become 
stronger to resist the loading. The external cortical portion of the bone becomes thicker as a result. 
The converse is true as well if the loading on a bone decreases, the bone resorbs (110).” Therefore 
bone must be continuously loaded to stay healthy. 
The modulus of human cortical bone ranges from 7 to 25 GPa. When a higher modulus metal is 
implanted, the resulting removal of normal stress from the bone by                           
the prosthesis causes  a reduction in the bone density. This phenomenon is referred to as “stress 
shielding” and it results in bone resorption (23). Among the materials mentioned above, Ti6Al4V is 
the most accepted option due to its low modulus compared to the other alloys (Table 2.1). The stress-
shielding effect is least for Ti6Al4V.  
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Table 2.1: Young’s modulus values for different alloys. 
Alloys Young’s Modulus (GPa)
316L stainless steel 200
Co-Cr alloy 230
Ti6Al4V 105
 
 
Ti6Al4V is the most commonly used material for orthopaedic implants due to the properties listed 
below (111): 
• low modulus 
• nontoxic and nonmagnetic 
• high corrosion resistance to all body fluids and tissue 
• biocompatible with human tissues and bones 
• low density 
Metal-alloy implants can sometimes fail due to micromotion at the interface between the implant 
device and tissue, which results in interfacial instability and wear of implant and leads to loosening of 
the implant, further deterioration of the host tissues, and finally a reduction in long-term stability of 
the prosthesis (112). The other factor that contributes to the difficulty of improving long-lasting 
implants is related to the quality and quantity of the surrounding bone in patients requiring the 
prostheses, i.e., patients aged 60 years old and higher, and sufferers from diseases such as 
osteoporosis (18).  
Designing artificial bone-like materials that can provide a strong bond between the implant and bone 
is one step towards improving implant performance. Since the implant life is strongly related to the 
strength of bonding between the implant and the bone, understanding the cell/tissue response to the 
implant and the cellular events that take place at the bone-implant interface in the biological 
environment are important. The following sections will focus on these concepts.  
2.3.2 Osseointegration 
Cellular Response at Bone-implant Interface 
In the case of bone replacement materials, it is essential to achieve osseointegration. This is a process 
in which bone is deposited directly onto implant materials without any intervening soft or fibrous 
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tissue. The result is a secure association between the bone and the implant (113;114). In 1977, 
Branemark defined osseointegration as “The re- and new-formed bone tissue enclosed the implant 
with perfect congruency to the implant form and surface irregularities, thus establishing a true 
osseointegration of the implant without any interpositioned connective tissue” (115). Later on, in 
1981, his co-worker Albrektsson defined it as “direct contact between living bone and implant at light 
microscopic level” (116). 
In order to achieve osseointegration, the gap between the implant and the tissue must be filled and any 
bone damaged during the implant procedure must be repaired. During this process, any relative 
motion of the implant and tissue will result in fibrous capsule formation (117). Several local factors 
can influence the implant osseointegration; these can be divided as follows (118):  
• Implant stability with regard to implant design, implantation technology, surgical technique 
and bone quality 
• Distance between the interfaces (host bone and implant) 
• Bioactivity of the implant surface and any material in the interfaces of bone and implant 
A better understanding of the events occurring at the bone-implant interface which enable bone cells 
to adapt to changes in their mechanical environment is essential for designing biologically driven 
implants with effective ossointegration. Therefore, the biological events at bone-implant interfaces 
will be discussed. 
Implant
Bone
Osteoclast
Cytokines and 
growth factors
Fibrin 
matrix
Blood cells
Adhesion of
osteogenic cell
Non-collagenous
matrix layer
Platelets 
aggregation and
adhesion
 
Figure 2.2: Schematic representation of the cascade of cellular and extracellular biological events that 
take place at the bone-implant interface.   
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As can be seen in Figure 2.2, the first event on implantation of a medical device is the contacting of 
blood cells including red cells, platelets, and inflammatory cells with the implant surface. Then the 
sequence of events is regulated by the release of cytokines, growth and differentiation factors from 
blood cells at the implant surface (119;120). The surface characteristics, particularly the chemistry 
and topography of the material, will determine which biological molecules adsorb (121). As a 
response to the foreign surface, platelets undergo morphological and biochemical changes including 
adhesion, spreading, and aggregation. A fibrin matrix is laid down which serves as a scaffold for the 
migration of osteogenic cells. From day one after implantation, osteoblasts migrate and attach to the 
implant surface, which has the ability to distinguish between subtle differences in surface roughness 
(122), and deposit bone-related proteins and the creation of a non-collagenous matrix layer on the 
implant surface that controls cell adhesion and binding of minerals. This matrix is an afibrillar layer 
that is rich in calcium, phosphorous, osteopontin and bone sialoprotein (123-125). Osteoblasts secrete 
osteoid and form new woven bone which subsequently remodels into lamellar bone, which forms a 
direct contact with the implant and covers the implant surface (121;123;126).  
 In summary, bone remodelling is important for new bone formation and bone cells especially 
osteoblast and osteoclast are required for this process. In the osteoporotic patients osteoclast cells are 
more active than osteoblast cells which results in osteoporotic bones. Using Sr at the early stage of 
bone healing in order to stimulate osteoblasts activity seems more beneficial.   
2.3.3 Types of Tissue Response to Implants 
Events resulting in the integration of an implant, and therefore affecting the performance of the 
medical device, take place largely at the tissue-implant interface and ultimately direct the response of 
the tissue (121). A biomaterial, that is, a natural or synthetic material that is used to replace a part of a 
living system, has the capacity to undergo tissue responses when implanted into living tissue (127). It 
is generally accepted that no foreign material implanted within a living body is completely 
compatible. Biocompatibility as re-defined by Williams in 2008 (128) is “The ability of a biomaterial 
to perform its desired function with respect to a medical therapy, without eliciting any undesirable 
local or systemic effects in the recipient or beneficiary of that therapy, but generating the most 
appropriate beneficial cellular or tissue response in that specific situation, and optimising the 
clinically relevant performance of that therapy”. From this definition it becomes clear that both the 
host response to the material and the material response to the host play an important role in the 
implant-tissue response (129). Table 2.2 summarises four general types of implant-tissue response and 
more details will be given in the following sections. 
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Table 2.2:  Consequences of implant-tissue interactions, adapted from (23). 
Implant-Tissue Reaction Consequence
Toxic Tissue dies
Biologically nearly inert
Tissue forms a non-adherent fibrous capsule around 
the implant
Bioresorption Tissue replaces implant
Bioactive Tissue forms an interfacial bond with the implant
 
 
• Toxic response to the material 
Materials that can cause a toxic response are considered to be highly unsuitable as implant materials. 
It is essential that implantation of any material avoids a toxic response that either kills cells in the 
surrounding tissues or releases chemicals that can migrate within tissue fluids and cause systemic 
damage to the patient (23).  
• Reaction to relatively inert materials 
The most common response of tissues to an implant is formation of a non-adherent dense fibrous 
tissue inside the body; a light microscopy image of fibrous tissue interposition of the bone-implant 
interface will be seen in subsequent chapter. The fibrous tissue is formed to “wall off” or isolate the 
implant from the host. The formation of fibrous tissue is considered to be a protective mechanism and 
ultimately can result in complete encapsulation of an implant within the fibrous layer (23;127). The 
thickness of the fibrous layer between the material and the tissue is an important consideration as it 
can affect the clinical longevity of the implant. A nearly inert implant forms a non-adherent fibrous 
layer at the interface and need to be tightly mechanically held (morphological fixation). If interfacial 
movement occurs, the thickness of the fibrous capsule can reach several hundred micrometres and 
loosening of the implant occurs which results in implant failure (112;130). It is important to mention 
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that the thickness of an interfacial fibrous layer also depends on motion and mechanical load at the 
interface, as well as the other factors listed in Table 2.3. 
 
Table 2.3: Factors affecting implant-tissue interfacial response, adapted from (23). 
Tissue Side Implant Side
Type of tissue Composition of implant
Health of tissue Phases in implant
Age of tissue Phase boundaries
Blood circulation in tissue Surface morphology
Blood circulation at interface Surface porosity
Motion at interface Chemical reactions
Closeness of fit Closeness of fit
Mechanical load Mechanical load
 
 
• Bioresorption 
 
Resorbable biomaterials are designed to degrade slowly with time and be replaced by the natural host 
tissue, (131) which results in a very thin or non-existent interfacial layer thickness. The problems 
associated with bioresorbable materials are the potential lack of stability during degradation, 
maintenance of the interfacial strength and the mis-matching of resorption rates to the repair rates of 
the body; these factors which themselves vary depending on a number of variables (Table 2.3). The 
main problem with resorbable materials is deterioration of their mechanical properties with time. This 
issue limits the use of these materials, however there are some successful examples such as tricalcium 
phosphate (TCP) ceramics, which degrade to calcium and phosphate salts and can be used for filling 
bone defects (131). 
• Reaction to bioactive materials 
When a bioactive material is implanted in the body, a bond forms across the interface between 
implant and the tissue due to a series of biophysical and biochemical reactions which result in the 
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formation of hydroxyapatite; a strong chemical interfacial bonding between implant and tissue (130). 
Bioactive materials are clinically desirable, as the hydroxyapatite formed supplies mechanical 
stability and minimises motion-induced damage to surgically traumatised tissue at the implantation 
site (132). In this manner, bioactive materials become quickly and firmly fixed to bone tissue before 
fibrous encapsulation can take place (23). Moreover, the compositional range of bioactive materials 
has been considerably expanded to include a wide range of rates of bonding and thickness of 
interfacial bonding layers. Such materials include bioactive glasses such as Bioglass®, bioactive glass-
ceramics such as Ceravital®, A/W glass ceramics and machinable glass-ceramics such as Bioverit®, 
dense calcium phosphate ceramics such as synthetic hydroxyapatite (HA), bioactive composites such 
as PE-HA mixtures and a series of bioactive coating materials (130). All of the materials named are 
able to form an interfacial bond with the adjacent tissue. However, their mechanisms and strengths of 
bonding, and the thickness of the bonding zone differ (106). 
Implants are often coated with bioactive materials, such as a HA layer, with the purpose of promotion 
of adhesion. This method is used to promote mechanical fixation as a result of active tissue growth or 
osseointegration. HA, with the chemical formula Ca10(PO4)6(OH)2, is bioactive and very similar to the 
mineral component of natural bones in terms of structure and composition. Therefore, it is not 
recognised by the human body as a foreign body and increases the speed of bone formation in the 
initial stages of osseointegration, thereby improving implant fixation (133). Bioactive glasses differ 
from HA in that they have greater osteoinductive properties, which encourage bone formation distant 
to the location of the glass. Bioactive glasses also are capable of bonding with both bone and soft-
tissues, unlike HA which may solely bond to bone (26). Structure, properties and different type of 
bioactive glasses with coating applications will be discussed latter. 
 
2.4 Glass As a Biomaterial 
2.4.1 Definition of Glass 
There are various definitions of glass for example; glass is an inorganic product of fusion which has 
cooled to a rigid condition without crystallizing” (134). Other definitions describe glass as a 
communal term for any materials in a vitreous state, regardless of its composition (135). Also, there 
are some opposing views of glass definition; some consider glass as a rigid liquid (136), whereas 
others describe it as an amorphous solid (137). In principal, glass is an amorphous and brittle material. 
The viscosity of a glass melt increases progressively as the temperature falls, such that the material 
behaves as a rigid solid. Similar X-ray diffraction traces are obtained for liquids and glasses, which 
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indicates that no long-range order is present in these materials. Therefore, to describe a glass in the 
liquid and solid state it is important to understand glass formation and structure.  
2.4.2 Glass Formation and Structure  
The relation between the glassy, liquid and solid states of glass can be explained with the volume-
temperature diagram in Figure 2.3. At higher temperatures, above Tm (the melting temperature), most 
liquids crystallise quickly with a significant decrease in volume, following the line B-C in the diagram 
below. However, if there are neither crystal nuclei nor foreign particles in the melt, the melt can be 
supercooled to some degree, following instead the line B-E. As the temperature decreases, the 
viscosity of the supercooled liquid increases continuously until a temperature, Tg, called the glass-
transition temperature is reached. Tg is in fact not a sharply defined feature occurring over a 
temperature rang and can be described as a second-order phase transition. The continuous increase of 
viscosity results in progressive freezing of the liquid until its final solidification. Only the material 
below this temperature is referred as a glass. The dotted line below point E can be achieved only when 
the supercooled melt is cooled slowly. As a supercooled liquid cools through the transition range, its 
atomic structure is maintained. Therefore, an inorganic silicate glass at room temperature is an 
amorphous solid with an atomic structure similar to that of the same material at Tg (138). Volume 
shrinkage continues from point E to F and the resultant product is known as a glass. 
T         Tg Tm
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Crystal 
Liquid 
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Figure 2.3: Volume-Temperature diagram showing relation between glassy, liquid and solid states, 
reproduced from (23).   
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Glass is considered to form a three-dimensional (3D) continuous random structure, lacking long-range 
regularity. The basic building block of a pure silicate glass structure is the SiO4 tetrahedron (Figure 
2.4, top). A silicon atom, which is positioned in the middle of the tetrahedron, is associated with four 
neighbouring oxygen atoms, which occupy the four corners of the tetrahedron. These SiO4 tetrahedra 
are joined at the corners to form a continuous 3D network (134;136). 
2.4.3 Glass Structural Theories 
Commercial glasses can be classified into three main groups: the soda-lime silica glasses, the 
borosilicate glasses and the lead silicate glasses. In order to better understand the fundamental 
structure of glasses, different theories and assumptions of glass formation have been developed 
describing opinions on the molecular structure of glasses (139). 
2.4.3.1 Goldschmidt’s Criterion 
For the first time, in 1926 Goldschmidt attempted to correlate glass formation to its structure. 
Goldschmidt hypothesised that for simple oxides with the stoichiometric formula AmOn, there is an 
association between the ability to form a glass and the relative sizes of the cation A and the oxygen 
anion (140). He calculated that the ratio of cation radius (rc) to anion radius (ro) must be between 0.2 
and 0.4 (141). This condition is satisfied by compounds such as SiO2, B2O5 and P2O5. From the 
considerations of crystal chemistry for ionic structures, there is a close relationship between this 
radius ratio and the coordination number of the central cation. The ratio proposed above translates 
into a tetrahedral coordination. In other words, the glass-forming oxides are required to be able to 
form a tetrahedron structure, according to Goldschmidt (138). 
2.4.3.2 Zachariasen’s Random Network Model 
In 1932, Zachariasen introduced a complex model to explain why some oxides fulfil Goldschmidt’s 
criterion but cannot form a glass. According to Zachariasen, the atomic arrangement in glass is 
characterised by an extended 3D  network that lacks symmetry and periodicity over long length scales 
(138). This network has recognisable order over a scale corresponding to nearest neighbour distances. 
Both the vitreous and crystalline forms of an oxide contain the same kind of oxygen polyhedra, which 
are bonded together in the same manner. In the glassy state, however, the relative orientation of the 
basic structural units is variable such that there is a certain range of bond lengths and bond angles 
available to these oxygen polyhedral (138).  
Zachariasen found that glass-forming oxides must follow a set of rules. For an oxide AmOn to form a 
glass, the number of oxygen atoms around a central atom, A, must be 3 or 4. None of the oxygen 
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atoms may be linked to more than two A cations. The oxygen polyhedra must only share corners and 
not edges or faces. At least three corners of each polyhedron must be shared with other polyhedra 
(23). Zachariasen divided all the oxides used as glass components into three different groups: network 
former, network modifier and intermediate (23). The categorisation depends on the effect of the oxide 
on the glass network. 
 
Table 2.4: Classification of the oxides according to Zachariasen, adapted from (23). 
Network 
forming oxides
Network 
modifying oxides Intermediates
SiO2 Li2O Al2O3
GeO2 Na2O PbO
B2O3 K2O ZnO
P2O5 CaO CdO
As2O3 BaO TiO2
As2O5
V2O5
 
 
Network forming oxides can form 3D random networks. The network modifying oxides are incapable 
of building up the continuous network. When such oxides are incorporated into a glass, they weaken 
the network by introducing non-bridging oxygens (NBOs). There are two types of bonds in the glass 
or crystal network, bridging oxygen (BO) bonds between neighbouring Si atoms, which hold the 
network together, and non-bridging oxygen bonds between Si and modifier atoms, which disrupt the 
network. When a network modifying oxide, such as Na2O, is added to SiO2 glass, each additional 
oxygen ion breaks a Si-O-Si bridge, creating a pair of NBOs. The two negative charges on the 
oxygens are locally neutralised by the nearby positively charged Na+ cations. This process is 
represented in Figure 2.4. Intermediate oxides are those oxides that are not usually capable of forming 
glasses on their own, but can take part in glass networks. Examples of such compounds are shown in 
Table 2.4.  
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Figure 2.4: 3D colour plot of SiO4 tetrahedral structure, the building block in silicate glasses (top). 
Breaking of Si-O-Si link by oxide modifier and replacing bridging oxygen with non-bridging oxygen 
(bottom).  
 
The number of bridging oxygens per tetrahedron is expressed by using Qn notation, where n is the 
number of bridging oxygen (142). For instance, the Q4 structure corresponds to silicon surrounded by 
four BOs while Q0 corresponds to the silicon surrounded by four NBOs.  
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2.4.3.3 Inorganic Polymer Model 
Holiday approached the study of glass structure with the view that silica and other inorganic glasses 
can be seen as inorganic polymers (143). It is worth pointing out that there are some similarities 
between glass and inorganic polymers, for instance both of them exhibit glass transition temperatures 
and high melt viscosities (144). He defined silicate glasses as inorganic polymers of oxygen cross-
linked by silicon atoms. By applying concepts from polymer science to glass, one can predict glass 
behaviour such as bioactivity by calculating the glass network connectivity (NC). The NC of glass is 
defined as the average number of linkages for the elements other than oxygen that form the network 
backbone. The calculation of NC of a glass is based on the number of BOs and NBOs (145). The 
formula for NC is shown in Equation 2.1. 
 
 
Equation 2.1: Equation for the network connectivity of the glass.  
 
2.4.4 Bioactive Glasses 
2.4.4.1 History of Bioactive Glass 
When bio-inert materials were first discovered, it was thought that the use of these materials would 
solve the problem of the human body’s rejections response to foreign materials. But an increased life 
expectancy requires a material which can survive longer by forming a strong bond with the host 
tissues. 
Bioactive glasses (BG) were first developed by Hench in the late 1960s (112). The story behind this 
success started when he was looking forward to give a talk on his research findings on a material that 
could survive high doses of energy radiation. Then the life changing question was put forward: ”If 
you can make a material that will survive exposure to high energy radiation can you make a material 
that will survive exposure to the human body?” (146). His motivation to help human beings and save 
limbs and lives resulted in the discovery of a biomaterial that is well known for forming a bond with 
the surrounding tissue. This biomaterial was termed Bioglass®. 
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The glass composition of 45% SiO2 – 24.5% Na2O – 24.5% CaO – 6% P2O5 (in wt%), called 45S5 
Bioglass®, was the first material to be prepared and tested for its ability to form bond to the host tissue 
without formation of scar tissue in vivo (147). Next, in vitro examination of the glass confirmed that 
this material was able to develop a hydroxycarbonate apatite (HCA) layer in solutions that did not 
contain calcium or phosphate ions. Furthermore, transmission electron micrographs of the bonded 
interface exhibited that the in vitro rapid formation of HCA was comparable to the interfacial HCA 
crystals found in vivo (148). It was found that the chemical bond between the HCA crystals and 
collagen fibrils produced by osteoblast cells at the interface resulted in the formation of a strong bond 
between bone and implant (148;149). 
After the discovery of Bioglass®, a series of questions was raised to understand the physical, chemical 
and biological nature of the bond and the mechanism behind the bioactivity of the Bioglass®. To date, 
investigation on different compositions of BGs has been carried out to develop glasses with multiple 
functions and for different applications. The concept of bioactivity, BG degradation mechanism and 
different compositions of BGs suitable for tissue engineering including coating applications will be 
summarised in the following section. 
2.4.4.2 Bioactive Glass Degradation Mechanism and Bioactivity 
The commonly accepted mechanism to explain the bioactive behaviour of glasses is related to the 
research of Hench et al. (148;149). However, there are other theories associated with the bone 
bonding and glass degradation mechanism; to name a few those of Kokubo et al. (150), Anderson et 
al. (151), Li et al. (152) and Hill et al. (153), which give additional explanations regarding apatite 
formation.  
The ability of a bioactive glass to form a bond with bone is dependent on the chemical reactivity of 
the glass surface in body fluids. The formation of a bond is a result of a series of chemical reactions 
which forms an HCA layer and silanol (Si-OH) groups. Before the implant bonds to the tissues, a 
layer of biologically active HCA must be deposited upon it (112).  
A series of reactions takes place at the glass surface which are a combination of 11 physiochemical 
and ultrastructural phenomena (18;23;112;154;154;155). The first five reaction stages happen on the 
surface of the glass without the necessity of tissue presence, and they can be activated in distilled 
water, Tris-buffer solution and simulated body fluid (SBF). Stages 6-11 are associated with bonding 
to tissue, therefore the cellular events at a molecular biology level relevant to this stage need to be 
completely understood in order to explain the effect of glasses on the tissue. It is important to mention 
that there is no actual evidence for these stages. All of these reactions are described below and the 
reactions taking place at the glass surface (stages 1-5) are schematically represented in Figure 2.5.    
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Figure 2.5:  Schematic representation of the first five reaction stages on the surface of silicate-based 
bioactive glasses to form HCA. Based on a figure from (23).  
 
Stage 1: Formation of silanol (Si-OH) 
The first step involves rapid exchange of cations such as Na+ with H+ or H3O+ from solution. 
Si-O-Na+ + H+ +OH- → Si-OH+ + Na+ (solution) + OH- 
Stage 2: Break-up of the silica network and continued formation of Si-OH bonds. 
Si-O-Si + H2O → Si-OH + OH-Si 
An increase in hydroxyl concentration leads to network dissolution. Soluble silica is lost to the 
solution in the form of Si(OH)4, which results from breakage of Si-O-Si bonds and formation of Si-
OH (silanols) at the glass-solution interface. 
Stage 3: Condensation and repolymerisation of an SiO2 rich gel-layer. 
Si-OH+ OH-Si → Si-O-Si + H2O  
This SiO2 gel-layer is characteristic of bioactive glasses and has a porous structure depleted of alkali 
and alkaline-earth cations. It is the silica gel surface that allows apatite formation to proceed. 
Stage 4: Formation of an amorphous calcium phosphate layer. 
Ca2+ and PO43- groups migrate to the surface through the SiO2 rich layer forming a CaO-P2O5 rich film 
on top of the SiO2 gel layer. This migration is followed by growth of an amorphous CaO-P2O5-rich 
film by incorporation of soluble calcium and phosphate from solution. The CaO-P2O5 layer protects 
the glass surface from further attack. In vivo , the body and the glass supply the necessary calcium and 
phosphorous ions. 
Stage 5: Crystallisation of HCA layer. 
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Crystallisation of the amorphous CaO-P2O5-rich film occurs by incorporation of OH- and CO32- anions 
from the surrounding solution to form an HCA layer that is similar in composition to living bone. 
Stage 6: Adsorption and desorption of biological growth factors. 
The crystalline HCA layer grows in thickness as the reactions continue, creating a bonding zone that 
osteogenic cells, such as osteoblasts or mesenchymal stem cells, can infiltrate and finally form a direct 
bond between the implant and the natural bone.   
Stage 7: Action of macrophages. 
Debris from the site is removed by macrophages to allow cells to occupy the space. 
Stage 8: Attachment of stem cells. 
Stage 9: Differentiation of stem cells to form osteoblasts. 
Stage 10: Generation of extracellular matrix by the osteoblasts to form bone. 
Stage 11: Mineralisation of matrix to enclose bone cells in a living composite structure. 
 
The occurrence of these reactions, in particular the first five stages, results in osteogenic cells, such as 
osteoblasts and mesenchymal stem cells encountering a bone-like surface and not a foreign material. 
Consequently, bioactive glass participates in the repair process that allows for the creation of a direct 
bond of the material to tissue (17). It is important to point out that HCA formation was shown to be 
helpful for the interaction between bioactive materials and bone but controlled chemical-release 
kinetics that operate simultaneously with the cellular cycles in tissue are a key factor also 
(18;112;154). If dissolution rates are too slow, the ionic concentrations released from the bioactive 
material are not enough to stimulate cellular proliferation and differentiation. On the other hand, if the 
rates are too rapid the concentrations are too high to be effective and may have a toxic effect on the 
cells/tissues. Studies by Oonishi et al. (156;157) and Wheeler et al. (158) showed that there are large 
differences in the rates of in vivo bone regeneration and the extent of bone repair depending on the 
bioactive materials used. Their results indicated that there are two classes of bioactive materials. Class 
A bioactivity results in both osteoconduction and osteoinduction (osteoproductive according to 
Wilson’s definition (159)) due to the quick reactions on the surface of bioactive materials 
(18;154;159). Osteoconduction is the growth of bone adjacent the implant surface where the implants 
contacts the host bone. Osteoinduction is the production of new bone on the implant surface, which 
surface does not necessarily need to be in contact with the host bone. Class B bioactivity happens 
when osteoconduction is present and only an extracellular response at the interface is displayed 
(154;156).      
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The bioactivity of glasses can be presented by the compositional diagram for bone-bonding as shown 
in Figure 2.6. Glasses in this diagram contain four components of SiO2, Na2O and CaO with a fixed 6 
wt % P2O5 content. The glasses in region A bond to bone. Moreover, the  centre of the region 
corresponds to higher bioactivity, which leads to an increase in the speed of reaction and apatite 
formation (region E). The glasses within the dotted line bond to soft tissues as well (region S). Glasses 
in region B with greater than 60% SiO2 behave as bio-inert materials, resulting in non-adherent 
fibrous tissue formation when implanted. The glasses in region C are resorbed into tissue within 10 to 
30 days. Finally, the compositions in region D are not technically practical and have not been 
implanted (146). This diagram shows that varying compositions of a glass can change both the level 
of bioactivity and rate of dissolution (160). The results from different studies (155;161) have shown 
that increasing the silica content of BGs inhibits the level of bioactivity by decreasing the accessibility 
of modifier ions and  reducing the silica gel layer formation on the surface. 
 
A = Bone bonding
B = Non-bonding (reactivity too low)
C = Non-bonding (reactivity too high)
D = Non-bonding (non glass forming)
S = Soft tissue bonding
E = Bioglass® composition 
B
D
C
A S E
Na2OCaO
SiO2
6% P2O5
 
Figure 2.6: Compositional diagram (in weight percent) for the bioactivity of melt-derived silicate 
containing bioactive glasses, adapted from (26;146).  
 
Despite much attention focussed on the compositional dependence of bioactivity and the vast amount 
of research carried out on BGs, still it is difficult to predict whether purely random glass composition 
will be bioactive. The bone bonding behaviour of a number of bioactive glasses cannot be explained 
based on Hench’s accepted model for bioactivity. This means that bioactivity does not only depend on 
the glass composition. The next section will discuss the effect of network connectivity on BGs.  
Chapter 2: Literature Review 
57 
 
2.4.4.3 The Influence of Network Connectivity on Bioactivity 
The bioactivity of BGs is strongly correlated with the NC (153;160). The network connectivity 
(explained in section 2.4.3.3) may be calculated according to Hill (153) but it is now recognised that 
phosphate in bioactive glasses does not form part of the silicate network and it is thought to exist as a 
distinct orthophosphate droplet phase (160); due allowance must be made for this phase in the 
calculation of NC.  
Recently Tilocca et al. (162-164) simulated the structure of bioactive glasses using molecular 
dynamics and emphasised the importance of the fragmented and discontinuous nature of the silicate 
network. They also looked at the structural role of phosphate and found evidence that glasses with 
greater than 5 mol% P2O5 exhibit amorphous phase separation into a silica rich and phosphate rich 
phase (164). This separation was confirmed by solid-state 31P magic-angle-spinning (MAS)-NMR 
spectra experiments, which showed an orthophosphate phase for all phosphate contents when NC <2.5 
(162-164). 
As a general rule the bioactivity is negligible or extremely low in glasses with NC values above 2.4, 
and it increases as NC reduces towards a value of 2.0, which corresponds to a linear Q2 silicate 
structure where each silicon has on average two BOs and two NBOs (165). For instance, the NC of 
45S5 Bioglass® is 1.9, which is lower than 2 and indicates a distribution of 90% Q2 and 10% Q1. In 
contradiction to the mechanisms proposed by Hench (112), it is important to note that dissolution and 
bioactivity are controlled by NC, and that the mechanism of dissolution and bioactivity involves little 
or no alkaline hydrolysis of Si–O–Si bonds, but instead involves the congruent dissolution of the glass 
as suggested by Hill (166). 
Furthermore, crystallisation inherently reduces bioactivity since crystal phases are in a lower energy 
state; the structure will be more tightly packed and the bonding will be stronger than the equivalent 
glass composition and as a consequence the crystal phase will be less soluble. Therefore, 
crystallisation of bioactive glasses is widely regarded as undesirable (112;167;168).  
2.4.4.4 Biological Response to Ionic Products Released From Bioactive Glasses  
An increasing amount of evidence in the literature suggests that the key factor to understand the 
behaviour of BGs in vitro and in vivo is to study the stimulation effects of dissolution products that 
are released from BGs as a result of the osteogenesis process. The biological response of bone 
cells/bone tissue to pure silicate-based BGs and strontium-substituted BGs produced either by melt or 
derived from sol-gel, and used in different forms such as powder, scaffolds, coated surfaces, 
monoliths and dissolution ions, will be discussed.  
Chapter 2: Literature Review 
58 
 
2.4.4.4.1 Silicate-Based Bioactive Glasses 
Since Hench et al. discovered 45S5 Bioglass® there has been a huge amount of research work on 
silicate-based BGs for biomedical purposes. It has been shown that the ionic dissolution products of 
glasses in the SiO2 – Na2O – CaO – P2O5 system mediate cell metabolism. Silver et al. added 45S5 
Bioglass® particles to cell-culture medium and showed a rise in Ca2+ concentration, which may affect 
a number of intracellular enzymes, and also an increase in ATP (Adenosine triphosphate) production 
in osteoblast cells (169), while Laquerriere et al. demonstrated that glass particles with a composition 
of 50 SiO2 – 20 Na2O – 16 CaO – 6 P2O5 – 5K2O – 2 Al2O3 – 1MgO (all in wt %) resulted in 
increasing cellular concentrations of phosphorus and sulfur which are related to phosphorylation 
status and protein content of the cells (170). They also showed that glass particles are more toxic for 
cells than their ionic dissolution products. Furthermore, a vast majority of studies has shown that 
silicate-based BGs have osteogenic effects such as increasing the number of osteoblast cells, 
enhancing cell proliferation and stimulating osteoblast cell differentiation, promoting extra cellular 
matrix formation and mineralisation (30;169;171-173). It is worth pointing out that some of these 
studies have shown bone-nodule formation and mineralisation without adding osteogenic supplements 
to the culture media (172). In 2001, interesting results reported by Xynos et al. showed that 
dissolution ions from 45S5 Bioglass® have the ability to up-regulate different gene families in human 
osteoblast cells by up to five-fold (30). The detected genes play an important role in cellular processes 
such as proliferation, cell cycle regulation, apoptosis control and different growth factors related to 
bone formation. In agreement with this study by Jell et al., up-regulation of bone sialoprotein (BSP) 
and alkaline phosphatase (ALP) was shown to occur in BG-conditioned culture medium, leading to 
cell differentiation (174). 
In vitro results have been obtained from sol-gel BGs that are parallel with those from melt-derived 
BGs. Bosetti et al. demonstrated that 77S BG powders (80 SiO2 – 16 CaO – 4P2O5 (in mol%)) with a 
particle size of 100 – 700 µm induced osteogenic differentiation of bone marrow stromal cells into 
osteoblast-like cells and provided a large amount of mineralised tissue (175). In another study it was 
found that with the ionic dissolution products from 58S BG powders (60 SiO2 – 36 CaO – 4 P2O5 ( in 
mol%)), a particle size range of 90 – 710 µm increased the proliferation of both murine and human 
primary osteoblast cells (171). Christodoulou et al. studied the effect of dissolution ions released from 
the same composition of 58S on human foetal osteoblast and showed an up-regulation of the 
expression of a number of genes including gp130, MAPK3/ERK1, MAPKAPK2, and IGF-I (176).  
Additionally, the molecular effects of silicate-based BGs were investigated in vivo. For example, BG 
microspheres of glass 13-93 (53 SiO2 – 6 Na2O – 20 CaO – 12 K2O – 5 MgO – 4 P2O5 (in wt%)) with 
a diameter of 250-315 µm were able to fill in medullary defects in a rabbit tibia, along with bone 
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morphogenic protein 2 (BMP-2) injection to the defects. The results revealed the high osteoinductive 
effect of this glass plus increased rates of new bone formation and resorption, which resulted in 
enhanced bone turn-over (177). It is worth pointing out that they evaluated the synergic effects of 
adding BG and BMP-2 on the bone formation.  
All the studies discussed in this section confirm that ionic dissolution products released from silicate-
based BGs, regardless of their shape, stimulate osteogenesis which can results in more bone 
formation. However, it is important to understand which ionic products and in what concentration 
they can activate cells towards osteogenesis. There is controversy in the results of the effects of the 
single dissolution products from BGs from different studies. Valerio et al. studied the effect of ionic 
products released from BG60S (60 SiO2 – 35 Ca – 5 P2O5 (in wt%)) and a biphasic calcium phosphate 
(BCP) on proliferation, metabolic activity and collagen production of rat primary culture osteoblasts 
(178). They reported higher osteoblastic proliferation and collagen secretion after treatment with 
BG60S dissolution products and, despite higher Ca2+ concentration due to BCP, no increased 
osteoblast activity was observed. In another study it was shown that a Ca2+ concentration  of around 
80 ppm was released from the mesoporous BG (MBG85) with the composition of 85 SiO2 – 10 CaO – 
5 P2O5 (in mol%) and this reduced proliferation of human Saos-2 osteoblasts (179). The same study 
reported that soluble silica concentration up to 60 ppm did not have a negative effect on cell 
proliferation. 
2.4.4.4.2 Strontium-substituted Bioactive Glasses 
Incorporating various ions in the silica network of BGs is a commonly acceptable method to promote 
a specific biological response from BGs in physiological environments, in particular to increase the 
stimulating effects of bioactive glasses on bone formation and promote the bioactivity of the glasses. 
Diverse BG compositions substituted with different ions have been approached, to name a few 
examples: cobalt-BG (180), zinc-BG (181) (182), silver-BG and magnesium-BG (183). Since Sr is the 
main interest for this thesis the following part will focus on the published data on the biological 
performance of Sr-BGs.  
In the previous study, we investigated the behaviour of Sr-substituted BG (46.46 SiO2 – 1.07 P2O5 – 
26.38 Na2O – 23.08 (SrO:CaO) (in mole %) in which Ca2+ was systematically replaced by Sr2+ up to 
100% (184). Our findings showed that ion release from Sr-substituted BG in the range of 5-23 ppm 
enhanced metabolic activity in osteoblasts and inhibited osteoclast activity in a dose-dependent 
manner. Additionally, osteoblasts cultured in contact with BG discs showed increased proliferation 
and alkaline phosphatase activity with increasing strontium substitution. In agreement with this study, 
it has been shown that ion-dissolution products from the sol-gel-derived Sr-substituted BGs (58.8 
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SiO2 – 11.0 P2O5 – 22.3 CaO – 7.9 SrO (in wt%)) exhibited optimal cell proliferation and ALP 
activity when applied to the cell-culture medium of rat calvaria osteoblastic cells (185).  
In the in vivo study by Gorustovich et al. the bone-bonding ability of the melt-derived Sr-substituted 
BG particles was compared with 45S5 BG when placed inside the medullary canal of the rat tibia 
(186). The results showed good bone-bonding ability of Sr-substituted BG particles and normal bone 
mineralisation without significant differences between the tested glasses. Moreover, Boyd et al. 
developed a series of Sr-substituted BGs which also contained Zn for bone-graft applications and 
evaluated in vitro cytotoxicity and in vivo biocompatibility. They showed that glass of composition 
0.4 SiO2 – 0.32 ZnO – 0.28 SrO (in mol%) exhibits higher cell viability on L929 mouse fibroblast cell 
compared to 0.4SiO2 – 0.32 ZnO – 0.28 CaO, 0.4 SiO2 – 0.32 ZnO – 0.14 CaO – 0.14 SrO and the 
commercially available bone graft Novabone. Additionally, in vivo study revealed new bone 
formation close to the implanted particles without evidence of an inflammatory response (187). 
Murphy et al. evaluated the Sr and Zn release from six different compositions of Sr-substituted BGs 
containing Zn at both pH 7.4 and 3 (188). They showed that glasses released Sr ions in the range of 0-
3500 ppm in both pH environments, which is within the therapeutic range. The glasses also released 
Zn ions in the range of 3-18 ppm at pH 7.4, which may have a potential therapeutic effect. However, 
zinc release was higher at pH 3 (89-750 ppm) which may be high enough to produce a cytotoxic 
effect.  
By taking all these facts into account one can state that controlled dissolution of ions released from 
BGs is an essential factor for developing biomaterials that can meet the required essential 
concentrations of specific ions released into physiological environments. 
2.4.4.5 Bioactive Glass Coatings 
Because of their brittleness and relatively poor mechanical properties, the clinical applications of BGs  
are limited to non-load-bearing implants, such as middle ear implants (189;190) and periodontology 
(191). As already mentioned, an alternative and promising solution could be utilising BGs as coatings 
on bio-inert metallic implants, in order to combine the high bioactivity of BG with the mechanical 
strength of metal alloys (23). Despite their great potential in this regard, BG coatings are still rarely 
applied.  
Different laboratories are studying new, effective techniques to produce reliable coatings. Not only 
well-established methods such as enamelling, thermal spray and rapid-immersion methods, but also 
alternatives, such as electrophoretic deposition and thin-film techniques, are under investigation. It 
has been shown that the simple enamelling technique is an appropriate way to coat an implant with a 
BG by considering several key issues as follows (192): 
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The purposes of the bioactive glass coating on the prosthetic metallic implants are to promote 
osseointegration in order to provide a bond between prosthesis and bone, and to protect the metal 
against corrosion from body fluids and the tissue from the corrosion products of the alloys. However, 
satisfactory adhesion between the metal prosthesis and the bioactive glass has not yet been achieved 
as a result of the large difference in the thermal expansion coefficient (TEC) between the glass and the 
metal (193). 
The importance of matching the TEC of the glass to the alloy used for prosthesis has largely been 
neglected in most of the published studies of bioactive glass coatings on alloys used for medical 
prostheses. The studies of bioactive glass coatings in the SiO2−Na2O−K2O−CaO−MgO−P2O5 system   
on Ti alloy by Gomez-Vega et al. (194;195) are a notable exception. Furthermore, Gomez-Vega et al. 
advocate an approach based on enamelling involving the sintering of glass particles at a temperature 
between the glass transition and crystallisation onset of a deposited coating. 
The commercially available 45S5 bioactive glass (Bioglass®) has not only too high a TEC for 
enamelling Ti6Al4V (16×10−6 K−1 and 8–10×10−6 K−1, respectively) but also crystallises almost 
immediately after heating above the glass transition temperature (196), which has two major 
drawbacks: a) it inhibits sintering by a high temperature viscous flow mechanism and b) any 
crystallisation will inherently reduce bioactivity in vivo. Both these aspects were recognised by 
Gomez-Vega et al.(194;197), and they successfully produced well-bonded glass coatings on Ti alloy; 
however, they failed to recognise the importance of the network connectivity (NC, (153;194)) of the 
glass in determining bioactivity, with the result that their coatings which bonded to Ti alloy had far 
from optimal bioactivity (198). The authors resorted to adding HA or 45S5 Bioglass® particles to the 
coating surface to alleviate this problem, and more recently they have advocated the use of bilayer 
coatings (199;200). In another study a series of glasses in the SiO2 – Na2O – CaO –K2O – MgO – P2O5 
system was synthesised with the aim of use as a coating for Ti-based and Co-Cr alloys for dental 
implants (201). The glass compositions were designed to have a TEC match with the alloys and  the 
silica contents were kept below 60 wt%. The authors suggested that control of the glass-alloy reaction 
is important during the fabrication.  Optimum adhesion through the formation of 100-200 nm thick 
interfacial layers was achieved (201). 
In all cases, it is possible to note that utilising silica-based BGs as a coating material on the prosthetic 
metallic implants by means of enamelling technique requires the TEC of the coating to be matched 
with that of with the substrate. This matching will be achieved not by increasing the silica content of 
the glasses since this affects the bioactivity of the glasses, but by substitution of cations in glass 
network and by considering the NC of the glass.  
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3.1 Introduction 
3.1.1  Design and Rationale  
The requirement for prosthetic metallic implants continues to grow as people live longer and more 
people are injured from physical activity and physical trauma. Metal alloys used in hip replacements 
do not bond or integrate well with bone, and therefore bioactive coatings are of interest to improve 
implant performance. BG, which degrade in the human body forming an apatite surface layer, were 
shown to form an integrated bond to mineralised tissue (23;112). One intended application of BG was 
for coating the femoral stem of hip prostheses for cementless fixation. The purpose of the BG coating 
was to promote osseointegration in order to provide a bond between prosthesis and bone, and the 
procedure involved dip-coating the prosthesis into the molten liquid glass at very high temperatures. 
As mentioned earlier, when designing glasses for coating applications the thermal expansion 
coefficient matching with the substrate needs to be taken into account (193). By tailoring the glass 
composition, the necessary thermal characteristics to give a good coating material can be combined 
with a glass that exhibits good bioactivity. All the glass compositions designed for this study were 
selected on the basis of their calculated TEC values by means of Appen factors (202); the Appen 
factors developed through the measurement of TEC for many glass compositions, which were later 
fitted into an equation. The calculated glass transition temperatures based on the equation reported by 
Andersson (203) with the objective of having a TEC close to the upper value for Ti6Al4V (Ti alloy) 
and a Tg as low as possible. For this purpose it is assumed that phosphorus is not part of the silicate 
glass network, but exists as a separate orthophosphate phase dispersed in a silicate glass matrix phase. 
It is also assumed that the TEC is determined by the composition of the silicate glass phase. In order 
to determine the TEC, the composition of the silicate glass phase is calculated by assuming equal 
partitioning of Ca, Na and K between the orthophosphate phase and the silicate phase. 
In order to facilitate sintering and aid processing of coatings, a large temperature difference between 
the glass transition temperature (Tg) and the onset temperature for crystallisation (To) is required in 
the differential scanning calorimetry (DSC) trace of a glass powder suitable for sintering. Figure 3.1a 
shows the DSC trace of the well-known 45S5 Bioglass® composition, and the DSC trace for a glass 
that is much more suitable for sintering is shown in Figure 3.1b. Figure 3.1b shows a much larger 
temperature difference between Tg and To, and this temperature difference we will refer to 
subsequently as the processing window. 
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Figure 3.1: DSC traces with glass transition (Tg) and onset peak crystallisation (To) temperatures and 
processing window for (a) Bioglass® 45S5 and (b) glass 100% Sr (see Table 3.1 for glass composition). 
Dotted lines are drawn as a guide to the eye. 
Crystallisation of bioactive glasses is widely regarded as being undesirable (112;167;168) since 
crystallisation will occur predominantly at the surface of bioactive glass particles and will thus reduce 
the volume fraction of glass for viscous flow sintering. Furthermore, crystallisation inherently reduces 
bioactivity since crystal phases are in a lower energy state; the structure will be more tightly packed 
and the bonding will be stronger than the equivalent glass composition, and as a consequence the 
crystal phase will be less soluble. 
In order to suppress crystallisation with the aim of having a large processing window 45S5 Bioglass®, 
it was decided to increase the number of network modifying oxides in the composition to suppress the 
onset temperature for crystallisation. Glasses incorporating equal molar percentages of Na2O and K2O 
were therefore produced. In addition, in order to suppress crystallisation MgO was also included, 
since it has been shown to act partially as an intermediate oxide and also to suppress crystallisation 
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(204). ZnO was also incorporated into the glass at less than 3 mol% to further restrict the tendency 
towards crystallisation and to provide a small amount of Zn2+ release from the glass, which has 
bactericidal properties and also plays an important role in wound repair and bone formation (205). 
These properties are considered to be major benefits in clinical applications because a high proportion 
of over 60 year olds suffer from low plasma zinc levels and in such patients zinc oxide incorporation 
in wound dressings is known to promote healing. 
Finally, SrO was included in the glass composition to provide localised Sr2+ release from the glass. As 
discussed in literature review chapter, strontium is known to stimulate osteoblasts and inhibit 
osteoclasts and also to stimulate bone formation (206). The Sr2+ cation is the active ingredient in the 
drug strontium ranelate, which recent clinical trials have shown to be of major benefit in treating 
osteoporosis (207;208). In addition it has been shown that molar substitution of Ca by Sr in bioactive 
glasses increases their dissolution rates by expanding the glass network and reducing the oxygen 
density of the glass. In addition, strontium released from the glass has also been shown to promote 
mineral formation by osteoblasts in cell culture (184).  
Taking all these facts into account the key factors which were considered in this study to produce the 
BG coatings on Ti alloy are summarised as follows:  
• A glass was designed to have a slightly higher TEC than the Ti alloy to avoid the compression 
of the coating. 
• The glass coating was sintered below the α→β phase transition temperature of Ti alloy 
(between 955 and 1010°C (209)) in order not to compromise the mechanical properties and 
the fatigue life due to the large thermal expansion change in the alloy at this point. 
• The glass coating was sintered well below the onset temperature for crystallisation. 
• The coating was sintered in a vacuumed environment to prevent excessive oxidation of the Ti 
alloy and remove any bubbles from the interfacial region and bulk of the coating. 
• A glass was designed to have a NC less than 2.4 and preferably as close to 2.0 as possible 
since the bioactivity of BG is strongly correlated with the NC (153;160), as this was 
explained in details earlier in the literature review chapter. 
The role of P2O5 within a BG system is highly controversial. Since 45S5 Bioglass® introduced, it is 
thought that the presence of P in the implanted material is essential in order to give the ability to the 
implant to bond to living tissue (112). Hench hypothesised that P has an important role to promote the 
HCA layer which is essential for the tissue to bond to the implant. In contrary to Hench’s model the 
bioactive behaviour of P2O5-free glass systems such as amorphous wollastonite was found 
experimentally (210). Additionally, it has been showed that incorporation of phosphate from the 
physiological fluid can progress nucleation and crystallization in the P2O5-free compositions 
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(3;210;211). Although the incorporation of P2O5 was found not necessary for bioactivity but small 
quantity of P2O5 was shown has ability to enhance HCA deposition and ability for bonding to bone 
(3;4;210;212). Based on these findings, Ebisawa et al. proposed that leaching of soluble phosphate 
species from the glass into solution causes the increase in the local supersaturation and consequently 
accelerate the HCA perception (210). But also leaching of soluble phosphate can buffer the local pH 
at the glass surface and aid to bone bonding due to the prevention of excessive surface acidity (213).  
There are such a wide range of analysis on the structural role of phosphorus in BGs showing that the 
presence of phosphate in the glass leads to the deposition of more HCA layer results in a strong bond 
with bone (3;4). Phosphate-containing glass compositions release silica into the solution faster and 
therefore they are more soluble (214). O'Donnell et al. studied the effect of the variation in phosphate 
content of the BGs on their bioactivity and showed that high-phosphate-content glasses exhibited 
increased apatite deposition (215). They concluded that phosphate leaching from the glasses in 
contact with the SBF solution may enhance apatite formation kinetics and that phosphate content is an 
important factor for bioactivity.  
In the present chapter, influence of substitution strontium for calcium on the glass sintering and 
crystallisation behaviour, with a view to making glass compositions with enhanced properties for 
coating applications will be discussed. In addition, the effect of increasing phosphate (P2O5) content 
on the bioactivity and physical properties of strontium-containing BGs will be described. 
 
3.2 Materials and Methods 
3.2.1 Glass Synthesis 
Three series of glass compositions studied are given in Table 3.1, Table 3.2 and Table 3.3 (all in 
molar percent). The glasses were synthesised by mixing analytical grade silica (Prince Minerals Ltd., 
UK) with CaCO3, SrCO3, MgO, Na2CO3, K2CO3, ZnO and P2O5 (all Sigma- Aldrich, UK) in the 
appropriate proportions and phosphorus pentoxide was always added last due to its very hygroscopic 
nature. Then the well-mixed batch was transferred to a 300 ml platinum crucible and placed into the 
preheated furnace (Lenton EHF 17/3, UK) at 1450oC for 1 hour. After this time the molten contents of 
the crucible were quenched immediately by pouring into cold tap water to prevent crystallisation. The 
resulting glass frit was collected and dried in an oven at 120oC overnight, then ground in a vibratory 
puck mill (Gyro Mill, Glen Creston, UK) for 14 min and sieved in a mechanical shaker through a 38 
µm sieves to obtain particles smaller than 38 µm. Particle size of the fine powders was analysed using 
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a laser particle size analyser (Cilas 1064, UK). Glass powders were stored in a desiccator when not in 
use. 
Table 3.1 shows the low-phosphate-content bioactive glass composition with 0, 10, 25, 50, 75 and 
100% of the CaO being replaced by SrO, with calculated TEC and NC values. All NC values were 
calculated by assuming that ZnO and MgO both act as network modifying oxides (216;217).  
 
Table 3.1: The composition of the low phosphate strontium-substituted glass series in mol. % with 
calculated TEC by means of Appen factor (Equation 3.3) and theoretical NC values (Equation 2.1).  
Glasses SiO2 P2O5 CaO SrO Na2O K2O ZnO MgO
Calculated TEC 
(×10-6 ºC-1) NC
0%Sr 49.96 1.07 32.62 0.00 3.30 3.30 3.00 7.25 9.71 2.15
10%Sr 49.96 1.07 29.38 3.26 3.30 3.30 3.00 7.25 9.81 2.15
25%Sr 49.96 1.07 24.46 8.15 3.30 3.30 3.00 7.25 9.96 2.15
50%Sr 49.96 1.07 16.32 16.32 3.30 3.30 3.00 7.25 10.20 2.15
75%Sr 49.96 1.07 8.15 24.46 3.30 3.30 3.00 7.25 10.44 2.15
100%Sr 49.96 1.07 0.00 32.62 3.30 3.30 3.00 7.25 10.69 2.15
 
 
The glass series with increasing P2O5 content from 1.07 to 6.42 mol% in which 10% or 50% of the 
CaO were substituted by SrO were produced to investigate. Sufficient cations were added to ensure 
charge neutrality in the PO43- complexes formed. The 10% and 50% strontium-substituted glasses 
with varying P2O5 content were called “phosphate series Ι” and “phosphate series ΙΙ”, respectively 
(Table 3.2 and Table 3.3). The phosphate series ΙΙ was produced and characterised by NMR for 
comparison to phosphate series I.   
 
Table 3.2: The composition of phosphate series Ι glass series in mol. % with calculated TEC by means of 
Appen factor and theoretical NC values. 
Glasses SiO2 P2O5 CaO SrO Na2O K2O ZnO MgO
Calculated TEC 
(×10-6 ºC-1) NC
10% Sr- 1.07P 49.96 1.07 29.38 3.26 3.30 3.30 3.00 7.25 9.81 2.15
10% Sr- 2.14P 47.51 2.03 29.74 3.66 3.34 3.34 3.04 7.34 10.01 2.15
10% Sr- 4.28P 43.93 3.76 30.83 3.80 3.46 3.46 3.15 7.61 10.40 2.15
10% Sr- 6.42P 40.86 5.25 31.76 3.91 3.57 3.57 3.24 7.84 10.74 2.15
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Table 3.3: The composition of phosphate series ΙΙ glass series in mol. % with calculated TEC by means of 
Appen factor and theoretical NC values. 
Glasses SiO2 P2O5 CaO SrO Na2O K2O ZnO MgO
Calculated TEC 
(×10-6 ºC-1) NC
50% Sr- 1.07P 49.96 1.07 16.31 16.31 3.30 3.30 3.00 7.25 10.20 2.15
50% Sr- 2.14P 47.68 2.04 16.58 16.58 3.35 3.35 3.05 7.37 10.38 2.15
50% Sr- 4.28P 44.08 3.78 17.19 17.19 3.48 3.48 3.16 7.64 10.80 2.15
50% Sr- 6.42P 40.98 5.27 17.72 17.72 3.59 3.59 3.26 7.88 11.15 2.15
 
 
3.2.2 Glass Casting 
Rods of 20 mm diameter were cast by remelting approximately 100 g of glass frit for one hour and 
half at 1450°C to ensure no bubbles were formed when casting. The melt was poured directly into a 
pre-heated (at 600°C) graphite mould and was subsequently annealed slowly to room temperature 
overnight to relieve stresses. 
3.2.3 Glass Coating 
3.2.3.1 Enamelling Technique 
Glass coatings on Ti6Al4V were produced by using an enamelling technique. A sedimentation 
method was used to deposit bioactive glass onto the Ti6Al4V alloy. 9.43 g of the selected glass 
powder (particle size <38 µm) was dispersed in 25 ml of ethanol by stirring thoroughly. A Ti6Al4V 
plate (5×5×1 mm), which had been previously polished with 1 µm diamond paper and cleaned in 
ethanol, was placed into the glass powder suspension. This was left in an oven at 80°C for 1.5 h so 
that the glass powders were deposited on the metal substrate, to produce a uniform surface. After 
confirming that the glass powder was totally settled, the specimen was introduced into a porcelain 
furnace (Centurion Quartz, Dentsply Ceramco, York, PA, USA) that was pre-heated to 250°C. The 
furnace was heated at a rate of 60°C min−1 to 750°C followed by a 30 min hold at this temperature. 
This entire heating process was performed at -90 kPa vacuum (Figure3.2). 
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Figure 3.2: Schematic representation of the enamelling process. 
3.2.3.2 Plasma Spraying Technique 
The plasma-sprayed coatings were produced by Plasma Biotal Ltd, UK using a standard procedure 
and similar conditions to those used for plasma spraying HA. The complete process included grit-
blasting with alumina powder (14 µm) before coating the plates. 0%, 10% and 50% strontium 
bioactive glass powders (particle size <38 µm) were used to produce the plasma-sprayed coatings.  
Electrode
Water cooling
Ti alloy  plate
Powder
Plasma gas delivery
Flame
Powder delivery
 
 
Figure 3.3 : Schematic representation of the plasma-sprayed technique adapted from (218). 
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The BG powders were fed into the plasma flame separately, where the temperature was on the order 
of 10,000K; the powder was melted into the flame and propelled towards a substrate. The molten 
droplets flattened, rapidly solidified and formed a deposit on the surface of the Ti6Al4V plates 
(Figure 3.3). Unfortunately, parameters such as plasma gas composition and flow rate, energy input, 
torch offset distance and substrate cooling temperature were not forthcoming from the company. 
3.2.4 Bioactive Glass Characterisation 
The synthesised BG was analysed to understand how different percentages of strontium and 
phosphate content affect the glass properties and structure. Different techniques were used including 
X-ray diffraction, differential scanning calorimetry and scanning electron microscopy. 
3.2.4.1 X-Ray Diffraction  
X-ray diffraction (XRD) is a non-destructive technique that reveals detailed information about the 
chemical phases present and crystallographic structure of materials. The principle of this technique is 
based on the fact when X-ray radiation is incided on a material, the radiation interacts with the 
electrons in the atoms, resulting in scattering of the radiation. In crystalline solids, atoms are 
organized in a structure based on planes of atoms. XRD patterns for each glass powder were 
determined using a diffractometer (Philips PW1700 series Automated Powder Diffractometer) and 
(PANanlytical X'Pert Pro MPD). Cu-Kα radiation (0.154056 nm) at 40 kV / 40 mA was used. The 
diffraction pattern was taken in the 2θ range of 10º to 80º with a step size of 0.04º. Under the same 
conditions XRD was done for the coatings on the Ti substrate. 
3.2.4.2 Particle Size Analysis  
The glass powder, sieved through a 38 µm sieve, was characterised using a particle size analyser 
(PSA, CILAS 1064). The measurements were performed by immersing one spatula of powder in 
deionised water with a drop of a multipurpose detergent TEEPOL as a dispersive agent. The 
measurements were obtained using the Particle Expert software and were performed three times to 
obtain average values. The particle sizes of the glass powder present in the solution at 10%, 50% and 
90% of the distribution curve were obtained. 
3.2.4.3 Fourier Transform Infrared Spectroscopy 
An infrared spectrum represents a fingerprint of a sample with absorption peaks which correspond to 
the frequencies of vibrations between the bonds of the atoms making up the material. Because each 
different material has a certain unique combination of atoms and bonding, no two compounds will 
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produce the same infrared spectrum. Infrared is only adsorbed by covalent bonds with a dipole 
moment, but then each bond will vibrate at a specific wavenumber. Powders were analysed using 
Fourier-transform infrared spectroscopy (FTIR, Perkin-Elmer Spectrum GX). Data were collected 
from 1600 to 500 cm_1 with a spectral resolution of 4 cm−1. The analysis was performed directly on 
the <38 µm sample powders and collected powders after bioactivity study. 
 
3.2.4.4 Magic Angle Spinning - Nuclear Magnetic Resonance Spectroscopy 
Magic Angle Spinning Nuclear Magnetic Resonance (MAS-NMR) is used to study the response of 
the nuclei of specific atoms under high magnetic field (several Tesla) when a second electromagnetic 
field is applied. The nuclear magnetic resonance frequency of the nuclei depends on its electronic 
environment and is compared with the frequency of a reference sample, specific for each atom. The 
difference, called chemical shift, is sensitive to short and medium range order of the atoms. Therefore 
it is very useful for studying the structure of amorphous materials. The change in chemical shift 
determines the Qn proportions as well as the influence of the charge balancing cations in the vicinity 
of the studied atom. 29Si and 31P Magic Angle Spinning - Nuclear Magnetic Resonance (MAS-NMR) 
was used to analyse the different glass samples. The measurements were run on a 200 MHz Bruker 
FT-NMR spectrometer operating at the Larmor frequencies of 39.8MHz and 81.0MHz for the 29Si and 
31P respectively. Powdered samples were packed into a 4 mm zirconia rotor and spun at the magic 
angle to remove anisotropy effects. The 29Si and 31P MAS NMR spectra of the glasses were recorded 
at spinning frequencies from 4-7 kHz using π/2 pulse for both silicon and phosphorus nuclei. The 29Si 
and 31P NMR measurements were done using 30 s and 120 s recycle delays, respectively, with initial 
dummy scans. All spectra were recorded at an ambient probe temperature with 29Si chemical shift 
referenced relative to tetrakis trimethylsilyl methane (C(Si(CH3)3)4) as a secondary standard material, 
which gives a signal at -1.5 ppm relative TMS. 85% (v/v) H3PO4 solution was used for referencing the 
31P chemical shift. 
3.2.4.5 Density Measurements 
Densities of the glass samples were measured using Archimedes’ principle. Glass rods of 20 mm 
diameter were used, which were free from bubbles during the casting process. The measurements 
were performed at room temperature and distilled water used as the immersion fluid. The weights of 
glass rod samples in air and in distilled water were measured using a balance with an accuracy of ±0.1 
mg. In order to minimise the sources of error the weight of samples were measured three times and an 
average was taken. The samples density was calculated using Equation 3.1:  
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Equation 3.1: Equation for the density measurement. 
Where: Md is the mass of dry glass, Mi is the mass of immersed glass and ρw is the density of water at 
the measurement temperature (ρw (23oC) = 0.9975 g.cm−3). All of the cast samples were fully wetted 
when immersed in the distilled water. The measurements were taken three times for each sample to 
get an accurate value. 
3.2.4.6 Oxygen Density 
The compactness of the glass network was estimated by calculating the oxygen density. The mass of 
oxygen from the molar composition is divided by the volume of the glass, which is given by the 
experimental density to calculate the oxygen density. 
3.2.4.7 Differential Scanning Calorimetry 
50 mg of each glass sample powder was put in an inert platinum crucible and was analysed by 
differential scanning calorimetry (DSC) using analytical grade alumina powder as a reference 
material. The experiments were carried out in air, using a Stanton-Redcroft DSC 1500 (PL Thermal 
Sciences, Epsom, UK) at a constant heating rate of 10 °C min−1 up to a maximum temperature of 
1050°C. The Tg, Tp and To values were determined for each glass. The processing window was 
calculated as the difference between To and Tg. The tendency of the glasses to undergo surface 
nucleation was determined by performing DSC runs using two particle sizes: frit particles (approx. 1–
2 mm) and fine powder (<38 µm). Activation energies for crystallisation, Ea(Tp), were determined 
using the method outlined by Marotta et al. (219). The basis of the method is shown in Equation 3.2:  
 
Equation 3.2: Equation used for calculating activation energies. 
Where: β is the reciprocal of the heating rate, Ea is the activation energy of the process, Tp is the 
crystallisation peak temperature, R is the universal gas constant (8.314 JK−1 mol−1), and C is a 
constant. The activation energy can be obtained from linear interpolation if ln(β) is plotted against 
1/Tp for varying heating rates (1/β). Five DSC heating rates of 5, 10, 15, 20 and 25 ºC min−1 were 
used for the analysis. The gradient of the line of best fit (m in y=mx+c) is equal to Ea/R. The 
activation energies for the onset temperature for crystallisation and the glass transition temperature 
(which is often correlated with that for viscous flow) were calculated in a similar manner. The 
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activation energy plots were extrapolated to ln(β)=0 (i.e., the y-axis intercept), which corresponds to a 
heating rate of 1°C min−1, to obtain values for the glass transition temperature and the onset 
temperature for crystallisation at a heating rate of 1°C min−1. These values are important because 
during the isothermal sintering temperature of the coatings the heating rate is 0°C min−1, and these 
values can be used to select the most appropriate sintering/processing temperatures. The value of the 
activation energy for viscous flow is important as it gives a measure of the ability of the glass to flow 
during sintering. The lower this value the easier the glass will be expected to undergo viscous flow 
sintering. In contrast, the activation energy for the onset temperature of crystallisation gives a measure 
of the energy barrier to crystallisation, and a high value is preferred. 
3.2.4.8 Dilatometry 
The thermal expansion coefficients for produced glasses were measured in a calibrated dilatometer 
(Netzch GmbH). The 25 mm long glass bar samples were analysed between 20°C and 700°C at a rate 
of 10°C/min. TEC values were determined using the system software. This value will be referred to as 
experimental TEC. In order to compare the theoretical values of the thermal expansion coefficient 
with experimental ones, Appen factors given in Equation 3.3 were used. This value will be referred to 
as calculated TEC.  
 
Equation 3.3: Anderson equation for calculating TEC (203). 
 
Where: X is the value of the TEC, ai is the Appen’s factor for each constituent and  Ci   is the 
concentration (in mole%) of each constituent present (202). Appen factors for components in the 
glasses studied are given in the appendix (Table A.1) (220).  
3.2.4.9 Scanning Electron Microscopy and Energy Dispersive X-Ray Spectroscopy 
Fusibility of the glass, appearance of the coatings and adherence of the coatings to the alloy were 
analysed using a scanning electron microscope (JEOL 5610, Jeol Ltd., UK) at 15 kV with associated 
energy dispersive spectroscopy analysis (SEM-EDS). In order to look into the cross-section of the 
fabricated glass coating, the glass-coated alloy mounted in a resin was ground at the cross-section 
with 1200 grit SiC paper and polished with a 1 µm diamond suspension. Line scans were performed 
for each glass cross-section sample with SEM-EDS. Line-scan data were normalised by dividing the 
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measurements by the average of each element. Diffusion coefficients were calculated from a least 
squares fit of this complementary error-function (erfc) by Equation 3.4: 
 
         
Equation 3.4: Equation for calculating diffusion coefficient. 
Where: N is the concentration of the element in question at distance x after time t from the 
concentration at x=0 (N0). 
3.2.5 Evaluation of Ion Release Profiles from Bioactive Glasses 
Dissolution studies were carried out on the Sr series and their fabricated coatings and also on 
phosphate series I glass series. 75 mg of <38 µm glass powder or corresponding fabricated glass 
coating were immersed in 50 and 16 ml  respectively in solution (Tris-buffer or simulated body fluid 
(SBF)) at pH 7.25. The soaked materials were placed in an orbital shaker incubator (New Brunswick 
Scientific C24 Incubator) at a constant temperature of 37°C  for time periods of 0.5, 1, 2, 7, 14, 21 and 
28 days. After removing the samples from the shaker the pH was measured using a pH meter (Oakton 
Instruments, NL). The fabricated coatings or glass powders were both withdrawn from the solution 
then the solution was filtered through medium porosity filter paper (5 µm particle retention, VWR 
International). Acetone was sprayed on the collected powder or fabricated coatings to stop any further 
reaction. The solutions were filtered (0.2 µm cellulose acetate syringe filters, Anachem, UK) and kept 
at 4 °C. Samples were diluted by a factor 1:10 (for analysis of silicon (Si), calcium (Ca), strontium 
(Sr), phosphorus (P), magnesium (Mg) and zinc (Zn)) and quantitatively analysed by inductively 
coupled plasma-optical emission spectroscopy (ICP-OES) (iCAP 6000, Thermo Scientific, Waltham, 
MA, USA) each sample read in triplicate. 
3.2.5.1 Tris Buffer Preparation 
In order to prepare the Tris buffer the following standard procedure from USBiomaterials Corporation 
(SOP-006) was used. A graduated flask was filled with 400 ml of deionised (DI) water then put on a 
water bath set at 37°C. 7.545g of Tris (hydroxymethyl) aminomethane was transferred slowly into the 
flask. The mixture was stirred till the contents dissolved completely. Once the Tris dissolved, 22.1 ml 
of 2N HCl was added and the pH of the solution was adjusted to 7.40 ± 0.1. The flask was then 
topped up to 1 litter with DI water and adjusted to pH 7.40. The solution was transferred into a 
polyethylene container and stored in a refrigerator (4°C). Since the pH of Tris buffer is temperature 
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sensitive (pH = 7.4 at 37°C increases to pH = 7.6 at 25°C) all the testing solution temperatures were 
controlled to be at 37°C. 
3.2.5.2 Simulated Body Fluid Preparation 
The simulated body fluid (SBF) solution emulates the ionic concentration of human blood plasma. 
Immersion of bioactive glass powders in SBF initiates a series of reactions that result in the formation 
of a HCA layer on the surface (221). 
The preparation of simulated body fluid was carried out according to the method proposed by Kokubo 
et al. (150;222) and also ISO 23317 (223). 700 ml of DI water was poured into a plastic container 
with smooth surface and without any scratches with a magnetic stirrer on a hot plate and heated to 
37°C. The reagents shown in Table 3.4 were added sequentially, in the order shown, into the water. 
After the addition of each reagent, sufficient mixing was allowed to ensure that it was completely 
dissolved. Following the last addition, the solution was made up to 900 ml and the pH was checked 
and adjusted to pH 7.40 with 1 N HCl. Solution in the beaker was then topped to 1 litter and the pH 
adjusted to 7.40 once again. The solution was stored in a refrigerator in polyethylene bottles for no 
longer than 1 month. Prior to use, the solution was heated to 37°C in a water bath. 
 
Table 3.4: Reagents for the preparation of SBF, adapted from (222). 
Order Reagent Amount
1 NaCl 8.035 g
2 NaHCO3 0.355 g
3 KCl 0.225 g
4 K2HPO4.3H2O 0.231 g
5 MgCl2.6H2O 0.311 g
6 1N HCL 39 ml
7 CaCl2.2H2O 0.292 g
8 Na2SO4 0.072 g
9 Tris 6.118 g
10 1N HCl 0-5 ml
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3.3 Results   
The results separated into two sections: the characterisation of strontium-substituted BG series is 
discussed first, followed by the phosphate series Ι BG series. 
 
Part I: Characterisation of Strontium-Substituted Bioactive Glasses and 
their Coatings on Ti6Al4V 
3.3.1 Structural Analysis 
3.3.1.1 X-Ray Diffraction  
All compositions were obtained in a glassy state with the amorphous structure being confirmed by 
XRD (Figure 3.4). The maximum in the amorphous scattering shifts to smaller 2θ values with 
increasing strontium substitution. 
 
 
Figure 3.4: X-ray diffraction patterns of the Sr series after quenching, drying and milling; curves were 
smoothed by five point adjacent average smoothing. 
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3.3.1.2 Particle Size Analysis  
Particle size distribution values are shown in Table 3.5. Mean diameter and 50% diameter differ 
considerably which suggests that the particle size distribution is non-Gaussian. The 50% particle size 
distribution for 50% strontium-substituted glass was around 2.7 µm, which is in agreement with the 
SEM micrograph of 50% Sr glass powder presented in Figure 3.24a. It can be seen that the glass 
particles are angular with relatively sharp edges. 
 
Table 3.5: Particle size distribution values, mean and standard deviation for 0%, 10% and 50% Sr glass 
particles. 
0%Sr Test 1 Test 2 Test 3 Average SD
D 10 (µm) 0.69 0.68 0.68 0.68 0.01
D 50 (µm) 2.62 2.859 2.49 2.66 0.19
D 90 (µm) 16.98 18.24 18.07 17.76 0.68
Mean (µm) 6.15 6.42 6.43 6.33 0.16
10%Sr Test 1 Test 2 Test 3 Average SD
D 10 (µm) 0.66 0.64 0.65 0.65 0.01
D 50 (µm) 2.76 2.69 2.61 2.69 0.08
D 90 (µm) 17.92 16.74 15.77 16.81 1.08
Mean (µm) 6.25 5.85 5.63 5.91 0.31
50%Sr Test 1 Test 2 Test 3 Average SD
D 10 (µm) 0.7 0.68 0.7 0.69 0.01
D 50 (µm) 2.82 2.63 2.7 2.72 0.10
D 90 (µm) 17.89 17.72 18.09 17.90 0.19
Mean (µm) 6.63 6.74 6.44 6.60 0.15
 
 
3.3.1.3 Fourier Transform Infrared Spectroscopy  
FTIR spectra for unreacted 0, 10 and 50% Sr glasses showed that these glasses have almost similar 
spectra (Figure 3.5). The location of the FTIR spectra and optical modes of the Si-O-Si groups will be 
disscussed in section (3.4). 
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Figure 3.5: Fourier transform infrared spectra of the unreacted 0%, 10% and 50% Sr glasses. 
 
3.3.1.4 Magic Angle Spinning Nuclear Magnetic Resonance  
Figure 3.6a presents 31P MAS-NMR spectra of the Sr glass series. The 31P MAS-NMR spectra for this 
series revealed single broad peak positioned between 3 and 4 ppm. The position of the 31P MAS-NMR 
peak does not change gradually with increase in Sr content. For the Sr series glasses with low Sr 
substitution the position of the peak remains at about 3.4 ppm, whereas for the glasses with high Sr 
fraction the peak position is at slightly higher chemical shift value, about 4.2 ppm. 31P MAS-NMR 
spectra were deconvoluted using dmfit software (224) and the results of the deconvolution show that 
the amount of the pyrophosphate changes slightly within the strontium-substituted series (Table 3.6). 
The 29Si MAS-NMR spectra for the Sr series of glasses are given in Figure 3.6b. All three spectra 
show single broad and slightly asymmetric peak at a constant position about -83 ppm.  
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Figure 3.6: MAS-NMR spectra of the Sr series, (a) 31P MAS-NMR spectra, (b) 29Si MAS-NMR spectra. 
 
Table 3.6: The proportion of Q1 determined from peak deconvolution of 31P MAS-NMR spectra of 
strontium series. 
0%Sr 10%Sr 50%Sr 75%Sr 100%Sr
Q1 fraction (%) 10.3 9.1 11 10.5 11.6
 
 
 
Chapter 3: Strontium-Substituted and High-Phosphate Strontium-Containing Bioactive Glasses for 
Coating on Medical Metallic Implants – Structure and Properties 
81 
 
3.3.1.5 Density 
Density analysis can be used to study the character and degree of structural changes in glasses. The 
density of the Sr series glass increased from 2.84 g.cm−3 for 0% Sr glass to 3.34 g.cm−3 for the 100% 
strontium-substituted glass (Figure 3.7). 
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Figure 3.7: Density measurement of the Sr series as a function of the strontium content (mol %). 
 
Figure 3.8 shows the effect of varying Sr content on the oxygen density. The oxygen density decreases 
with Sr substitution.  
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Figure 3.8: Variation in oxygen density with strontium content for Sr series. 
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3.3.2 Thermal Analysis 
3.3.2.1 The Influence of Heating Rate on DSC Traces  
DSC traces of all the glasses exhibited peak crystallisation temperatures that shifted to higher 
temperatures with increasing heating rates, shown in Figure 3.9 for glass 100% Sr. It can be seen that 
Tg becomes more prononuced by increasing heating rates. Furthermore, it was found that for all the 
glasses in the Sr series there is one Tg and one Tc temperatures.  
 
Figure 3.9: DSC traces of glass 100% Sr in different heating rates. 
 
3.3.2.2 The Influence of Particle Sizes on DSC Traces  
DSC traces of all the glasses exhibited peak crystallisation temperatures that shifted to higher 
temperatures with increasing particle size, shown in Figure 3.10 for glass 50% Sr.  
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Figure 3.10: DSC traces of glass 50% Sr for fine particles (<38 µm) and frit (about 1–2 mm) at a heating 
rate of 10 °C min−1. 
 
3.3.2.3 The Effect of Substitution Strontium for Calcium on Processing Window  
Table 3.7 summarises the DSC results; extrapolated Tg values show a very slight general decrease 
with increasing strontium substitution (Figure 3.11a) from 605°C (0% Sr) to 588°C (100% Sr). 
Crystallisation onset temperatures (Figure 3.11a) decrease from 809°C (0% Sr) to 758 °C (100% Sr); 
however, the reduction is not linear. To is approximately constant for the 0% Sr and the 50% Sr 
glasses but reduces significantly for the 100% Sr glass to 758°C. 
 
Table 3.7: Summary of DSC results for Sr series (Ea: activation energy; To–Tg: processing window; Tg0 
and To0 are extrapolated values; error is ±5°C). 
Glasses Tg0 (ºC)
Ea (Tg)
To0  (ºC)
Ea (To) Ea (Tp)
To-Tg ( ºC)(KJmol-1) (KJmol-1) (KJmol-1)
0% Sr 605 -370 809 -346 -344 204
10% Sr 596 -400 812 -307 -349 216
25% Sr 606 -439 808 -259 -269 201
50% Sr 590 -329 807 -246 -233 217
75% Sr 572 -340 793 -245 -300 221
100% Sr 588 -325 758 -208 -281 171
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Processing windows (Figure 3.11b) are between 200 and 221°C for all compositions apart from glass 
100% Sr, which gave a processing window of 171°C. The processing window seems to increase for 
glasses with 0, 10, 50 and 75% strontium substitution and then decreases for 100% Sr glass.  
 
 
 
Figure 3.11: (a) Extrapolated values Tg0 and To0 and (b) processing window vs. strontium substitution for 
calcium (in %). The error is less than the size of the symbols. (Lines are drawn as a guide to the eye.) 
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3.3.2.4 The Effect of Substitution Strontium for Calcium on Activation Energies  
Tg, Tp and To were plotted in an analogous fashion (plots for 75% Sr glass was shown in Figure A.1, 
appendix). From the slopes of the straight lines, activation energies (Ea) for glass transition, onset 
crystallisation and crystallisation temperatures were calculated (Figure 3.12). 
The activation energy for Tg rises from 370 kJ mol−1 (0% Sr) to 439 kJ mol−1 (25% Sr) and then falls 
down to 325 kJ mol−1 (100%Sr) with increasing strontium content. Activation energy for To decreased 
from 346 kJ mol−1 (0% Sr) to 208 kJ mol−1 (100% Sr), and activation energy for Tp decreases from 
344 kJ mol−1 (0% Sr) to 281 kJ mol−1 (100% Sr).  
 
Figure 3.12: Ea for Tg, To and Tp vs. strontium substitution for calcium content (in %). The error is less 
than the size of the symbols. (Lines are drawn as a guide to the eye.) 
 
3.3.2.5 Dilatometry 
 Figure 3.13 compares the experimental and calculated TEC values obtained from dilatometry and 
Appen factors (Equation 3.3), respectively. Both experimental and calculated TEC values increase 
with addition of Sr content of the glasses in the Sr-substituted glass series.  
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Figure 3.13: Comparison of measured TEC values with those calculated using Appen’s factors for 
strontium-substituted glass series. 
3.3.3 Ion Release Profile and Glass Dissolution Behavior  
3.3.3.1 Effect of Increasing Strontium Content on pH Measurement  
The pH changes in SBF solution for the Sr-substituted BG series are shown in Figure 3.14. The pH 
increases with time for all the glasses. The Sr-substituted BGs showed a pH rise from about 7.39 (the 
initial pH of the SBF) to up to 7.77 over 21 days.  
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Figure 3.14: pH variation in SBF solution after immersion of glass powder for Sr-substituted BG series 
for up to 21 days. (Lines are drawn as a guide to the eye.) 
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3.3.3.2  Effect of Increasing Strontium Content on BG Ion Release Profile in Tris Buffer  
The dissolution behaviour of calcium, phosphorus, silicon, strontium and zinc ions released from Sr-
substituted BG series into Tris buffer in ppm are plotted as a function of time for 28 days (Figure 3.15 
a-e). The concentration of all these ions increased with time. The strontium release increases from the 
lowest strontium-containing glass to the highest strontium glass; compositions with a higher Sr mol% 
release more strontium ions into solution (Figure 3.15 d). The amount of strontium released is directly 
proportional to the strontium content of the glass at all the time points studied. The calcium ion 
concentration increases at the lowest strontium substitution (Figure 3.15 a). The glass compositions of 
Sr-substituted BG series have a constant 49.96 mol% of SiO2 in the glass and they all show a similar 
soluble silica release pattern (Figure 3.15 c). 
The P2O5 content is the same (1.07 mol %) for all the glasses in the Sr-substituted BG series. From the 
ICP results (Figure 3.15 b) it can be seen that the phosphorus concentration follows the same trend for 
these glasses and that all glasses in this series release the same amount of phosphate. Figure 3.15 e 
shows that strontium and non-strontium containing glasses release same amount of Zn2+.  
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Figure 3.15: Concentration of the different cations in Tris buffer as determined by ICP-OES as a function 
of time after incubation of glass powder from Sr-substituted BG series for up to 28 days; (a) Ca2+ 
concentration; (b) PO4 -3 concentration; (c) soluble silica concentration; (d) Sr2+ concentration and (e) 
Zn2+ concentration. 
 
In order to evaluate the data from Tris buffer and determine the ratio of the released ions, the 
concentration of ions in Tris was calculated by assuming that the glass was completely dissolved 
(Table 3.8). By comparing the calculated values from Table 3.8 with ion release profile in Tris (Figure 
3.15 e) it is clear that less than 10% of the available Zn2+ is released. 
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Table 3.8: Ion concentration for strontium series in Tris, assuming that glass completely dissolves (values 
in ppm). 
Glass                                  Ca2+ Sr2+ Soluble 
silica PO4
3- Zn2+
0%Sr 325 0 349 16 49
10%Sr 285 69 340 16 48
50%Sr 144 315 309 15 43
 
3.3.3.3 Effect of Increasing Strontium Content on BG Ion Release Profile in SBF Solution 
Ion release profiles of the Sr-substituted BGs in SBF solution were analysed by ICP-OES (Figure 3.16 
a-d). 
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Figure 3.16: Concentration of the different cations in SBF sulution as determined by ICP-OES as a 
function of time after incubation of glass powder from Sr-substituted BG series for up to 28 days; (a) Ca2+ 
concentration; (b) PO4 -3 concentration; (c) soluble silica concentration; (d) Sr2+ concentration. 
 
Soluble silica concentration in the solution increases steadily for the first seven days of immersion for 
all glasses, but plateaus afterwards (Figure 3.16 c). The time point at which the solution is saturated 
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with soluble silica occurs when a silica gel precipitates on the surface of the glass, which correlates 
with phosphate loss from the SBF and the presumed formation of a calcium/strontium phosphate layer 
on the surface of the glass and is thought to aid nucleation of apatite. The glasses in this series have 
similar amount of P2O5 content. So phosphate ions from the SBF are used during formation of apatite 
(Figure 3.16 b). 
Ca2+ concentration in SBF decreases with increasing strontium content (Figure 3.16 a), which can be 
explained by calcium ions being used up during formation of apatite and strontium. The concentration 
of Sr2+ is dependent on BG composition with increasing strontium substitution resulting in higher Sr2+ 
concentrations (Figure 3.16 d), the same pattern as we saw for Tris buffer.  
The experimental concentration of phosphorus in SBF before adding glass particles is 24.96 ± 0.1 
mg/l (Figure 3.16 b) and the calculated value is 31.41 mg/l. This discrepancy might be caused by 
precipitation of apatite in SBF, although no precipitate was noticeable. Also, hydration of chemicals 
during storage used for preparation of SBF could have resulted in lower actual concentrations in the 
solution. 
3.3.4 Characterisation of the Surface Precipitated Layers  
3.3.4.1 Fourier Transform Infrared Spectroscopy 
FTIR spectra of 50% Sr glass before and after immersion in SBF for different time points is 
shown in Figure 3.17. The bands for untreated glass powders were mostly due to Si-O 
vibrational modes (explained at section 3.2.4.3). After immersion of 50% Sr glass in SBF all 
spectra showed the following changes: the band arising from NBO at 910 cm-1 became broader 
and the Si-O-Si stretch band became sharp at 1030 cm-1. These changes indicate formation of a 
silica-gel surface layer after leaching of Ca2+ and Na+ ions and formation of Si–OH. After 28 
days of immersion in SBF the phosphate band around 550 cm-1 appears as a single band. 
However, here is no clear evidence of splitting of the phosphate band in the FTIR spectrum of 
this glass. There is a vibration around 1650 cm-1 corresponds to carbonate, something typical in 
biomimetic apatites. 
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Figure 3.17: FTIR spectra of unreacted 50% Sr glass (bottom) and after immersion in SBF for 7, 14 and 
28 days.  
In order to compare the rate of bioactivity of the Sr-substituted BG series, the FTIR spectra of the 
glasses that were soaked in SBF for 28 days were plotted as shown in Figure 3.18. At day 28 the 
phosphate peak at 550 cm-1 is clearer for 50% Sr glass in comparison with the 0 and 10% Sr glass.  
 
Figure 3.18: FTIR spectra of Sr-substituted BG series at 28 days immersion in SBF. 
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3.3.4.2 X-Ray Diffraction  
Figure 3.19 shows the 50% Sr glass before and after immersion in SBF at different time points. All 
experimental XRD patterns were compared to reference patterns of carbonated hydroxyapatite 
(JCPDS 19-272) and calcium carbonate (JCPDS 05-586). As seen previously, the non-reacted 50% Sr 
glass is completely amorphous. In the seven days spectrum, the small peaks at 2θ = 29° and 31° 
indicate the presence of calcite (calcium carbonate). These peaks tend to become sharper with time in 
SBF and at day 28 two peaks at 47° and 56° 2θ (JCPDS 05-586), also related to calcite, can be 
noticed. There is no obvious HCA peak formed for 50% Sr glass. Overall, the intensity of the XRD 
traces of 50% Sr glass are matched with calcite and no obvious evidence of HCA formation was 
found.  
no SBF
28 days
7 days
XRD 50% Sr glass
 
Figure 3.19: XRD patterns of unreacted 50% Sr glass (bottom) and after immersion in SBF for 7 and 28 
days. 
 
3.3.5 Characterisation of Strontium-Substituted BG Coatings on Ti6Al4V 
3.3.5.1 X-Ray Diffraction on Enamelled Coatings  
The XRD patterns of the coatings sintered at 750°C for 30 min are shown in Figure 3.20a, and they 
confirm that the coatings (except for 100% Sr) are amorphous. There is a small diffraction peak at 
2θ=38° for 10%, 25% and 50% strontium-substituted glasses, but this corresponds to a diffraction line 
in the Ti6Al4V alloy and arises from the fact that X-rays are diffracted from the alloy substrate 
beneath the glass coating, probably due to these coatings being slightly thinner than the others. XRD 
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of the 100% Sr coating sintered at 800°C for 0.5 h showed it to be highly crystalline (Figure 3.20b). 
However, the crystal phases formed did not match any known crystalline phase. We therefore heat-
treated glass powder (0% Sr, 50% Sr and 100% Sr) at 900°C and performed X-ray diffraction. Figure 
3.21 shows the XRD patterns of the heat-treated glass powders at 900°C; crystal phases are 
wollastonite (CaSiO3, JCPDS 27-0088; 0% Sr) and strontium silicate (SrSiO3, JCPDS 34-0099; 100% 
Sr). The peaks of the 50% Sr composition did not match any known crystal phases, but are similar to 
those for 100% Sr (strontium silicate) but shifted to higher 2θ values on the x axis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: X-ray diffraction patterns of (a) Sr containing bioactive glass coatings on Ti6Al4V alloy and 
uncoated Ti6Al4V alloy as control (sample 10% Sr was run using an increased count rate per step; all 
curves were smoothed by five point adjacent average smoothing) and (b) a bottom surface of delaminated 
piece of 100% Sr coating heat-treated at 800°C.  
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XRD patterns of glass powders heat treated at 900°C correspond to wollastonite (calcium silicate, 
CaSiO3, glass 0% Sr) and strontium silicate (SrSiO3, glass 100% Sr). The pattern given by heat-
treated 50% Sr powder is most likely to be a mixed calcium strontium silicate, where the differences 
in ionic radii of Sr2+ and Ca2+ caused a shift in peak positions in XRD patterns compared to that of 
SrSiO3 (100% Sr glass).  
 
 
Figure 3.21: X-ray diffraction patterns of glass powder 0% Sr, 50% Sr and 100% Sr heat-treated at 
900°C. Crystal phases are × wollastonite (CaSiO3) and + strontium silicate (SrSiO3). 
 
Furthermore, XRD was carried out on the glass coatings after immersion in SBF to characterise the 
surface precipitated layer. The XRD patterns of the 50% Sr glass coating before and after SBF 
immersion are shown in Figure 3.22. The reference patterns of carbonated hydroxyapatite (JCPDS 19-
272) and calcium carbonate (JCPDS 05-586) were used to compare with experimental XRD results. 
The diffraction lines at 2θ = 38°, 40° and 53° on day seven diffracted from the Ti alloy. The position 
of the amorphous halo has shifted as compared to in the unreacted glass. At 28 days in SBF the peaks 
at 29°, 31°, 32° and 47° 2θ (JCPDS 05-586) indicate the presence of calcium carbonate, which is 
consistent with the carbonate formation from the glass powder immersed in SBF (Figure 3.19). 
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Figure 3.22: XRD patterns of Ti alloy (bottom) and 50% Sr glass coating before and after immersion in 
SBF for seven and 28 days. 
 
3.3.5.2 X-Ray Diffraction on Plasma-Sprayed Coatings 
In order to determine if the coatings produced by plasma-sprayed technique were amorphous XRD 
was carried out on 0%, 10% and 50% strontium coatings. The absence of sharp peaks in Figure 3.23 
confirms that the coatings prepared did not contain crystalline structures. The amorphous scattering is 
more intense for the highest Sr content glass.  
 
Figure 3.23: XRD patterns for 0%, 50% and 100% strontium coatings using a plasma spraying 
technique; curves were smoothed by five point adjacent average smoothing. 
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3.3.5.3 Scanning Electron Microscopy on Enamelled Coatings  
SEM investigation of the 50% Sr coatings after sintering showed that they contained few pores and 
little evidence was found of any remnants of the original glass particles (Figure 3.24b). In addition, no 
cracks were observed on the surface of the coating sintered at 750°C. It can be seen that the surface of 
the 100% Sr coating (Figure 3.24c and d) contains pores and bubbles; at a low magnification several 
cracks were observed (Figure 3.24c). SEM results (back-scattered electron mode) presented in Figure 
3.25 show cross-sections of 50% Sr and 100% Sr glass coatings on Ti alloy fired at 750°C: A 120 µm 
thick glass coating can be seen to be well attached to the Ti6Al4V substrate for the 50% Sr glass, 
whereas a gap and cracks are clearly observed between 100% Sr glass and the Ti alloy substrate. 
Delamination of the 100% Sr coating occurred readily. 
 
 
Figure 3.24: SEM micrograph (secondary electron mode) of (a) 50% Sr glass powder, (b) 50% Sr-coated 
surface produced by enamelling, (c),(d) 100% Sr coating: (c) overview with crack and pores and (d) 
bubbles and pores at higher magnification. 
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Figure 3.25: SEM images (back-scattered electrons) of cross-sections of (a) 50% Sr and (b) 100% Sr 
coatings on Ti alloy. 
 
An elemental line scan was performed along the 50% Sr glass coating and the results indicate that the 
coating was homogeneous as the elemental concentrations remained constant throughout the scan 
(Figure 3.26). Figure 3.27 illustrates a line scan performed across the Ti alloy/glass interface: The 
results show sigmoidal curves of decreasing Ti, Al and V concentrations and sigmoidal curves of 
increasing concentrations for the elements comprising the glass composition over a distance of 5 to 10 
µm, as expected. Calculated diffusion coefficients are shown in Table 3.9. 
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Figure 3.26: Line-scan profile of 50% strontium-substituted glass coating. 
 
 
Figure 3.27: Line-scan profile across the interface between Ti alloy and 50% Sr glass coating produced by 
enamelling technique: (a), (b) SEM micrograph of area of scan and (c) normalised element 
concentrations. 
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Table 3.9: Diffusion coefficients for 50% Sr glass coated onto Ti6Al4V. 
Element D (× 10-15 m2s-1)
Glass
Si 6.49
Na 2.74
K 3.09
Ca 3.85
Sr 0.9
Mg 1.94
Zn 2.01
P 0.99
O 9.36
Metal
Ti 8.69
V 9.72
Al 5.79
 
3.3.5.4 Scanning Electron Microscopy on Plasma-Sprayed Coatings  
Figure 3.28 shows the typical surface morphologies of the plasma-sprayed 0%, 10% and 50% 
strontium coatings as deposited. Some of the molten BG droplets have kept their spherical shape 
however others have a flat structure and particles are on top of each other; pores also are clearly 
visible. The surface of the 10% strontium coating is smoother than those of the other coatings. This 
morphology is typical for the coatings which are made by thermal spraying technique. This 
microstructure may also be beneficial for promoting chemical reactions and cell growth in a 
biological environment. 
 
Figure 3.28: SEM micrographs of (a) 0% Sr, (b) 10% Sr and (c) 50% Sr coatings on Ti alloy produced by 
plasma spraying. 
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The cross-sections of the plasma-spraying coatings are presented in Figure 3.29. Porosity is evident in 
the PS coatings and all coatings exhibit a porous structure. The coatings have thicknesses ranging 
between 200 and 400 µm, but it is not easy to make an exact measurement because of the roughness 
of the material. 
 
Figure 3.29: SEM images of polished cross-sections of (a) 0%Sr, (b) 10%Sr and (c) 50%Sr coatings on Ti 
alloy produced by plasma spraying. 
 
The line scan for the 50% Sr glass coating which was produced by Plasma Biotal Ltd is shown in 
Figure 3.30. This coating does not show the sigmoidal diffusion profile as does the enamelling 
technique.  
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Figure 3.30: Line-scan profile across the interface between Ti-alloy and 50% Sr glass coating produced 
by plasma spraying: (a), (b) SEM micrograph of area of scan and (c) normalised element concentrations. 
 
3.4 Discussion 
3.4.1 Characterisation of Glasses 
Upon introduction of strontium into the glasses, the maximum of the amorphous halo in XRD patterns 
was found to shift progressively to smaller 2θ values (i.e., larger d-spacing) with increasing strontium 
substitution, which indicates an expansion of the glass network on incorporation of strontium. 
Fredholm et al. (225) found a similar result with strontium-substituted bioactive glass compositions 
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 along with a reduction in oxygen density and an increase in molar volume of the glass. The Sr2+ 
cation is slightly larger than Ca2+ cation (1.16 Å for Sr2+ and 0.94 Å for Ca2+), which results in it 
attracting nonbridging oxygen atoms less, which is thought to result in the expansion of the glass 
network. Furthermore, Xiang et al. studied the effect of Sr substitution on the structure of 45S5 
Bioglass® using molecular dynamic stimulations and found that the Sr-O bond distance is around 2.59 
Å (226) whereas the modelling based on Neutron and X-ray diffraction results showed the Ca-O bond 
length was 2.31 Å (227). So, Xiang et al. also reported the expansion of the glass network with 
SrO/CaO substitution (226). 
FTIR Spectroscopy identifies types of chemical bonding within a structure, therefore can be used for 
examine the nature of the bonds within the silicate-based bioactive glasses. The FTIR spectra for 
silicate-based bioactive glasses are characterised by two transverse optical modes of the Si-O-Si 
groups (228-231): 
• The bending Si-O(b) vibration is found in the region of 700 to 800 cm−1 
• The stretching mode Si-O(s) located in the range 1000 - 1200 cm−1 
Additionally, FTIR spectroscopy is very precise in recognising vibrations associated with NBO and 
silicon interactions (Si-O-NBO bonding) (229): 
• The Si-O(s) with one NBO per SiO4 tetrahedron (Q3 groups) is located in the range of 1020-
1052 cm-1   
• The Si-O(s) with two NBOs per SiO4 tetrahedron (Q2 groups) is located in the range of 920-
960 cm-1  
Knowing this data allows us to assign the peaks of Sr-substituted glasses in Figure 3.5. It is worth to 
mention that fully quantitative analysis cannot be done by FTIR. Since the produced glasses are multi-
component so there are different types of nonbridging species (made with sodium, strontium, calcium, 
potassium or magnesium ions) which cannot be distinguished. In fact the stretching mode and bending 
modes will have different intensities and frequencies as a function of the local environment and the 
nature of charge balancing cations. However having nearly similar spectra for 0, 10 and 50% Sr 
glasses (Figure 3.5) suggests that there are the same number of Si-O bonds and the same proportion of 
Qn species in each glass. This information confirms that 10 and 50% Sr-substituted glasses have same 
structure and network connectivity as well as 0% Sr glass. This is in agreement with the Fredholm et 
al. studies which showed that addition of Sr to silica network of BG did not change the FTIR spectra 
and all the glasses presented identical FTIR spectra (225). 
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The single broad peak positioned between 3 and 4 ppm (Figure 3.6a) in the 31P MAS-NMR spectra is 
due to orthophosphate species charge balanced by the available cations, Ca2+, Sr2+, Na+, K+, etc. 
Although the 31P NMR peak remains broad and shape of it does not change within the Sr series, it is 
clearly noticeable that the peak is not completely symmetric and there is some intensity on the right 
hand side of the peak. We assume that this is due to a small fraction of pyrophosphate present in all 
glasses. The peak at the position about -83 ppm which was found at 29Si MAS-NMR (Figure 3.6b) is 
assigned to a mixture of Q2 and Q3 silicon species, with the Q2 being predominant. This result 
indicates that silicon speciation in the network does not change with strontium substituting for 
calcium.  
According to the density data (Figure 3.7) Sr substitution increases the density since Sr is heavier than 
Ca (with atomic weight of 87.62 and 40.07 g mol-1, respectively). This is in agreement with the 
studies which has been shown that replacing Sr with Ca increases the density (225;226).  
Oxygen density is a measure of the compactness of the glass network. With increasing Sr substitution 
the oxygen density decreases (Figure 3.8), which indicates that the glass network expands and 
becomes less compact with increasing strontium content. This expansion is a result of the larger 
strontium cations attracting non-bridging oxygens less readily in comparison with the slightly smaller 
calcium cations (232), as confirmed with XRD results also. 
The DSC traces of all the glasses exhibited peak crystallisation temperatures that shifted to higher 
temperatures with increasing particle size, which indicates a surface induced nucleation process. This 
phenomenon appears to be a characteristic of bioactive glasses. It has been observed in a number of 
previous studies (165;233) and is related to the particle size effects on heat transfer (234). 
All glasses in Sr-substituted glass series show a processing window significantly increased compared 
to Bioglass® 45S5 (Figure 3.1). This increase overcomes the main drawback of the 45S5 glass for the 
sintering above Tg without some crystallisation occurring by conventional enamelling techniques. The 
wide processing window in our series increases slightly with increasing strontium substitution for 
calcium, but decreases by over 50°C for the 100% strontium-substituted glass, largely as a result in 
the reduction in To. We should therefore expect 100% Sr glass to be the least easy to sinter without 
crystallisation occurring. 
Extrapolated Tg values show a slight general decrease with increasing strontium substitution. 
Similarly, activation energy for Tg decreases with increasing strontium content. The activation energy 
for the glass transition temperature is often associated with that for viscous flow; a lower value is 
therefore likely to give rise to more efficient sintering for a given particle size distribution. 
Extrapolated To values decrease with increasing strontium content, and activation energies for both To 
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and Tp show a slight overall decrease with increasing strontium substitution. There are probably two 
factors influencing these results: On substituting Sr for Ca the glass network will become weaker, and 
it would be expected that the glass would be able to rearrange to the crystalline state more readily as a 
result. Opposing this is that incorporating Sr into an all Ca glass would be expected to increase the 
entropy of mixing and stabilise the disordered glass state. We would therefore expect the 100% 
strontium-substituted glass to crystallise more readily than any of the other glasses and to exhibit the 
lowest activation energies for Tg, To and Tp. Our results show that this glass, indeed, crystallises at a 
significantly lower temperature than the other glasses and gives the smallest processing window. 
As discussed before, TEC mismatch between the glass and Ti6Al4V generates high thermal stresses, 
which result in interfacial cracks and a poor coating adhesion, which causes delamination during 
fabrication. Therefore, TEC is the prime factor that needs to be considered for bioactive glasses that 
are used for metallic implant coatings. Using dilatometry enabled us to measure the TEC of produced 
glasses. Gomez-Vega et al. (192;235) and Bloyer et al. (236) have noted previously the importance of 
matching the TEC of BGs in order to use them as implant coatings.  
Here, the experimental TEC increases by addition of strontium content of the glasses (Figure 3.13). 
This finding is parallel with the XRD and oxygen density results confirming the expansion of the 
glass network. The less rigidly cross-linked glass network makes the glass expand more on heating. 
There is a fair agreement between the calculated and experimental values of TEC because the lines 
are approximately parallel to each other. However, there is a gap between the measured and the 
calculated TEC. This might be attributed to the fact that Appen factors are based on soda-lime-silicate 
glasses whereas the produced glass compositions are complicated and multicomponent.  
The bioactivity of a glass is closely related to its solubility. Dissolution properties can therefore be 
used to determine the influence of glass composition on bioactivity. In general it is accepted that (both 
in vitro and in vivo) the formation of an apatite layer in body fluids helps attachment of osteoblasts on 
bioactive glasses via proteins and thus enables bonding to bone (146). Degradation experiments of 
BGs in buffered solutions such as Tris buffer can give us insight into glass dissolution, pH changes 
and apatite formation. 
Soda-lime phosphosilicate-based bioactive glasses, such as 45S5 Bioglass® are famous to lead a pH 
rise in aqueous solutions upon immersion (181). The Sr-substituted BGs in this work clearly showed a 
pH rise within the first 24 h of immersion in SBF solution (Figure 3.14). At the latest time point (21 
days in SBF) with increasing Sr content the pH change increases more quickly and to a greater extent, 
which can be explained on the basis of the more weakly bonded network and a more expanded 
network because of the substitution of Sr with Ca.  
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The effect of Sr2+on the dissolution behaviour of BGs has been studied experimentally. There are 
contradictory results of the effect of Sr substitution with Ca on the dissolution of glasses reported in 
the literature. For example, one study reported that the glass dissolution rate of Sr containing silica 
based glasses (SiO2 – CaO – P2O5 – SrO) derived from the sol-gel process is reduced while 
transformation of apatite phase at the surface has a higher rate (237). Whereas, another study on the 
strontium-containing phosphate glasses (Na2O – CaO – P2O5) found that glass degradation and 
dissolution are accelerated by addition of strontium (238). The discrepancies in the results from 
different laboratories on the effect of Sr on the glass dissolution may explained by the usage of weight 
or molar basis while glasses are designed (239). Since substituting Sr with Ca in weight percentages 
results in increasing of the NC which retards the glass dissolution. In general, Sr substitution in 
silicate glasses is believed to increase the glass dissolution rate (239). In the present study, the 
increased release of strontium from the lowest strontium containing glass to the highest strontium 
glass was observed in Tris buffer and SBF solution (Figure 3.15 and Figure 3.16). Furthermore, the 
dissolution of the Sr-substituted BG series in Tris buffer clearly showed that Zn2+ release was limited 
(Figure 3.15 e) and less than 10% of the Zn2+ is released (Table 3.8). One possible explanation would 
be Zn2+ acts as an intermediate oxide. If this is the case, a cross-linked network will be formed and 
this does not let Zn2+ release from the glass readily.  
Depend on the application of the BGs HCA formation can be desirable or undesirable. For example 
HCA formation is an advantage for bone regeneration application while it is considered disadvantage 
for cartilage tissue engineering or wound healing process. Ion release in SBF is one way to 
characterise the bioactivity of glasses and is used to monitor the ability of the glasses to form a HCA.  
The initial ionic concentration of SBF solution is similar to the human blood plasma and it differs 
from a Tris buffer. The HCA forming ability of the produced Sr-substituted BGs was assessed using 
the SBF test (222;223). It is worth to mention that there are some controversies regarding to the usage 
of SBF test for BGs to predict the HCA formation (239;240). 
According to the FTIR spectra of the Sr-substituted BGs after immersion in SBF solution there is no 
clear evidence of splitting of the phosphate band up to 28 days (Figure 3.17 and Figure 3.18) which 
suggests that no formation of a crystalline HCA layer. The phosphate band around 550 cm-1 for 50% 
Sr glass appears as a single band after incubation in SBF at day 28 (Figure 3.18). Jones et al. showed 
that the presence of a single band at 560 cm-1 suggests the existence of non-apatitic or amorphous 
calcium phosphate (ACP) (241). ACP is generally considered as a precursor to hydroxyapatite. Most 
of the bands present in any spectrum of 50% Sr glass are broad and consequently undistinctive. This 
fact can be explained by the one to one ratio of CaO and SrO in this glass composition. The mixture 
of Ca2+ and Sr2+ ions forms a solid solution owing to their similar lattice parameters. As a result, the 
ions exchange readily with each other; they keep disordering the structure, thereby continuously 
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disrupting the network. Therefore, it would be very difficult to detect any chemical bonds vividly 
using FTIR. This disorder may also lead to broadening of the phosphate vibrational modes and the 
loss of the characteristic splitting band of apatite.  
In agreement with FTIR data, XRD patterns for 50% Sr glass after soaking in SBF (Figure 3.19) and 
other Sr-substituted BGs (results not shown) did not show obvious evidence of HCA formation. It is 
worth to pointing out that several studies has been shown that the presence of Zn retards the glass 
degradation (242) and slows down the HCA formation (181). Therefore, Zn causes a reduction in ion 
leaching and reduces the bioactivity of the glasses which may explain the low bioactivity of Sr-
substituted BG series. Additionally, it has been suggested that when Mg2+ content in the BG 
composition is increased the Mg2+ ions block the active sites of calcium phosphate nucleation and 
results in delaying of calcium phosphate layer precipitation (243). Furthermore, Hesaraki et al. studied 
the effect of Sr in the bioactivity of sol-gel derived glasses based on CaO – SrO – SiO2 – P2O5 system 
and reported that substituting 10 mol% of SrO for CaO delayed the formation of apatite layer (244).  
Furthermore, the dissolution data discussed above may suggest that Zn2+ acts as an intermediate oxide 
results in an increase in the network connectivity and reduces the bioactivity of the glasses studied. It 
is important to point out that the glasses studied in the present study are multicomponent, therefore the 
reduced bioactivity may be the result of one or several ions, either alone or in combination.  
3.4.2 Characterisation of Strontium-Substituted BG Coatings on Ti6Al4V 
3.4.2.1 Enamelling Technique 
According to the DSC results, of all the compositions studied the 100% strontium- substituted glass 
should be the most difficult to sinter without crystallisation occurring. The sintering temperature of 
750°C is very close to the crystallisation onset of the glass 100% Sr (753°C). However, lowering the 
temperature of sintering of the 100% Sr glass resulted in an opaque white but amorphous coating that 
had not sintered fully and scattered light as a result of a significantly high residual porosity in the 
coating (results not shown). XRD patterns of the coatings sintered at 750°C for 30 min showed a 
typical amorphous halo except for that of the 100% Sr glass, which presented crystalline peaks and an 
amorphous halo (Figure 3.20 a). Due to the small number and low intensity of the peaks, these peaks 
were difficult to assign to a crystal phase. The delaminated 100% Sr coating was therefore heat-
treated at 800 -°C for 30 min; XRD showed it to be highly crystalline (Figure 3.20 b). However, the 
diffraction pattern did not match any known crystal phase, even if presence of elements from the alloy 
(titanium, aluminium or vanadium) was considered. This pattern might be caused by the fact that the 
peaks are shifted slightly, most likely a result of the non-stoichiometry of the interfacial region or of 
formation of mixed cation phases in this multicomponent system. 
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SEM micrographs of 50% Sr sintered coatings show that the thermal expansion of glass and Ti-alloy 
is well matched with coating (Figure 3.25 a) and that the viscous flow sintering process has occurred 
efficiently. Glass with 100% Sr, on the other hand, is less suitable for coating using an enamelling 
technique due to the smaller processing window than the other glasses in the series, as shown in 
section 3.3.2.3. This smaller window results in partial crystallisation of the coating as well as poor 
adhesion and delamination (Figure 3.25 b). Indentation testing was not carried out but would be one 
possibility for further study, as a relatively inexpensive way of examining adhesion between the metal 
prosthesis and BG coatings (201).  
The elemental line scan across the Ti-alloy/glass interface shows sigmoidal curves of decreasing Ti, 
Al and V concentrations and increasing concentrations of the elements comprising the glass 
composition (Figure 3.27 c). A sigmoidal curve represents a classical diffusion profile in both alloy 
and glass composition: Diffusion rates of the alloy species (Ti, Al and V) dropping off to zero around 
5 to 10 µm into the coating. This can be reduced further by reducing the sintering temperature and/or 
time. 
SEM and XRD characterisation of the enamelling coatings confirmed a coherent interface between 
Ti6Al4V and glass, with no obvious crystallisation at the interface, and no Al, Ti or V was detected in 
the glass away from the interfacial region. There were very few pores or bubbles in the sintered 
coatings, which indicates that the sintering was efficient. 
3.4.2.2 Plasma-sprayed Technique 
Similar to the XRD results obtained for enamelling technique, XRD patterns from plasma-sprayed 
coatings (0, 10 and 50% Sr glass) indicated their amorphous nature (Figure 3.23). However, it should 
be noted that the plasma-sprayed coatings did not show the same degree of interdiffusion of ions 
(Figure 3.30 c) compared with enamelled coatings. The plasma-spraying technique is a fast splat-
quenching method so there is not enough time for diffusing ions (245). This method results in lower 
rates of diffusion of Ti, Al and V from the Ti alloy into the glass. Also the alloy was grit-blasted 
before spraying and this makes the interface between coating and alloy rough. So, calculating 
diffusion coefficients for coatings which are produced by plasma spraying cannot give us further 
details. 
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Part ΙΙ: Characterization of Phosphate Series Ι  
All the results presented in this section relate to the phosphate series Ι. As mentioned in the glass 
synthesis section, only NMR results for phosphate series ΙI are shown here, for comparison with 
phosphate series Ι. 
3.4.3 Structural Analysis   
3.4.3.1 X-Ray Diffraction  
The XRD spectra showed that glasses in phosphate series Ι contains a broad glassy amorphous halo in 
the range 25–35 (2θ) and free of any significant crystalline phases (Figure 3.31).  
 
Figure 3.31: X-ray diffraction patterns of phosphate series Ι after quenching, drying and milling; curves 
were smoothed by five point adjacent average smoothing. An XRD patterns for 1.07P glass has been 
shown in Figure 3.4.  
 
3.4.3.2 Fourier Transform Infrared Spectroscopy  
Figure 3.33 shows FTIR spectra of unreacted phosphate series Ι. The peaks for the unreacted glass 
powder were mostly attributed to Si-O (Q2) vibrational modes at the range of 900 to 940 cm-1 and the 
peak at 1000 cm-1 is related to Si-O-Si stretching vibrations. The peak which is in the range of 900 to 
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940 cm-1 becomes clearer as we move through the series and phosphorus is added (from bottom to 
top). 
 
Figure 3.32: FTIR spectra of unreacted phosphate series Ι. 
 
3.4.3.3 Magic Angle Spinning Nuclear Magnetic Resonance  
The 31P and 29Si MAS-NMR spectra for phosphate series Ι and phosphate series ΙΙ are presented in 
Figure 3.33 and Figure 3.34, respectively. Similar to the glasses of the Sr series (Figure 3.6a), only a 
single broad peak that corresponds to the predominant orthophosphate species Q0 is seen. The position 
of the peak does not change with constant Sr substitution. The phosphate series Ι shows the 
corresponding signal at 3.4 ppm. The peak is observed in the phosphate series ΙΙ at the slightly higher 
chemical shift of 4 ppm. The deconvolution of the single broad peak showed that there is a small 
fraction of the pyrophosphate species, Q1. The results of the estimated Q1 fractions for phosphate 
series I and II are given in Table 3.10. The data show that pyrophosphate fraction has a tendency to 
decrease in glasses with higher P2O5 content in both phosphate series Ι and ΙΙ. 
The 29Si MAS-NMR spectra for the phosphate series Ι and phosphate series ΙΙ are shown in Figure 
3.34bFigure 3.35b, respectively. Unlike the 31P MAS-NMR results, no changes are observed in the 
29Si MAS-NMR spectra. All the signals arise from the mixture of Q2 and Q3 species which remains 
the same within a wide range of phosphate variation.  
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Figure 3.33: MAS-NMR spectra of the phosphate series Ι, (a) 31P MAS-NMR spectra, (b) 29Si MAS-NMR 
spectra. 
 
Figure 3.34: MAS-NMR spectra of the phosphate series ΙΙ, (a) 31P MAS-NMR spectra, (b) 29Si MAS-NMR 
spectra. 
 
Table 3.10: The proportion of Q1 determined from peak deconvolution of 31P MAS-NMR spectra of 
phosphate series I and II. 
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3.4.4 Density 
Figure 3.35  and Figure 3.36 show the effect of addition of P2O5 in phosphate series Ι glasses on the 
density and oxygen density respectively. It is obvious both values increase with phosphate content.  
 
 
Figure 3.35: Density measurement of the phosphate series I as a function of the phosphate content 
(mol%). 
 
Figure 3.36: Variation in oxygen density with phosphate content for phosphate series I. 
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3.4.5 Thermal Analysis 
3.4.5.1 The Influence of Increasing P2O5 Content on Processing Window  
DSC traces of phosphate series Ι exhibited two glass transition temperatures. Neither the first or 
second glass transition temperatures
 
changed significantly with increasing P2O5 content. All activation 
energies in this glass series were calculated based on the second Tg and it will be referred to as Tg (2). 
Tg (2) is coupled with the sintering effect. Peak crystallisation temperatures shifted to higher 
temperatures with increasing P2O5 content with the exception of the highest P2O5 content glass (6.24 
mol% P2O5), shown in Figure 3.37.  
 
Figure 3.37: The effect of varying P2O5 content on Tg and Tc (heating rate is 20°Cmin-1). 
 
Table 3.11 summarises the DSC results. The extrapolated Tg (2) values are at the similar range 
between 675 to 689. The values decrease linearly for glasses with 2.14, 4.28 and 6.42 mol% P2O5 
content. The extrapolated To values decrease for phosphate series Ι glasses (Figure 3.38). 
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Table 3.11: Summary of DSC results for phosphate series Ι (Tg(2)0 and To0 are extrapolated values; error 
is ±5°C). 
Glasses Tg(2)0 (ºC)
Ea (Tg(2)) To0  (ºC)
Ea (To) Ea (Tp) To-Tg ( ºC)(KJmol-1) (KJmol-1) (KJmol-1)
10% Sr- 1.07 P     675 -276 804 -334 -276 129
10% Sr- 2.14 P     689 -315 799 -263 -333 110
10% Sr- 4.28 P     688 -420 808 -285 -308 120
10% Sr- 6.42 P     679 -228 774 -340 -527 95
 
 
Processing windows are between 95 and 129°C for all compositions in this glass series. The highest 
P2O5 containing glass shows the lowest processing window, which is mostly related to the lower onset 
crystallisation temperature of this glass. 
 
 
Figure 3.38: Extrapolated values Tg(2)0 and To0 of phosphate series Ι. The error is less than the size of the 
symbols. The error is less than the size of the symbols. (Lines are drawn as a guide to the eye.) 
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3.4.5.2 Dilatometry 
Figure 3.39 compares the TEC values calculated using Appen factors (Equation 3.3) for the 
phosphate series I with those determined experimentally. The results indicates that as P2O5 is 
added, a TEC of the phosphate series I glasses increases.  
 
Figure 3.39: Comparison of measured TEC values with those calculated using Appen’s factors for 
phosphate series Ι. 
 
3.4.6 Ion Release Profile and Glass Dissolution Behavior  
3.4.6.1 Effect of Increasing Phosphate Content on pH Measurement 
In order to understand how glass composition has an effect on pH and apatite formation, as this 
information would enable us to design BGs for specific applications, the variation in pH with time for 
phosphate series I after immersion in SBF solution was measured (Figure 3.40). The pH of SBF 
solution shifts towards acidity as the P2O5 content of the glasses is increased. 
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Figure 3.40: pH variation in SBF solution after immersion of glass powder for glasses with increasing 
phosphate content (phosphate series Ι) for up to 21 days. (Lines are drawn as a guide to the eye.) 
 
 
 
 
3.4.6.2 Effect of Increasing Phosphate Content on BG Ion Release Profile in Tris Buffer 
Figure 3.41 shows ionic concentrations of different cations in Tris buffer after immersion of glass 
powder of glasses with increasing phosphate content for 28 days. The patterns of release of Ca2+, Sr2+ 
ang Mg2+ in Tris are similar for all glasses in this series.  
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Figure 3.41: Concentration of the different cations in Tris buffer as determined by ICP-OES as a function 
of time after incubation of glass powder of the phosphate series Ι for up to 28 days; (a) Ca2+ 
concentration; (b) PO4-3 concentration; (c) Sr2+ concentration; (d) soluble silica concentration; (e) Mg2+ 
concentration and (f) Zn2+ concentration. 
 
With increased phosphate content up to 4.28 mol% the release of calcium in Tris increases. The glass 
with low phosphate content releases less phosphate than the higher phosphate-content glass. 
Interestingly the 4.28 phosphate content glass releases a greater amount of Sr2+, Ca2+and Mg2+ in Tris 
than other glasses in this series (Figure 3.41 a, c, e); however the ion concentration of phosphate does 
drop after day seven in Tris for this glass. Initial soluble silica release is faster and more in glasses 
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with higher amount of P2O5 content (Figure 3.41 d). The glasses with low phosphate content (1.07P 
and 2.14P) release higher amount of Zn2+ compared with higher phosphate-content glasses (Figure 
3.41 f). 
In order to understand why 4.28 phosphate-content glass behaves differently we have done the 
following calculations. 
The ion concentration of phosphate series Ι was calculated, by assuming that all glass dissolves in Tris 
(Table 3.12). Based on the theoretical values by increasing the phosphate content of the glass the 
release of Sr2+ and Ca2+ is expected to increase. But the ICP data for 4.28P phosphate content glass 
(Figure 3.41 a, c) shows a greater release of Sr2+ and Ca2+.  
 
Table 3.12: Ion concentration of phosphate series Ι in Tris assuming glass completely dissolves (values in 
ppm). 
Glass                                  PO43- Ca2+ Sr2+ Zn2+ Mg2+
10%Sr-1.07P 16 285 69 48 43
10%Sr-2.14P 30 286 77 48 43
10%Sr-4.28P 55 290 78 48 43
10%Sr-6.42P 75 293 79 49 44
 
 
The released fraction of Sr2+ in Tris was plotted against phosphate content (Figure 3.42). Increasing 
P2O5 content of the glasses accelerates release of Sr2+ ions. This result suggests that phosphate phase 
contains Sr and dissolves faster than the silicate phase, i.e., dissolution and bioactivity are dominated 
by phosphate. However, there is a reduction in the Sr2+ fraction of 6.42 phosphate-containing glass at 
all different time points (Figure 3.42). Similar plots for Ca2+ and Mg2+ were observed for this glass 
(not shown). Figure 3.43 shows that there is a reduction in the fraction of phosphate released from 
4.28 phosphate-containing glass. This data suggest that 4.28 phosphate-containing glass precipitates 
more apatite compare with other glasses in the phosphate series I.  
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Figure 3.42: The fraction of strontium released from phosphate series Ι vs. phosphate content in Tris 
buffer at different time points. 
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Figure 3.43: The fraction of phosphate released from phosphate series Ι vs. P2O5 content of glasses  in 
Tris buffer at different time points (Lines are drawn as a guide to the eye). 
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Moreover, the correlation between the fraction of Sr2+ and Ca2+ in Tris was plotted (Figure 3.44). 
From the correlation data (R2=0.997) and the slope of the line (equal to 0.992) it can be concluded 
that Ca2+ and Sr2+ behave identically (dissolve and precipitate together).  
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Figure 3.44: Plot of fraction of Sr2+ in Tris as compared to Ca2+ in Tris. 
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Figure 3.45: The Zn2+ ion release as a function of square root of time for the phosphate series I glasses 
after immersion in Tris buffer. 
 
Figure 3.45 shows that increasing P2O5 content reduces Zn2+ release. 
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3.4.7 Characterisation of the Surface Precipitated Layers  
3.4.7.1 Fourier Transform Infrared Spectroscopy  
The FTIR spectra for the phosphate series I showed significant changes after immersion in SBF for 1 
day or longer in comparison to the spectrum of unreacted glass (shown in Figure 3.46 for 4.28 P 
glass). The Si–O bending vibration reappears at ≈ 800 cm-1 which, compared to the unreacted glasses, 
is at higher wavenumber; this shows that some degree of repolymerisation has occurred. This change 
indicates condensation of the silica gel formed in the SBF. Serra et al. showed that with increased 
silica content, from 44 to 66 wt%, this band shifted to higher wavenumber in bioactive glass samples 
(230). On exposure to SBF, intensity of the vibrations from the silicate glass network reduces and 
bands related to the crystalline hydroxyl-carbonate apatite become dominant. Especially, the P–O 
bend and P–O stretch at around 550 and 1010 cm-1 sharpen and increase intensity, respectively 
(214;246). 
 
Figure 3.46: FTIR spectra of unreacted 4.28P glass (bottom) and after immersion in SBF for 1, 7 and 28 
days. 
From Figure 3.46 it can be seen that after SBF immersion the spectrum shows either a single peak at 
approximately 560 cm-1or a split peak in the most characteristic region for apatite at 560 and 600 cm-1. 
This result relates to P–O bonding vibrations in a PO43- tetrahedron and indicates the presence of 
crystalline calcium phosphates including HA and HCA (247).  
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Figure 3.47 shows that the intensity of the splitting of the P-O bend becomes sharp as the phosphate 
content of the glass increases up to 4.28 mol%. After immersion in SBF, a C-O stretch (v2) around 
860 cm-1 and C–O asymmetric stretching (v3) at 1410 and 1450 cm-1 indicative of carbonate 
formation, provide evidence for formation of crystalline HCA (241).  
 
Figure 3.47: FTIR spectra of phosphate series Ι at 28 days immersion in SBF. 
 
3.4.7.2 X-Ray Diffraction  
Figure 3.48 shows XRD traces of selected glass (4.28P) from phosphate series Ι before SBF treatment 
and at different time points after immersion in the SBF. XRD patterns demonstrated that after the SBF 
soaking, the intensity of broad hump of amorphous peak increases with time. Reference patterns 
including carbonated hydroxyapatite (JCPDS 19-272), calcium carbonate (JCPDS 05-586) and 
hydroxyapatite (JCPDS 09-432) were used to compare with the experimental data. However, as these 
patterns overlap, the hydroxyapatite pattern will be referred to in the following. The peaks at 2θ = 26°, 
28°, 32° , 39° and 53° indicate presence of apatite (JCPDS 09-432). These peaks are superimposed on 
an amorphous halo. As opposed to with the unreacted glass, the formation of Bragg peaks associated 
with apatite crystallisation can be seen with progressing time. The peaks become clearly pronounced 
at 28 days; however, the lines remain very broad, which hints at the highly disordered character and 
the small size of the crystals. The amorphous Si peak grows, which suggests that a silica-gel layer 
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forms and the glass degrades. Formation of Bragg peaks related to apatite after 28 days is consistent 
with the presence of characteristic apatite spectra in FTIR for this glass (Figure 3.47). 
 
Figure 3.48: XRD patterns of unreacted 4.28P glass (bottom) and after immersion in SBF for 7, 14 and 28 
days. 
 
XRD patterns for phosphate series Ι after 28 days immersion in SBF are shown in Figure 3.49. With 
increasing phosphate content of the glasses the peaks related to apatite become clear in the spectra. 
For 4.28P glass the peak intensity for hydroxyapatite is higher than that of the other glasses in this 
series. This result is due to the fact that high P2O5 content glass (6.42P) causes significant pH 
decrease, reducing more hydroxyapatite formation.  
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Figure 3.49: XRD patterns for phosphate series Ι glasses after 28 days immersion in SBF, with increasing 
phosphate content from bottom to top. 
 
3.4.7.3  31P Magic Angle Spinning Nuclear Magnetic Resonance  
The 31P MAS-NMR study on glasses after the SBF treatment versus the initial glasses is presented in 
Figure 3.50 (a-d). The bottom spectra in each figure are for the initial glass powder before soaking. In 
all compositions a relatively broad signal is observed after the treatment in SBF. The position of the 
signal in all the spectra is at about 3-3.5 ppm which is quite close to the position of the calcium 
apatite, and amorphous calcium phosphate. However, since the signal from the original glass occurs at 
nearly the same position it is problematic to distinguish the signal from the initial glass and the signal 
formed from the new species formed on soaking, if any exists. It is certainly noticeable that the 
asymmetry on the right-hand side of the peaks in the initial glasses disappears in the samples after 
soaking. This observation could be explained by easier dissolution of the pyrophosphate species 
compared to the orthophosphate. The 31P MAS-NMR signal from 4.28P sample is noticeably different 
from the other glasses after immersion in SBF. The spectrum is composed of contributions from two 
species, at about 4.2 ppm and 10 ppm. Both signals are quite sharp which speaks for the higher 
crystallinity of these species versus all other signals observed in the spectra. However, the assignment 
of these signals is quite problematic due to poor signal-to-noise of the spectra which originates from 
the small amount of the sample available for running the experiment. If the sharp feature at 4.2 ppm is 
close to the substituted apatite, the smaller feature at 10 ppm is probably associated with a significant 
amount of sodium and potassium cations. Both sodium and potassium orthophosphates have a very 
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high chemical shift compared to that of the other phosphates (14 Na and 11 K). No more details on 
this assignment can be given. 
 
 
Figure 3.50:31P MAS-NMR spectra of the phosphate series Ι glasses before and after 7,14 and 28 days in 
SBF, (a) 1.07P, (b) 2.14P, (c) 4.28P and (d) 6.42P. 
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3.5 Discussion 
XRD spectra confirmed that by increasing up to 6.42 mol% P2O5 content the amorphous nature of 
phosphate series I glasses did not change (Figure 3.31). The 31P MAS-NMR spectra for phosphate 
series I and II glasses (Figure 3.34 and Figure 3.35) clearly illustrated a single broad peak centred on 
chemical shift values associated with an orthophosphate species Q0, providing direct evidence of the 
existence of phosphorus within such an environment, rather than the conventional view of 
phosphorous entering the silicate network. Recently Tilocca et al. (162-164) simulated the structure of 
bioactive glasses using molecular dynamics modelling and emphasised the importance of the 
fragmented and discontinuous nature of the silicate network. They also looked at the structural role of 
phosphate and found evidence that glasses with greater than 5 mol% P2O5 exhibit amorphous phase 
separation into a silica rich and phosphate rich phase (164). This separation was confirmed by 31P 
MAS-NMR spectra experiments, which showed an orthophosphate phase for all phosphate contents 
when NC <2.5 (162-164). 
Furthermore, deconvolution of the single broad peak showed the existence of small fraction of 
pyrophosphate specious Q1 with the remaining majority of orthophosphate type species Q0 for both 
phosphate series I and II glasses (Table 3.10). This finding is in agreement with FitzGerald et al. 
MAS-NMR studies which have been reported that  a small fraction of pyrophosphate species coexist 
with the majority of orthophosphate species in 45S5 Bioglass® (227). In the present study, the amount 
of pyrophosphate fraction is found to be small and can be neglectable. Therefore, within each 
phosphate series all the spectra show similar pattern confirming that incorporating phosphate has a 
minimal affect on the silicate network condensation (248). 
The 29Si MAS-NMR spectra reveal that no changes observed in the mixture of Q2 and Q3 species as 
the phosphate content of the glasses is increased. This explains the fact that as P2O5 is added through 
the series, charge balancing ions such as Na+, Ca2+ and K+ are also added to compensating the charges 
of orthophosphate type species. By adding charge balancing ions there would not be a need for the 
modifiers to be removed from their role in silicate network. Therefore, this particular result from 
NMR confirms that the NC of glasses remains the same even though the phosphorus content in the 
glasses was varied. The glasses were designed in such a way as to provide enough cations to charge-
balancing increasing amounts of phosphorus as orthophosphate.  
According to the FTIR spectra (Figure 3.33), all the glasses in phosphate series I show the peaks 
associated with Q3 and Q2. There is no obvious change of the peaks associated with Q2 and Q3 silicate 
species by increasing the P2O5 content of the glasses. This is parallel with NMR data which confirmed 
that as P2O5 is added into the series the silicate network polymerisation does not change. Watts et al. 
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studied the effect of substitution phosphate in the structure of BGs in two series of glasses, in the SiO2 
– Na2O – CaO – P2O5 system (215;249). In the first series phosphate was added to replace SiO2 and 
the ratio of Ca to Na was kept constant. In the second series phosphate was added to the glass and 
sufficient modifier was added to charge balance the orthophosphate species. The FTIR data showed 
that there is an evolution of the peak related to Q3 species as phosphate is added whereas, this affect 
did not see for second series (249). Also, NMR data from her studies confirmed that no change in Q 
structure of the silicate network.  
As the density of phosphate series I glasses increase with P2O5 content (Figure 3.35), it may indicate 
the presence of a higher density component in the glasses such as an amorphous orthophosphate and 
pyrophosphate. As mentioned previously, NMR results confirmed the presence of Q0 and Q1 for 
glasses in the phosphate series I. Similar to this finding O’Donnell et al. reported that the addition of 
P2O5 to the BGs in the system SiO2 – Na2O – CaO – P2O5  (charge balanced series) increases the 
density of the glasses (250). 
Furthermore, oxygen density increases as P2O5 content goes higher (Figure 3.36), this may explain 
due to the higher density of the orthophosphate phase. It would be expected a linear relationship 
between oxygen density and P2O5 content of the glasses in this series, but from the Figure 3.36 it can 
be seen that the plot tend to be curved shape. As we add P2O5 we are adding more ZnO to charge 
balance it whilst in fact it is not acting to charge balance it but acts as an intermediate. The NC drifts 
upwards with P2O5 content which could cause the curvature to the oxygen density plot. 
DSC results showed that these glasses in phosphate series I contain two Tg values (Figure 3.37). One 
of the values is related to the silica rich phase and the other one is related to the phosphate rich phase 
of the glass (251). The NMR data, which was discussed earlier, supports the hypothesis that there are 
two phases in these glass series. DSC results showed that Tp increases with P2O5 addition, however 
there is a decrease in crystallization temperature for the highest phosphate content glass (6.42 P). This 
may explain by the fact that as phosphate content is increased the size of the phosphate phase 
increases. Consequently, the phosphate phase increases the surface area of heterogeneous nucleation 
sites (phosphate droplets) which aids the nucleation event and crystallisation. This phenomenon is 
illustrated in Figure 3.51. 
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Figure 3.51: Schematic representation of low and high P2O5 content glass, in the high P2O5 content glass 
the small droplets of phosphorus phase combined together and create large droplets of phosphate which 
makes the glass readily crystallisable. 
 
The experimental TEC values obtained by dilatometry showed relatively good match to calculated 
values (Figure 3.39). Dilatometry is known to be governed considerably by the dominant matrix phase 
of a glass (250). From the NMR and DSC results, we know that there are two separate phases in the 
phosphate series I. With P2O5 addition, the amount of separate phosphate phase increases which 
results in increase to the dimensions of phosphate phase to contribute to the TEC of the glasses. The 
mentioned results suggest that as P2O5 content increases the amount of weaker P-O bonds increases 
compared to the strong Si-O bonds and consequently the glass expand more with temperature rise.   
To understand the details of dissolution behaviour of phosphate series I, the pH changes in SBF 
solution were measured after different time periods represented in Figure 3.40. There is a greater 
reduction in pH for the highest P2O5 content glass. The release of more phosphate from the highest 
P2O5 content glass may buffer the alkalinity caused by the release of ions such as calcium and sodium. 
It has been shown that the optimal pH for apatite deposition in physiological fluid is about 7.3 (252), 
therefore the decrease in pH may be advantage for bioactivity. However, the highest phosphate 
content glass in the current study (6.42P) did not precipitate apatite as much as 4.28P glass (data will 
be discussed later, Figure 3.43) as an indication of more bioactivity. 
Dissolution study performed on the phosphate series I glasses demonstrated that the high phosphate 
content glass (6.42P) does not release more Ca2+, Sr2+ and phosphate. This may explained by a slight 
increase in NC as a result of an increase in MgO and ZnO. We have assumed that ZnO and MgO are 
network modifiers and charge balance PO43-. This assumption is probably incorrect and MgO and 
ZnO may act partially as intermediate oxides and serve to increase the NC slightly. Another 
explanation is that there is a change in microstructure of the 6.42P phosphate-containing glass relative 
to that of the others. Perhaps it was quenched faster and the droplet size is smaller.  
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Moreover, higher phosphate content glasses (4.28P and 6.42P) released a much smaller fraction of 
Zn2+ in Tris buffer, which also dropped with time (Figure 3.45). This may suggest that Zn-O-P bonds 
form in the glass, i.e. P5+ locally charge balances a ZnO4-2 and more Zn-O-P bonds form with 
increasing P2O5. Even by NMR it is difficult to prove these Zn-O-P bonds because of 
multicomponency of the glass system studied. Additionally, if there are some Zn-O-P linkages the 
amount would hardly change from composition to composition due to nearly constant Zn2+content. 
FTIR spectra on phosphate series I glasses after immersion in SBF provide evidence for formation of 
crystalline HCA (Figure 3.47). In agreement with FTIR data, XRD patterns also showed the peaks 
related to apatite after soaking in SBF (Figure 3.49). O’Donnell et al. showed that the formation of 
apatite occurs more rapidly in high phosphate-containing glasses, however the apatite formed was 
quite disordered even after 28 days (215). The reason why our produced glasses form apatite slowly is 
because these glasses are multicomponent. As discussed earlier the presence of Mg2+ and Zn2+ in the 
BG significantly delays the formation of a HCA layer (181;242;243). 
Furthermore, 6.28 phosphate-containing glass showed less phosphate precipitation in compare with 
4.28P glass (Figure 3.43) and also the reduced pH increase of 6.42P glass (Figure 3.40) compared to 
other glasses in phosphate series I fits with its reduced apatite forming ability which was confirmed 
by NMR spectra also (Figure 3.50 d). This finding does not agree with Eden’s finding that bioactivity 
of BG enhances monotonically with increasing phosphate content, providing that the degree of 
polymerisation of the silicate network remains constant (253). 
Comparing these data mentioned about phosphate series I glasses with strontium-substituted glass 
(section 3.3.4.2) may suggests that bioactivity comes almost exclusively from orthophosphate 
phase/species (215). In other words, the increased rate of apatite formation with increasing P2O5 
content (up to 4.28 mlo%), regardless of the NC of the silicate phase, can be explained as a result of 
phase morphology. For instance, Pyrex® glass is considered as a phase separated glass which contains 
sodium borate rich droplets surrounded in a silica rich matrix. The sodium borate droplets are more 
soluble compared to highly cross-linked insoluble silica matrix. Therefore, these droplets degrade 
when exposed to a corrosive medium and the bulk of silica remains unaffected. A comparable 
structure could be exists in the P2O5 containing glasses studied, which NMR spectra and glass 
transition temperatures confirmed the existence of two separate phases in the phosphate series I 
glasses.  Moreover, the presence of isolated nanometre size phases of orthophosphate groups may 
promote a microstructure with regions where the chemical connection of the glass structure is 
disrupted. With regard to nano crystalline phosphate phases, it has been shown that the mentioned 
regions could provide preferential sites for chemical sites in SBF (231;254). Therefore, it is expected 
that P2O5 content glasses with an interconnected orthophosphate structure exposed to SBF results in 
continuous leaching and enhances apatite formation.   
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3.6 Conclusion 
3.6.1 Strontium-substituted Series 
Multicomponetnt strontium containing glass coatings with a TEC match to the Ti alloy were 
successfully produced and the addition of different amounts of strontium ions in the glass network 
was studied. Substituting strontium for calcium in the glass composition reduces the glass-transition 
temperature and lowers the activation energy for crystallisation whilst increasing the onset 
temperature of crystallisation. Processing windows are significantly increased compared to Bioglass® 
45S5. The mixed calcium/strontium glasses exhibit a larger processing window (200°C and more), 
which favours the occurrence of sintering without crystallisation to obtain amorphous well-sintered 
coatings. However the glass with complete strontium substitution favours crystallisation due to its 
smaller processing window. Furthermore, it has been found that the orthophosphate and silicate 
network exist as two separate phases. NMR data show that silicon speciation in the network does not 
change when strontium is substituted for calcium. Glass dissolution studies indicate that zinc acts 
partially as an intermediate oxide in Sr-substituted glass series and makes the glass more stable 
resulting in the reduced bioactivity of the glasses. 
3.6.2 Phosphate Series I  
Multicomponent fixed strontium containing BGs with different amount of P2O5 content (charge 
balanced and TEC match with a Ti alloy) was produced. Two Tg was found for the glasses in this 
series. NMR data revealed that as P2O5 is added through the series no changes observed in the mixture 
of Q2 and Q3 silicate species. An increase in P2O5 content of phosphate series I aids to formation of 
HCA layer in SBF and allowed for apatite formation at lower pH, which is desirable for the 
applications such as orthopaedics and dentistry. The multicomponent structure of the glasses produced 
makes it difficult to predict their behaviour and need further investigation for a deeper understanding 
of the bioactive behaviour of high-phosphate containing glasses and how the cations such as zinc acts 
in the high-phosphate rich environment.   
 
  
CHAPTER 4 : In Vitro Assessment of Biological Activity of Strontium-
Substituted and High-Phosphate Strontium-Containing Bioactive 
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4.1 Introduction 
Metallic prostheses are widely used to treat joint and skeletal injuries and disease. However, metal 
alloy implants can sometimes fail due to complications of fibrous encapsulation and poor stress 
transfer between the bone and the implant. Bioactive glass coatings may promote the formation of a 
strong bond with living bone tissue, thus decreasing the likelihood of fibrous encapsulation and they 
have the added benefit that their dissolution ions stimulate cell activity (255). Other groups have 
shown that a BG that was designed for implant coatings enhanced the osteogenic markers of 
osteoblast-like cells which are important for the bone repair process (256). Furthermore, BG can 
stimulate osteoprogenitors to differentiate into mature osteoblasts that produce bone-like nodules 
while releasing ions (257). 
As discussed in in the literature review chapter, strontium ranelate (SrR), a drug used to treat and 
prevent osteoporosis under the commercial name of Protelos®, has been shown to decrease the 
number of hip and vertebral fractures in post-menopausal women (76). SrR works via the action of Sr 
ions which stimulate the formation of new bone and prevent osteoclast-mediated resorption (258;259). 
Findings from the chapter 3 on strontium-substituted glasses showed that mixed strontium-substituted 
BGs had provided coating without crystallization and better attachment than those of the non-
strontium and all strontium-containing glasses. Therefore, mixed strontium-substituted glasses (10% 
Sr and 50% Sr) were selected for in vitro biological evaluation. Since we were interested in studying 
the effect of strontium on cellular response, non-strontium containing glass (0% Sr) was included. It 
has previously been shown by our group that simple Sr-substituted BGs promote osteoblast activity in 
vitro (184) and our group has explored the effect of altering phosphate content on the material 
structure of soda-lime-phosphosilicate glasses (215). The effect of increasing P2O5 content in Sr-
substituted BG coatings on cultured osteoblasts, however, remains unexplored. Therefore, the effect 
of Sr-substituted BG coatings with different concentrations of P2O5 on cell viability, proliferation, 
differentiation and interaction will be discussed in the present chapter which will be referred to as 
phosphate series I. 
4.2 Materials and Methods 
The cellular response to BG was investigated indirectly, via culture in dissolution ions and directly, 
via culture on BG coatings, as shown schematically in Figure 4.1. 
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Figure 4.1: Schematic representation of the procedure performed in the cell-culture studies to analyse the 
cellular response to BG dissolution ions either from extracts or directly from coatings. 
 
4.2.1 Dissolution-Ion Studies 
4.2.1.1 Cell Culture with Dissolution Ions 
The human osteosarcoma cell line, Saos-2, was obtained from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK) and routinely cultured under standard conditions (37°C, 5% 
CO2/95% air, 100% humidity) in RPMI 1640 (GIBCO®) medium supplemented with 10% (v/v) foetal 
bovine serum (FBS), 1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin (all reagents from 
Invitrogen). This medium was used throughout all experiments in this study.  
Initial culture was performed in 75 cm2 flasks at 37°C in a humidified atmosphere of 95% air with 5% 
CO2 and cells were supplied with fresh medium every 2-3 days. When cells reached the 90% 
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confluence state they were detached using trypsin–EDTA (GIBCO®), and a haemocytometer was used 
to count cells. Cells were resuspended to the appropriate concentration for seeding. 
Saos-2 cells with a density of 30,000 or 15,000 cells/cm2 were seeded on tissue-culture plastic in a 48-
well plate with RPMI 1640 (GIBCO®) containing glass-dissolution products with different 
concentrations from the strontium series and phosphate series I, and cultured for up to 28 days. The 
wells were topped up with media, which were changed every other day. 
4.2.1.2 Preparation of BG-Conditioned Media 
Culture media containing ions from glasses were created by incubating 1.5g/L of 0, 10 and 50% 
strontium-substituted BG powder (<38µm) in RPMI 1640 (GIBCO®) on a roller for 4 h at 37°C and 
then passing through a 0.2 µm filter. Samples of dissolution-ion media were collected after 10, 30, 60, 
120 and 240 min for elemental analysis. Media were supplemented as described in section 4.2.1 and 
equilibrated in a vented flask in a 37°C and 5% CO2 incubator for 2 h prior to use on cells. 
4.2.1.3 Elemental Analysis 
In order to study the concentration of the ions released from BGs, the cell-culture media samples 
containing dissolution ions were diluted by a factor of 10 in deionised (DI) water. The concentration 
of the following ions: calcium, phosphorus, silicon, strontium, magnesium, sodium, potassium and 
zinc were assessed by inductively coupled plasma – optical emission spectrometry (ICP-OES) (iCAP 
6000, Thermo Scientific, Waltham, MA, USA) and each sample read in triplicate. 
4.2.1.4 Metabolic Activity of Cells 
The metabolic activity of cells was determined by reaction with the tetrazole MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma®); this test measures the intracellular 
reduction of a tetrazolium salt by mitochondrial dehydrogenase into formazan in viable cells. 
50 ml of a 5 mg/ml solution of MTT in phosphate-buffered saline (PBS) was added to the culture 
media of live cells at the indicated time points. After 4 h, medium was removed and the formazan was 
solubilised by adding 200 µl of dimethylsulfoxide (DMSO). Absorbance was measured using a 
microplate reader (SpectraMax M5, Molecular Devices) at a wavelength of 570 nm with a reference 
wavelength of 620 nm. 
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4.2.1.5 Total DNA 
Total DNA was determined by the use of Hoechst 33258 (Sigma®, Poole, UK) dye. DNA was 
extracted from cells lysed by three freeze\thaw cycles (30 min at -80oC and 20 min at 37oC). Hoechst 
33258 was added to the lysate and allowed to react for 5 min in the dark. 
Fluorescence was measured using a fluorescent plate reader set to 360 nm (excitation wavelength) and 
460 nm (emission wavelength). To measure the amount of DNA per well, Calf Thymus DNA was 
used (Sigma®, Poole, UK) at concentrations of 0, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 µg/ml in TNE 
buffer (pH 7.4) to determine a standard curve. The results of this assay were used to normalise 
alkaline phosphatase and osteocalcin results. 
4.2.1.6 Alkaline Phosphatase Activity 
The alkaline phosphatase activity (ALP) assay depends upon the hydrolysis of p-nitrophenyl 
phosphate by the alkaline phosphatase enzyme, which produces p-nitrophenol and inorganic 
phosphate. The ALP solution was prepared as follows: A 5 mg 4-nitrophenyl phosphate disodium salt 
hexahydrate (PNP) tablet (Sigma, N9389100) was added for every 5 ml of a solution of 100 mM 
glycine, 0.1 mM ZnCl2 and 0.1 mM MgCl2 in DI water. The pH was adjusted to 10.4 at 37°C. At 
indicated time points, cultures were lysed in dH2O and 50 µl of ALP solution were added. The well 
plates were placed on an orbital shaker for 30 minutes at room temperature. Then the reaction was 
stopped by addition of 100 µl of 1 M NaOH. The absorbance was subsequently read at 405 nm using 
a microplate spectrophotometer.  
 
4.2.1.7 Osteocalcin Production 
The osteocalcin (OC) level in the cell culture supernatants was determined by using a 96-well plate 
enzyme immunosorbent assay (EIA) kit for intact OC (Takara Bio Inc, Japan) using the cell-culture 
supernatants according to the manufacturer’s instructions.  
Cells were seeded and cultured in the presence of glass dissolution products for up to 28 days. Cell 
culture lysate was collected at the different time points. 100 µl of each sample and carboxylated-type 
of osteocalcin (Gla-OC) were added onto the microtitre plate which was coated with anti-Gla-OC. 
The plate was covered tightly with the provided adhesive and incubated for 2 h at room temperature 
(20-30°C). Supernatant was aspirated and the plate washed three times with 400 µl PBS wash buffer 
with vigorous tapping following every wash. Then 100 µl of horseradish peroxidase anti-OC reagent 
was pipetted into all wells. The plate was mixed by swirling and incubated at room temperature for 1 
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h. Another wash was performed and 100 µl substrate solution (hydrogen peroxide) was added to each 
well and incubated at room temperature in the dark for 15 min.  
The reaction was stopped by addition of 100 µl stop solution (sulfuric acid) and the absorbance was 
measured at 450 nm using a plate reader. The amount of OC in the culture medium was expressed as 
ng/ml calculated using a standard curve constructed by using a range of osteocalcin standards (0-16 
ng/ml) provided in the kit and was normalised to total DNA content.  
4.2.2 Bioactive Glass Coatings Studies 
4.2.2.1 Cell Culture  
Glasses were coated either by enamelling or plasma spraying on the surface of Ti6AL4V coupons 
with the dimensions of 5×5×1 cm3. The BG coatings were sterilised under UV light for 2 h per side. 
10,000 Saos-2/cm2 were seeded onto the BG coatings. Cells were allowed to attach for 30 minutes 
before standard cell-culture media were added. Cells were cultured for 1,7 or 14 days in media, which 
were replaced three times per week. 
4.2.2.2 LIVE/DEAD Assay  
Cell viability on the glass coatings was exhibited using the LIVE/DEAD viability assay (Molecular 
Probes). The LIVE/DEAD assay can be used to measure cell viability on the coating materials 
utilising two dyes (260): 
1) Ethidium homodimer-1 (EthD-1) which stains the nucleus of dead cells red. Dead cells have 
damaged membranes; EthD-1 enters damaged cells and is fluorescent when bound to nucleic 
acids. EthD-1 produces a bright red fluorescence in damaged or dead cells. 
2)  Calcein acetoxymethyl (Calcein AM) which stains the cytoplasm of live cells green. Live cells 
have intracellular esterases that convert nonfluorescent, cell-permeable calcein acetoxymethyl 
(calcein AM) to the intensely fluorescent calcein. 
At each time point (day 1, 7 or 14) cell-culture media were removed, cells were washed twice with 
phosphate buffered saline (PBS) to remove the non-adherent cells and then samples were incubated 
with LIVE/DEAD solution (2 µM Calcein-AM and 4 µM EthD-1) at 37°C for 30 minutes in the dark. 
Microscopy was carried out using an Olympus BX-URA2 (Olympus UK Ltd., London) 
epifluorescence microscope. Images were captured using a Zeiss AxioCam digital camera. 
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4.2.2.3  Cell Attachment Assessment using SEM 
BG coatings were prepared for scanning electron microscopy (SEM) imaging to study Saos-2 cell 
attachment and their spreading on the coatings. On the selected day of culture, samples were washed 
with PBS twice and fixed with 2.5% (v/v) glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) 
for 40 min at 4ºC. Then samples were rinsed with PBS twice and dehydrated with a graded series 
(increasing concentration) of ethanol. 
a. 25% - 5 minutes 
b. 50% - 5 minutes 
c. 70% - 5 minutes 
d. 90% - 5 minutes 
e. 100% - 5 minutes (two times) 
 
The samples were incubated in hexamethylsilasane (HMDS) for 5 min, followed by fresh HMDS for 
another 5 min. After the samples dried, they were sputtered with gold and observed using SEM (LEO 
1525: Gemini 1525 FEGSEM) at 10 kV.  
 
4.2.3 Statistical Analysis 
All data for the cell culture experiments are expressed as mean ± standard deviation (SD) and were 
obtained from two experimental repeats, each with n=6 per composition per time point. All data 
analysis was performed in Excel. Statistical analysis in MTT, ALP and OC assays was assessed by 
ANOVA with post-hoc LSD test to determine statistical significance between individual groups and 
p-values less than 0.05 were considered statistically significant. The data for ion extract 
concentrations were analysed using paired t-test between groups and control comparisons and 
significance was assigned at p<0.05. All statistical analysis was performed using SPSS. 
 
4.3 Results 
The results separated into two sections: the strontium-substituted BG series is discussed first, 
followed by the phosphate series I. Within each section, the cellular response is described for both the 
indirect method (dissolution ions from BG) and the direct method (cell viability and attachment on 
BG coatings).  
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Part I: Strontium-Substituted Bioactive Glasses 
4.3.1 Dissolution Ion Studies 
4.3.1.1 Ion Concentration Analysis  
In order to determine the dissolution behaviour of ions released from the BG into the cell-culture 
media (RPMI 1640) we analysed the elemental concentrations of bioactive glass particles incubated in 
RPMI 1640 over 4 h by using ICP-OES (Figure 4.2).  
The elemental concentration of the ions changed mainly during the first few hours of dissolution. The 
dissolution of calcium into RPMI was dependent on BG composition. The glass with higher calcium 
content released more calcium ions into the media. The decrease in phosphorous concentration was 
observed for all BG compositions in this series over the 4 h release period. Simultaneously with 
decreasing phosphorus concentration, the silicon content of the media increased. The silicon released 
into RPMI 1640 rapidly over 60 minutes of the initial incubation period and increased with 
dissolution time for all BG compositions. Increasing strontium substitution resulted in releasing 
higher strontium concentrations in the media. The dissolution of magnesium into RPMI 1640 was 
dependent on BG composition; with an increase in the strontium substitution, the release of Mg2+ to 
the cell-culture media decreases (Figure 4.2). 
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Figure 4.2: Dissolution behaviour of Ca2+, PO4-3, Sr2+, Mg2+ and soluble silica in cell culture media (RPMI 
1640) over 4 h incubation period with strontium-substituted BG particles, as determined by using ICP-
OES (RPMI ionic concentration is also shown as a control). 
 
The ionic concentrations of BG dissolution after 4 h incubation in RPMI are compared in Table 4.1. 
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
140 
 
Table 4.1: ICP-OES of ionic products of control RPMI and 0, 10 and 50% strontium-substituted BG 
dissolution in RPMI at 4 h. Data represent mean±SD and are expressed in ppm. 
Ca2+ PO4-3 Soluble silica Na+ K+ Sr2+ Mg2+ Zn2+
Control RPMI 16.12 ± 0.29 206 ± 0.50 0 ± 0.01 2568 ± 9.00 292.4 ± 1.40 0 ± 0.01 9.99 ± 0.09 0 ± 0.00
0% Sr in RPMI 17.24 ± 0.74 142 ± 0.60 54.5 ± 0.31 2518 ± 55.00 287.1 ± 6.80 0 ± 0.01 13.35 ± 0.25 0.0417 ± 0.00
10% Sr in RPMI 14.39 ± 0.17 151.6 ± 0.40 60.49 ± 0.44 2626 ± 46.00 306.1 ± 22.3 4.40 ± 0.13 12.56 ± 0.26 0.062 ± 0.00
50% Sr in RPMI 8.75 ± 1.72 155.7 ± 0.90 49.33 ± 0.39 2657 ± 32.00 313.1 ± 20.10 24.03 ± 0.19 11.18 ± 0.25 0 ± 0.07
 
The ionic concentrations of PO4-3, Mg2+ and soluble silica in the 0, 10 and 50% Sr glass dissolution 
products were significantly different from those in the control media (p<0.05). Na+, K+ and Zn2+ 
concentrations were not significantly different from those of the control or between samples. ICP-
OES results showed significantly increased concentration of Si for 10% Sr in comparison with 0 and 
50% Sr glasses. Also, Mg2+  and Ca2+  concentrations for 10% Sr were higher than for 50% Sr glass 
(p<0.05). However, non-strontium-containing glasses showed a higher Ca2+ concentration than those 
of strontium containing glasses (p<0.05). The significant difference of ionic concentration of Sr2+ was 
obtained between 10 and 50% Sr glass dissolution products (p<0.05).  
4.3.1.2 Metabolic Activity of Cells 
Metabolic activity was evaluated using the MTT assay. MTT activity increased in Saos-2 cells treated 
with BG dissolution ions from 0, 10 and 50% strontium-substituted BGs and control (RPMI 1640) 
with time in culture until 14 days and then decreased at day 28 (Figure 4.3). 
There were no significant differences in the MTT activity of Saos-2 cells treated with BG dissolution 
ions compared to cells in RPMI after day 1 and 7 in culture. At day 14, cells treated with dissolution 
ions from 0, 10 and 50% strontium-substituted BGs had higher MTT activities than the control 
(ANOVA, p<0.05). No significant differences were observed between the different concentrations of 
strontium-substituted BGs at any time point (ANOVA, p>0.05).  
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
141 
 
 
Figure 4.3: Normalised MTT activity of Saos-2 human osteosarcoma cells after treating with dissolution 
ions from strontium-substituted BGs with different strontium concentration into RPMI compared to the 
control (cells cultured with standard cell-culture media) for 1, 7, 14 and 28 days in culture. Data 
represent mean±SD and are normalised to the mean value of controls after 1 day in culture.   indicates 
significantly higher MTT activity in the indicated group compared to in the control at the same time 
point (p<0.05). 
 
4.3.1.3 Total DNA 
Figure 4.4 shows the amount of total DNA of Saos-2 cells treated with different concentration of 
dissolution products from strontium glasses after 7, 14 and 28 days in culture. After 7 days in culture, 
there was significantly more total DNA in the 10 and 50% strontium-substituted BG dissolution 
products compared to in either 0% or control media. In addition, 10% strontium- substituted BG 
showed significantly higher DNA content compared to 50%. After 14 days in culture, 10% strontium-
substituted BG showed a higher level of DNA compared to the control, 0 and 50% strontium-
substituted glasses. However, no significant differences were observed between the samples and the 
control at day 28 (p>0.05).  
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Figure 4.4: Total DNA of Saos-2 human osteosarcoma cells per well treated with glass dissolution 
products with different strontium concentrations after 1, 7, 14 and 28 days in culture. Data represent 
mean±SD.  indicates significantly more cells compared to control,  indicates significantly more cells 
compared to 0%Sr and  indicates significantly more cells compared to 50% Sr, all at the same time 
point (p<0.05). 
 
4.3.1.4 Alkaline Phosphatase Activity 
The effect of ion dissolution products on osteoblast differentiation was assessed by measuring the 
alkaline phosphatase (ALP) activity. Saos-2 cells treated with ion-dissolution products showed 
increased total ALP activity over the culture time (Figure 4.5a). After 24 h in culture, there were no 
significant differences in total ALP. However, at every other time point, ALP activity per well was 
found to be significantly higher when cells were cultured in the 10% strontium-substituted BG 
dissolution products than in the control and 0% strontium-substituted BG (p<0.05). At day 28, the 
same level of ALP activity was observed for the cells treated with the 10 and 50% strontium-
substituted BGs. At day 28, the total ALP activity per well was higher for the cells cultured with 10% 
strontium-substituted BG dissolution products when compared with the control and the 0% strontium-
substituted BG. ALP activity was normalised to total DNA content (Figure 4.5), and no significant 
differences in ALP activity per cell were observed. 
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
143 
 
 
 
Figure 4.5: (a) Total alkaline phosphatase activity of Saos-2 cells after treating with dissolution ions from 
strontium-substituted BGs with different strontium concentration in RPMI compared to the control (cells 
cultured with standard cell-culture media) for 1, 7, 14 and 28 days in culture. Data represent mean±SD. 
 indicates significantly greater total ALP activity compared to control,  indicates a comparison to 
0%Sr and  a comparison to 50%Sr, all at the same time point (p<0.05). (b) Normalised alkaline 
phosphatase activity to total DNA of Saos-2 cells after treating with dissolution ions from strontium-
substituted BGs with different strontium concentration into RPMI compared to the control (cells 
cultured with standard cell culture media) for 1, 7, 14 and 28 days in culture. ALP activity is expressed as 
nmols of PNP normalised to total DNA (µg) of the cell lysates per minute. Data represent mean±SD. 
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4.3.2 Bioactive Glass Coating Studies 
4.3.2.1 LIVE/DEAD staining 
Cell viability was assayed on bioactive glass coatings within an observation period of 1, 7 and 14 
days. LIVE/DEAD fluorescence microscopy images of Saos-2 cells showed that cells were alive on 0, 
10 and 50% strontium-substituted BG coatings with very few dead cells (Figure 4.6). However, more 
cells were visible on the 10% strontium-substituted BG coating at day 14 compared to on the 0% and 
50% coatings. The LIVE/DEAD assay indicated that BG coatings were non-cytotoxic under the 
condition tested.  
 
Figure 4.6: LIVE/DEAD staining images of Saos-2 cells cultured on different strontium-substituted 
bioactive glass coatings at 1, 7 and 14 days. The live cells fluoresce green and the dead cells red. Scale bar 
represents 200 µm in all images. 
 
4.3.2.2  SEM 
The attachment and cell morphology of Saos-2 cells cultured on both non-strontium and strontium-
substituted BG coatings were investigated using SEM. Figure 4.7 demonstrates that the Saos-2 cells 
spread well over the surface and the coatings successfully encourage the attachment of the cells. 
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Granule-like structures can be seen on the surface of the cells and EDS analysis showed that the 
spectra of the cells is dominated by carbon and oxygen (Figure 4.7d). 
 
Figure 4.7: SEM images of Saos-2 cells on the surface of the (a) 0%, (b) 10% and (c) 50% strontium-
substituted bioactive glass coatings after 28 days in culture. Cells can be observed growing on the surface 
of the bioactive glass coatings with a flattened appearance and extended cytoplasm. Cellular projections 
are more noticeable in image (c). (d) EDS spectra of the granule-like structures indicated by black arrow. 
SEM accelerating voltage=10 kV at different magnifications; (a) 3k , (b) 6k  and (c) 8k .  
 
4.4 Discussion 
In general, an ideal biomaterial for bone tissue engineering can control the appropriate cellular 
response such as cell attachment, proliferation, differentiation and mineralisation by releasing ion 
dissolution products based on its composition. The ion-exchange mechanism occurring at the 
material-solution interface changes the elementary composition of solutions exposed to bioactive 
glasses (155).  
Cell culture medium contains ions such as Ca2+, PO4-3, Mg2+ and silica which can affect the release of 
ions from the BG into the media during incubation. My ICP-OES data show that the calcium 
concentration in RPMI 1640 decreased with incubation time. The incorporation of phosphate ions 
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together with calcium ions which form the CaP layer on the BG particles causes the depletion of 
calcium in the culture media during incubation. This assumption is supported by the reduction of 
phosphorous concentration in the media over the incubation period. It has been shown that the higher 
calcium content in glass composition causes a higher calcium concentration to be released into the 
media and provides the conditions that allow a CaP layer to be precipitated on the surface (161).  
It has also been shown that soluble Si ions is released into culture media over time due to the breakup 
of the outer silica layers of the BG network (26). Sepulveda et al. showed that silicon content of cell-
culture media which releases from melt-derived 45S5 powders increased rapidly (4 h) and increased 
during the longer time of incubation (161). Our data from ICP-OES showed that silicon content of 
cell-culture media increases for all the BG studied over 4 h of incubation (Figure 4.2). 
Strontium has chemical similarity with calcium and can accumulate in bone by exchanging with 
calcium in the hydroxyapatite crystal lattice (59). As discussed in chapter 3, the Sr2+ cation is slightly 
larger than the Ca2+ cation, the lower charge to size ratio of the strontium ion compared to the calcium 
ion results in the expansion of the glass network and a more loosely cross-linked glass network. 
Therefore, the high strontium-content glass releases a larger amount of strontium in the media. This 
hypothesis is supported by our ICP-OES data, which confirmed that substitution of strontium for 
calcium in the BG increased the strontium concentration in the media (Figure 4.2). The concentration 
of strontium released from the 50% Sr-substituted glass was approximately five times that of the 10% 
Sr-substituted glass which is consistent with its composition. 
At the early time points in the cell culture there was no significant difference between the metabolic 
activity of the cells treated with dissolution products and the cells cultured with control media, which 
indicates that the dissolution products of 0, 10 and 50% strontium-substituted BGs were non-
cytotoxic. Lack of cellular adhesion on BG materials indicates cytotoxicity because cells require 
adhesion for survival (23). The data from the LIVE/DEAD staining and SEM images showed that the 
bioactive glass coatings produced are non-toxic and support cell attachment (Figure 4.6 and Figure 
4.7). According to the EDS analysis the granule-like structure on the surfaces of the Saos-2 cells are 
likely to be protein sedimentation. However, Qiu et al. studied the morphology of osteoblastic cells 
seeded on the surface of the porous strontium-doped calcium polyphosphate (SCPP) scaffolds using 
SEM and confocal laser scanning microscopy (261). At day 14 of the culture they also described the 
granule–like structures as calcium granules which were sedimented on the surface of cells (261).   
Moreover, it has been shown that after two weeks in culture, the metabolic activity of Saos-2 cells 
treated with ions released from all BGs was significantly enhanced when compared to the control. 
Xynos et al. showed increased proliferation compared to controls in primary human osteoblasts 
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treated with 45S5 Bioglass® (262). Also, our previous study showed that dissolution ions released 
from both non-strontium-containing BGs and strontium-substituted BGs (SiO2–P2O5–Na2O–CaO–
SrO) promote osteoblast activity in vitro (184). Moreover, the same study showed that treatment with 
ionic dissolution products of strontium-substituted BGs resulted in significantly increased MTT 
activity of Saos-2 cells in comparison with non-strontium-containing BGs at day 14 and 28. However, 
in the current study the data did not show a significant difference between the metabolic activity of 
the cells treated with dissolution ions released from non-strontium-containing BGs and strontium-
substituted BGs. The multi-component nature of the glass studied may explain this discrepancy. 
According to the results, 10% strontium-substituted BG promoted significantly higher ALP activity 
per well of Saos-2 cells via its dissolution ions. When ALP activity was normalised per total DNA 
content, ANOVA determined that 10% strontium-substituted BG was not significantly different from 
any other group at any time point (Figure 4.5). This is because the DNA content of cells for 10% 
strontium-substituted glass were higher than other samples. We have previously shown that strontium-
substituted BG enhanced ALP activity (184). It is worth pointing out that our previous study 
investigated the ALP activity while directly in contact with cells and in the present study dissolution 
ions were used from ground powders <38 µm diameter, which are likely to release far more strontium 
ions than discs, because of their much higher surface area. It has previously been shown that the high 
concentration of Sr ions in the cell-culture medium decreases ALP and MTT activity of the 
osteoblastic cells (261). Also, Hesaraki et al. (244) studied sol-gel-derived glasses based on the 
system of CaO-SrO-SiO2-P2O5 and showed that ion-dissolution products from low-dose strontium 
disc-shaped specimens (5 mol% of strontium) exhibited optimal cell proliferation and ALP activity 
when applied to the cell-culture medium of rat calvaria osteoblastic cells. Thus the proper 
concentration of strontium is an important factor which can affect cell differentiation. 
Now, the question is why 10% strontium-substituted BG resulted in higher DNA content than other 
groups; ICP-OES data may explain this. From ICP-OES results we know that the concentration of Si 
and Mg released from 10% Sr glass in cell-culture media was higher than for the other samples except 
from 0% strontium-containing glass. Consequently, the significantly increased total DNA content 
seen as early as day 7 for 10% Sr substituted BG may be explained by a synergistic effect from Si and 
Mg in the presence of Sr. Silicon is known to play an essential role in formation and calcification of 
bone tissues (89). In the present study, increased Si concentration in the 10% Sr-substituted BG 
(60.49 ppm; 2.14 mM) may have had an impact on the observed enhanced total DNA content and 
ALP activity per well. Reffitt et al. (92) studied the effect of soluble Si on ALP activity and 
osteocalcin in the human osteosarcoma cell line (MG-63) and showed that 3 days after cell confluence 
both ALP activity and OC synthesis significantly increased at the Si concentration of 10 and 20 µM 
(0.28 and 0.56 ppm). In another study, Si concentration of 45S5 glass-conditioned media (47.9 ppm; 
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1.7 mM) had a higher level of Si in comparison with other bioactive-coated glass studied but there 
was no statistically significant difference in the osteogenic markers between them (256). 
Magnesium is also necessary for bone metabolism and stimulates new bone formation (101). Varanasi 
et al. (256) studied the bioactive glass coating in the system of (SiO2–CaO–P2O5–MgO–K2O–Na2O) 
and showed that although Mg concentration in culture medium did not change significantly after 
treating with the BG specimen, dissolution products from this Mg-containing BG significantly 
enhanced osteoblastic differentiation. So, the ability to stimulate osteogenesis of this Mg-containing 
BG might be associated with increased levels of Si or Ca. Moreover, Saboori et al. (263) have shown 
that ALP activity of the human foetal osteoblastic cells cultured on sol-gel-derived Mg-containing BG 
was enhanced significantly in comparison to those cultured on tissue culture plastic. It is worth 
pointing out that Mg-containing bioactive glasses have not been compared to the non-Mg containing 
BGs, so it is unclear if Mg released from the BGs has a unique effect on bone cells. 
We were interested to see if there is any relation between the concentrations of strontium that can 
promote cellular response and the serum levels of strontium which can enhance osteoblast activity in 
human bones. The following text will discuss this idea.  
Staub et al. (264) developed a model for strontium metabolism by studying the plasma levels of 
strontium in post-menopausal women who received oral administration of different doses of strontium 
ranelate. They showed that for oral doses between 1 and 4 g per day, the serum level of strontium 
changes between 2 and 15 µg/ml. The in vitro study by Verberckmoes et al. (71) using primary rat 
osteoblasts cells showed that an increased number of bone nodules was observed in the concentration 
range of strontium between 2 to 5 µg/ml, whereas at 20 and 100 µg/ml there was a decrease in 
mineralisation in comparison to in the control groups. Verberckmoes et al. used the chloride 
compound SrCl2.6H2O as a source of strontium and three different control groups were prepared. 
Cells in all groups grew in the osteogenesis-inducing culture medium (β-glycerophosphate and 
ascorbic acid). Taken together these two in vivo and in vitro studies show that the concentrations of 
strontium that yield an increase in the number of bone nodules seem quite similar to those reported in 
the serum of women who received normal doses of strontium ranelate.  
The strontium concentration released from different strontium-substituted glass into simulated body 
fluid (SBF) after 12 hours at 37°C is shown in Figure 4.8 as a function of strontium substitution (a 
detailed explanation of the SBF study can be found in chapter 3). According to the blood plasma 
levels reported by Staub et al. (264) and in vitro data from Verberckmoes et al. (71), 10% strontium-
substituted BG fits within the range of strontium which can enhance bone mineralisation. However we 
interpret this with caution of strontium ranelate plasma levels are likely to be lower than the 
concentration in bone. According to this finding, the in vitro study was carried out on 10% Sr-
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
149 
 
substituted BG with varying phosphate content, which was referred to as phosphate series I, to study 
the influence of increasing P2O5 content on cellular response. In agreement with this finding, recently 
Xiang et al. have reported that in Sr-containing BGs strontium concentration should be less than 5 
mol% in order to show a beneficial effect on bone (226).  
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Figure 4.8: Strontium release into SBF for glasses with different strontium substitution after 12 hours. 
 
To our knowledge, the mechanism by which ions released from BGs affect cells has remained unclear 
but studies on standard BG have shown that they stimulate the expression of a number of osteogenic 
genes (reviewed in (255)). Pi et al. (265) demonstrated that strontium’s effect is mediated by a cation-
sensing receptor rather than a calcium-sensing receptor. This agrees with the study has been shown 
that neither calcium nor sodium ranelate had the same effects as their strontium equivalent (266). 
However, this finding has been questioned by another study which showed that strontium’s effect is 
dependent on calcium-sensing receptors (63). 
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
150 
 
Part II: Phosphate Series I (10% Sr) 
4.4.1 Dissolution-Ion Studies 
4.4.1.1 Ion Concentration Analysis 
As a result of bioactive glass dissolution, ion concentration changed in the cell-culture media. ICP-
OES results (Table 4.2) showed significantly increased concentrations of Ca2+ and PO4-3 (p <0.05) for 
all samples over 1.07P glass. The 1.07P glass released the highest amount of souluble silica into the 
media and there were significant differences in the silica content of the dissolution products between 
all the samples. 2.14P glass showed a significant increase in concentration of Sr2+ and Mg2+ over 
1.07P and other samples. Na+, K+ and Zn2+ concentrations were not significantly changed in 
phosphate series I BGs as compared with 1.07P glass (p >0.05). The elemental concentrations of the 
ions (Ca2+, PO4-3, Sr2+, Mg2+ and soluble silica) released from phosphate series I BG particles into cell 
culture media during the first four hours of incubation period are shown in Figure 4.9. 
Table 4.2: ICP-OES of ionic products of phosphate series I BG dissolution in RPMI at 4 h. Data represent 
mean±SD and are expressed in ppm. 
Ca2+ PO4-3 Soluble silica Na+ K+ Sr2+ Mg2+ Zn2+
10%Sr- 1.07P 14.39 ± 0.17 151.6 ± 0.40 60.49 ± 0.44 2626 ± 46.00 306.1 ± 22.3 4.40 ± 0.13 12.56 ± 0.26 0.062 ± 0.00
10%Sr- 2.14P 16.92 ± 0.08 160.1 ± 0.90 44.5 ± 0.25 2699 ± 23.00 320.8 ± 3.00 5.43 ± 0.091 13.24 ± 0.16 0.0 ± 0.01
10%Sr- 4.28P 17.1± 0.35 180.1 ± 1.20 15.67 ± 0.09 2678 ± 23.00 314.2 ± 0.80 4.40± 0.086 12.64  ± 0.03 0.0 ± 0.00
10%Sr- 6.42P 19.98± 0.30 193 ± 0.50 14.47 ± 0.15 2678± 4.00 314.6 ± 2.30 4.55± 0.012 12.69  ± 0.16 0.0 ± 0.00
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Figure 4.9: Dissolution behaviour of Ca2+, PO4-3, Sr2+, Mg2+ and soluble silica in cell-culture media (RPMI 
1640) as released from phosphate series I BG particles over a 4 h incubation period and determined by 
using ICP-OES (RPMI ionic concentration is also shown as a control medium).  
 
4.4.1.2 Metabolic Activity of Cells 
Results of the metabolic activity of Saos-2 cells treated with BG dissolution ions from 10% strontium-
substituted glass with varying amounts of phosphate are shown in Figure 4.10. Metabolic activity is 
not exactly same as proliferation, however the measurement of MMT assay is often used as an 
indication of cell proliferation. 
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After one day in culture, the metabolic activity of the cells cultured with dissolution products from 
2.14P was significantly higher than that from all other glasses used (ANOVA, p<0.05). At day 7, the 
metabolic activity of the cells treated with 2.14P and 4.28P glass extracts increased significantly 
compared to that of those treated with 1.07P. Also, cells in 4.28P glass dissolution products showed 
significantly higher MTT activity compared with 6.42P glass (ANOVA, p<0.05). From Figure 4.9, it 
is noticeable that, at day 21, cell proliferation was significantly enhanced with exposure to the highest 
phosphate content glasses (4.28P and 6.42P) compared to proliferation with the lowest phosphate 
content glass (1.07P). Overall, metabolic activity of the cells increased during the first 7 days and 
decreased at day 14 but then started to increase and at day 28 it had almost reached the same value as 
that on day 7. 
 
 
Figure 4.10: Normalised MTT activity of Saos-2 human osteosarcoma cells after treating with dissolution 
ions from phosphate series I (10% strontium-substituted BG) into RPMI for 1, 7, 14, 21 and 28 days in 
culture. Data represent mean±SD and are normalised to the mean value of controls after 1 day in culture 
(control not shown).  indicates significantly higher MTT activity in the indicated group compared to the 
lowest phosphate content glass (1.07P),  indicates significantly higher metabolic activity compared to 
highest phosphate content glass (6.42P) and  indicates significantly higher MTT activity compared to  
4.28P glass at the same time point (p<0.05). 
 
Chapter 4: In Vitro Assessment of Biological Activity of Strontium-Substituted and High-Phosphate 
Strontium-Containing Bioactive Glasses 
153 
 
4.4.1.3 Total DNA 
The DNA content of the Saos-2 cells increased up to day 21 in culture. Proliferation continued but 
was less rapid from day 14 onwards (Figure 4.11). At day 1 in culture there was no significant 
difference in total DNA amount for the cells treated with BG dissolution ions with different 
concentrations of P2O5. At day 7, the cells treated with 2.14P glass extracts showed a significantly 
higher amount of DNA than all other glass dissolution products used (ANOVA, p<0.05). Total DNA 
of cells increased markedly from day 7 to day 14 in culture; at least a four-fold increase in cell 
proliferation was observed. Although the total DNA content kept increasing till day 21 in culture, the 
different concentrations of the P2O5 did not significantly affect the DNA content at days 14, 21 and 28 
in culture (ANOVA, p>0.05). From the strontium-substituted BG series data (section 4.3.1.3), it was 
observed that 1.07P glass had a significantly higher amount of total DNA compared with the control 
(Saos-2 cells treated with standard media). Taken together, these data suggest that the total DNA 
content was higher in phosphate series I-treated cells compared with control-treated cells. 
 
Figure 4.11: Total DNA of Saos-2 human osteosarcoma cells per well in glass dissolution products from 
phosphate series I (10% strontium) after 1, 7, 14, 21 and 28 days in culture as an index of cell number.  
indicates significantly higher total DNA content in the indicated group compared to the other samples at 
the same time point (p<0.05). 
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4.4.1.4  Alkaline Phosphatase Activity 
Figure 4.12a shows that the total ALP activity of Saos-2 cells increased over the 28-day culture period 
with exposure to the ion-dissolution products of BGs from phosphate series I. The level of ALP 
production was not statistically different between samples at the same time points (ANOVA, p>0.05). 
ALP activity was normalised to the DNA content and used as an index of cell number (Figure 4.12b). 
At day 7, there was a significant difference in ALP activity per cell between the high phosphate 
content group (6.42P) and 2.14P. There were no significant differences in ALP activity per cell after 
14, 21 and 28 days in culture within samples at the same time point with different concentrations of 
P2O5. 
 
Figure 4.12: (a) Total alkaline phosphatase activity of Saos-2 cells after treating with dissolution ions 
from phosphate series I (10% strontium) for 7, 14, 21 and 28 days in culture. Data represent mean ±SD. 
 indicates significantly greater total ALP activity than 2.14P glass at the same time point (p<0.05). (b) 
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Alkaline phosphatase activity normalised to total DNA content of Saos-2 cells after treating with 
dissolution ions from phosphate series I BGs with different phosphate concentrations into RPMI for 7, 14, 
21 and 28 days in culture. ALP activity is expressed as nmols of PNP normalised to total DNA (µg) of the 
cell lysates per minute. Data represent mean ±SD. 
 
4.4.1.5 Osteocalcin Production 
To study the effect of dissolution ions from BGs with different P2O5 content on osteoblast 
differentiation, osteocalcin known as a marker of osteoblast final differentiation, was determined 
using enzyme immunosorbent assay. 
Levels of osteocalcin production from the cells treated with ion dissolution products from high 
phosphate series I BGs and also in control media are shown in Figure 4.13. There were no significant 
differences in OC production per cell between samples and control during 14, 21 and 28 days in 
culture (ANOVA, p>0.05). Increasing P2O5 substitution had no detrimental effect on the production of 
osteocalcin, a bone-specific protein and late marker of osteoblast proliferation, compared to controls 
grown in standard culture media. 
 
Figure 4.13: Osteocalcin production by Saos-2 cells cultured in RPMI (as a control medium) and 
dissolution ions from phosphate series I BGs with different P2O5 concentration into RPMI for 14, 21 and 
28 days in culture. Data represent mean±SD of OC produced from cell lysates and normalised to the total 
DNA of the cell lysates. 
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4.4.2 Bioactive-Glass Coating Studies 
4.4.2.1 LIVE/DEAD Assay 
Cell viability of Saos-2 cells on various phosphate content BG coatings at 7 days of culture is shown 
in Figure 4.14. LIVE/DEAD fluorescence microscopy images demonstrated that cells were alive on 
phosphate series I BG coatings and few dead cells were spotted. All materials allowed cell attachment 
and growth. 
1.07P 2.14P
4.28P 6.42P
 
 
Figure 4.14: LIVE/DEAD staining images of Saos-2 cells cultured on different phosphate-content 
bioactive glass coatings at day 7. The live cells fluoresce green and the dead cells red. Scale bar represents 
200 µm in all images. 
 
4.4.2.2 SEM 
Not only it was necessary to study a non-cytotoxic effect of BG coatings on cells but it was also 
important to discover whether the phosphate content coatings could support the attachment of the 
Saos-2 cells. Cell morphology of Saos-2 cells cultured on 4.28P bioactive coating glass at different 
magnification are shown in Figure 4.15  using SEM. Cells were observed spreading over the BG 
coating. Cytoplasmic extensions as well as filopodia can clearly be seen. 
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Figure 4.15: SEM images showing morphology of Saos-2 cells spreading on the surface of the BG coatings 
at day 14 in culture. Saos-2 cells on (a) 4.28P BG coating at lower magnification 2k, (b) 2.14P BG 
coating 7k, (c) 4.28P BG coating 10k and (d) 6.42P BG coating 8k. Accelerating voltage=20 kV in 
all cases. Black arrows indicate filopodia (b-d).    
 
4.5  Discussion 
In part I, the effect of different concentrations of strontium on Saos-2 cells was studied and it was 
shown that 10% strontium-substituted BG which contains 1.07 mol% P2O5 is the most appropriate 
glass among the other compositions to enhance metabolic activity and total DNA amount. In part II, 
the effect of addition of P2O5 (within the range of 2.14 to 6.42 mol%) on the cytotoxicity, 
proliferation, ALP activity and cellular attachment of the Saos-2 cells was studied in vitro.  
The elemental concentrations of the ions  (Table 4.2), shows that it is not possible to investigate only 
the effect of phosphate content in the media, since the glass composition releases different ions such 
as Si which changes significantly during the first 4 hrs in RPMI and this has affect on cells.     
According to the results of the MTT assay (Figure 4.10) the Saos-2 cells cultured in the ion-
dissolution products from BGs with concentration of P2O5 from 1.07 to 6.42 did not show a cytotoxic 
response. The MTT activity decreased at day 14 and then started to increase. From the total DNA 
results (Figure 4.11), it can be seen that cells decreased their proliferation rate after day 14, too. Taken 
together, the reduction in metabolic activity and proliferation rate at day 14, suggest that cells reach 
confluency around this time. 
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It has been shown that silica-based glasses with low P2O5 content (1.1 mol%) caused an undesirably 
high pH rise due to an initial release of alkali ions (267). This undesirable effect of local pH rise can 
be tailored by increasing the P2O5 content of the BGs. Data on pH measurement of phosphate series I 
in SBF showed that by increasing the P2O5 content of the glasses, pH decreased (Chapter 3, Figure 
3.40). At early time points in the culture, increased metabolic activity was observed for the cells 
treated with higher P2O5 content dissolution ions (Figure 4.10). This increase may be a result of the 
effect of pH changes by higher P2O5 content ion dissolution which may affect the cell metabolic 
activity. The same effect was observed at late time points in the culture (21 and 28 days).  
It is known that ALP enzymatic activity increases during cell differentiation and then decreases to 
mark the production of extracellular matrix and its mineralisation (268;269). It has been shown that a 
phosphate-free BG scaffold enhanced ALP enzymatic activity of primary human osteoblast (pHOB) 
cells without using osteogenic media (29). We noted that ALP activity per cell was not significantly 
altered by any of the materials after two weeks in culture. This result suggests that various P2O5 
concentrations in this study did not appear to affect the ALP activity of Saos-2 cells. It has been 
shown that release of phosphate from the glass is not required for mineralisation and bone cells can 
produce extracellular matrix in the presence of phosphate in the medium (29). In another study, the 
effects of phosphorous and silicon dissolution ions from silica-calcium phosphate composites on 
osteoblast differentiation were investigated in the presence or absence of exogenous phosphate 
supplementation (270). The results showed that in the presence of exogenous phosphate supplements, 
in addition to ionic dissolution from silica-calcium phosphate composites, resulted in down-regulation 
of osteoblast gene expression. In the absence of exogenous phosphate supplements, the dissolution 
products from silica-calcium phosphate composites were sufficient to stimulate bone-cell 
differentiation (270). Phosphate was shown to act as an important signalling molecule for the protein 
synthesis by osteoblast-like cells (269). It has been shown that phosphate is essential for calcium 
phosphate deposition and extracellular matrix mineralisation, whereby higher inorganic phosphate 
concentrations in osteoblast culture medium resulted in more rapid mineral deposition (271). 
However, it has also been reported that exposure to elevated phosphate concentration influences the 
metabolic activity and initiates apoptotic response. When osteoblast-like cells were exposed to 
inorganic phosphate in the concentration of 1–7 mmol/l, there was a time-and dose-dependent 
decrease in the cell viability (272). Adams et al. studied the increasing effect of both inorganic 
phosphate and calcium on osteoblast viability. In the presence of elevated inorganic phosphate, a 
relatively small rise in the calcium concentration (0.1-1 mmol/l), above the 1.8 mmol/l in the medium 
caused apoptosis in osteoblasts and also chondrocytes. According to the ICP-OES data shown here the 
concentrations of the phosphate in phosphate series I glasses were in the range of 5-6.2 mmol/l and 
this did not affect cell viability. These studies draw attention to the fact that several factors may 
control the effect of phosphate on the cellular responses. These factors could be the stage of 
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differentiation, cell type, the exogenous supplements added to the FBS, and pH value of the materials 
used. The mentioned reasons may considerably alter the cell response to phosphate. Since the glass 
produced here was multi-component, it is difficult to determine whether the cell responses were due 
to the presence of phosphate in the glass or to the other dissolution ions from the glass. 
It has been shown that osteocalcin is expressed at a later stage of the osteoblastic differentiation (268). 
The results presented here indicate that the various concentrations of P2O5 tested, 152-193 ppm, did 
not affect osteocalcin production of the Saos-2 cells during the culture period assessed (Figure 4.13). 
Maeno et al. (56) investigated the effect of different ranges of calcium concentrations on proliferation, 
differentiation and bone formation of mouse primary osteoblasts. Their results indicate that 0-160 
ppm (0-4 mM) calcium stimulates expression of ALP and proliferation, while 240-320 ppm (6–8mM) 
calcium stimulates expression of osteocalcin and differentiation of osteoblasts. In another study, the 
increased level of osteocalcin was shown for osteoblast-like cells treated with 6P53-b and 45S5 glass-
conditioned media with Ca concentrations of 57 and 70 ppm, respectively (256). In the present study, 
the concentration of calcium ions dissolved in the cell-culture media was between 14-20 ppm and may 
not have been enough to increase the level of osteocalcin. A suitable level of calcium concentration 
should activate the mechanism to which osteoblastic cells respond via a calcium receptor (94). 
Siggelkow et al. (273) investigated the osteocalcin expression from primary human osteoblast-like 
cells after 1,25-dihydroxyvitamin-D3 stimulation and showed that osteocalcin protein and gene 
expression were greatly stimulated by vitamin D3 (p<0.001). Bone-related genes such as osteocalcin, 
bone sialoprotein, and osteopontin are expressed at the beginning of mineralisation, parallel to the 
accumulation of mineral (274). Siggelkow et al. (273) showed that there was not a significant increase 
in OC expression or protein secretion in pHOB cells, even after 25 days in culture, when mineral 
accumulation was slowed down as a result of β-glycerophosphate deficiency. It can be concluded that 
OC production is enhanced by 1,25-dihydroxyvitamin-D3. It is worth mentioning that in the current 
study vitamin D3 has not been used. This fact may explain why the OC production did not enhance 
when P2O5 content of the glasses was increased.  
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4.6 Conclusion  
This study demonstrates that the dissolution products of strontium-substituted bioactive glasses create 
an environment which enhances the metabolic activity of Saos-2 cells and supports osteoblast 
proliferation and differentiation. Furthermore, ions released from the strontium-substituted bioactive 
coated glasses have a non-toxic effect and maintain cellular attachment; this should allow us to create 
a biomaterial that may lead to an increase in mineralisation of cells. The bone remodelling benefits of 
strontium and BG with increasing P2O5 content and decreasing silica content of the glass in a 
controlled range can mediate pH changes which may affect cell viability and proliferation. The data 
described in this chapter show that higher phosphate-content Sr-substituted glasses can enhance Saos-
2 cells metabolic activity without any negative effect on viability.  
Taken together, these data suggest that Sr-substituted bioactive glasses with high-phosphate contents 
may be an effective means to promote bone-implant bonding and may find use in a range of bone-
regeneration therapies. 
 
 
  
CHAPTER 5 : In Vivo Implant Study of High-Phosphate Strontium-
Containing Bioactive Glass Coatings  
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5.1 Introduction  
For successful skeletal reconstructive surgery it is essential to promote the fastest, long-lasting and 
most reliable osseointegration of an implant device. This need becomes more important and 
challenging in osteoporotic patients in order to enhance the implant fixation. Experimental models 
have shown that the osteoporosis influences osseointegration, which can be avoided by treatment 
(275). It has been shown that oral administration of strontium ranelate enhances the osseointegration 
of titanium implants (87). Furthermore, the administration of systemic strontium enhanced the 
fixation of HA-coated screws in osteoporotic rats (80). HA has proven to be an effective implant 
coating on metallic implants for use in dentistry and orthopaedics (276-278). However, it has no 
significant effect on bone formation or mineral content of bone, which would be desirable attributes 
for patients with reduced bone-mineral density. Surface coating with HA is effective but it is also time 
consuming and expensive to apply. A strontium-containing BG coating, which stimulates rapid bone 
formation and is cheap and simple to apply, would have significant application, particularly in those 
areas of the skeleton where the bone-implant interface may be subjected to tension or shear stresses. 
In theory this treatment would combine the osteoinductive and osteoconductive properties of 
bioactive glass with the beneficial outcome of strontium on bone mineral density. 
The aim of this study is to investigate the degree of osseointegration and implant fixation of a 50% 
strontium-substituted bioactive glass with high-phosphate content coating on Ti alloy implants using a 
lapine model. The hypothesis is that plasma-sprayed coating of strontium-containing BG will promote 
more rapid osseointegration in vivo than conventional plasma-sprayed HA. The study will also 
evaluate the impact of the coating on the surrounding bone, with the hypothesis that the combination 
of strontium and bioactive glass will have an osseoinductive effect that is not demonstrated by 
hydroxyapatite. The glass composition was used for in vivo study is a potentially commercial 
formulation from RepRegen Ltd and the choice of this glass for a coating application was based on its 
thermal properties and the results of cell culture study which showed that this glass dissolution 
products enhanced the ALP activity of Saos-2 cells. 
As discussed in the literature review chapter, osseointegration is defined as the formation of a direct 
and functional connection between living bone and the surface of an implant (115;116). In vivo 
assessment of implant osseointegration is divided into histological and mechanical parts (279). 
Measurement of bone-implant contact, peri-implant bone volume and push-out testing are established 
methods for assessing the extent of osseointegration. Our results will be discussed on the basis of 
these parameters. 
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5.2 Methods and Materials 
5.2.1 Glass Synthesis 
The 50% strontium-substituted bioactive glass with high phosphate content is termed HP1 in the 
following was synthesised using a melt-quench protocol optimised by RepRegen Ltd (Imperial 
Bioincubator, London, UK).  
The HP1 glass was produced by mixing analytical grade silica (Prince Minerals Ltd., UK) with 
CaCO3, SrCO3, MgO, Na2CO3, K2CO3, ZnO and Ca3(PO4)2 (all Sigma-Aldrich, UK) in the 
proportions shown in Table 5.1. The well-mixed batch was transferred to a 300 ml platinum crucible 
and placed into the preheated furnace (Lenton EHF 17/3, UK) at 1450°C for 1 hour. After this time 
the molten contents of the crucible were quenched immediately by pouring into cold tap water to 
prevent crystallisation. The glass frit was collected and dried in an oven at 120°C overnight. Then the 
frits were milled using a micromill PULVERISETTE 7 premium line (Fritsch GmbH). Five grinding 
balls of 10 mm diameter were used for 5 minutes at 500 rpm to grind the glass frits. The resulting 
glass particles were sieved through 100, 50, and 20 µm sieves using a vibrating platform. Glass 
particles of greater than 50 µm in diameter were milled further and those of less than 20 µm were 
discarded. The size of the glass particles was measured using a Cilas 1064 laser particle size analyser 
to ensure that the size distribution of HP1 glass matched the Captal 30 hydroxyapatite (Plasma Biotal 
Ltd, Buxton, UK) used. The calculated thermal expansion coefficient (TEC) value and network 
connectivity of HP1 glass are shown in Table 5.1.  
 
Table 5.1: The composition of the 50% strontium-substituted bioactive glass with high phosphate content 
(HP1) in mol.% with TEC value calculated by means of Appen factor and theoretical network 
connectivity by assuming that zinc and magnesium act as  network modifiers (NC).  
Glasses SiO2 Ca3(PO4)2 CaO SrO Na2O K2O ZnO MgO Calculated TEC (×10-6 °C-1) NC
HP1 51.5 5.2 3.18 18.79 4.62 4.62 3.47 8.67 11.1 2.33
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5.2.2 HP1 Glass Characterisation 
5.2.2.1 Particle Size Analysis 
The glass powder sieved through a 50 µm sieve was characterised using a particle size analyser 
(CILAS 1064 Particle Size Laser Analyser). The measurements were performed by immersing one 
spatula of powder in deionised water with a drop of a multipurpose detergent TEEPOL as a dispersive 
agent. The measurements were obtained using the Particle Expert software and were performed three 
times in order to obtain average values. The particle sizes of the glass powder present in the solution 
at 10%, 50% and 90% of the distribution curve were obtained. 
5.2.2.2 X-Ray Diffraction 
XRD patterns of the HP1 glass powder and its plasma-sprayed coating on Ti substrate were 
determined using an X-ray powder diffractometer (PANanlytical X'Pert Pro MPD). Ni filtered Cu-Kα 
radiation at 40 kV and 40 mA was used. The diffraction pattern was recorded in the 2θ range of 10º to 
80º with a step size of 0.04º.  
5.2.2.3 Differential Scanning Calorimetry 
50 mg of HP1 sample powder with particle sizes of 20<x<50 µm was placed in an inert platinum 
crucible and analysed by using DSC with analytical grade alumina powder as a reference material. 
The experiments were carried out in air, using a Stanton-Redcroft DSC 1500 (PL Thermal Sciences, 
Epsom, UK) at the different heating rates (5, 10 and 25 K min−1) up to a maximum temperature of 
1050°C. Tg, Tp and the To were determined. 
5.2.3 Implant Preparation 
Ti6Al4V cylinders of 3.5 mm diameter and 6.2 mm length were produced by Plasma Biotal Ltd. A 1 
mm diameter hole was drilled into one end of each implant to allow mounting for plasma-spraying. 
Each implant was grit blasted with alumina, ultrasonically washed in acetone and plasma-sprayed 
with either hydroxyapatite (Captal 30, Plasma Biotal, UK) or HP1 glass. For the mechanical study, the 
curved surfaces of the implants were coated and for histological evaluation the apical flat surfaces 
were also coated. A digital micrometer was used to measure the implants diameter before and after 
plasma spraying to determine coating thickness. Implants with the coating thickness of 50-100 µm 
and the length within the range 6.2±0.2 mm were selected. Subsequently, implants were individually 
packed in sealed polyethylene packets and sterilised using gamma irradiation at 35kGy (Swann 
Morton, Sheffield, UK).  
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5.2.4 Animal Models  
Thirty-one 6-month-old male skeletally mature New Zealand White rabbits (B&K, Hull, UK) with 
starting weights of 3.0-3.8 kg were allowed to acclimatise for 7 days. They were maintained in 
individually ventilated cages at 22°C, 50% humidity and food and water were provided ad libitum.  
A schematic diagram summarising the research plan for the in vivo work is shown in Figure 5.1.  
 
 
 
 
Chapter 5: In Vivo Implant Study of High-Phosphate Strontium-Containing Bioactive Glass Coatings 
166 
 
 
 
Figure 5.1: Schematic representation of in vivo study: (a) Ti6Al4V implants were prepared and coated 
with HA or HP1; * axial drill hole for mounting during plasma spraying,  (b) animals were randomised to 
one of three timepoints, (b,c) two implants were placed in each lower limb with HA-coated implant in one 
limb and HP1-coated implant in the other. Animals were euthanased at the appropriate timepoint with 
femora used for (d) histological sectioning and SEM analysis (e) and tibia for mechanical testing. See 
Figure 5.9 for the numbers of animals used in the study. 
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5.2.4.1 Pre-operative Procedure 
Animal experiment was performed under appropriate ethical approval and UK Home Office licencing. 
Animals underwent pre-medication with 0.1 ml/kg fentanyl/fluanisone (Hypnorm, VetaPharma, 
Leeds, UK) intramuscular injection, 15 minutes prior to the surgery. Venous cannulation was 
performed following the application of EMLA cream (AstraZeneca, London, UK) on the ear area. 
Thiopentone (30mg/kg iv, Merial, Harlow, UK) was used for induction of anaesthesia. Animals were 
preoxygenated and endotracheal intubation was performed. For anaesthesia maintenance isoflurane 
(Isoflurane-Vet, Merial, Harlow, UK) was used. Before surgery animals were administered a dose of 
prophylactic enrofloxacin (10 mg/kg, Baytril, Bayer, Leverkusen, Germany). Heart rate, respiratory 
rate, oxygen saturation and temperature were monitored during the surgery. Prior to surgery the 
animals’ legs were shaved with electric shaver from hip to ankle and cleansed with alcoholic 
chlorhexidine (Hibriscrub, Regent Medical Ltd., UK). 
5.2.4.2 Surgical Procedure 
Surgery was performed with the aid of orthopaedic surgeon, Mr Simon Newman, on a heated 
veterinary operating table with full aseptic techniques. Each knee was approached through a medial 
incision. Implant insertion sites were defined in the femur with the knee flexed to 90o. The origin of 
the medial collateral ligament (MCL) was identified and a line was extended from the MCL origin to 
the trochlea in the direction of the MCL. The midpoint of this line was the femoral insertion site. In 
the tibia, the insertion point was in the metaphysis, 6 mm below the joint line at the midpoint of the 
tibial tuberosity and posterior cortex (Figure 5.2). A small flap of periosteum was elevated on the 
femur and tibia overlying the implant insertion sites. Low speed drilling with saline irrigation was 
undertaken with sequentially greater diameter drill bits (2.0 mm, 3.0 mm, 3.6 mm); the cortex was 
drilled to 3.7 mm. Implants were inserted using a press-fit technique with gentle impaction using a 
punch and mallet. Bioactive glass and hydroxyapatite implants were placed in opposite limbs, the 
sides determined by a pre-operative randomisation process. Wounds were closed in layers with 3-0 
Vicryl to the fascia and 3-0 Nylon to the skin. A dose of buprenorphine (0.1 mg/kg, Vetergesic, 
Alstoe, York, UK) was administered at the end of the procedure. 
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Figure 5.2: Position of implants in distal femur and proximal tibia in a practise (deceased) specimen; 
MCL: medial collateral ligament.  
 
5.2.4.3 Post-operative Procedure 
Animals were kept in cages for the first week after surgery and then transferred to individual floor 
pens. They had access to food and water ad libitum. Animals were monitored throughout the study by 
trained technicians and veterinary staff. Wounds were reviewed and sprayed with betadine 
(Molnlycke Healthcare, Dunstable, UK) daily until suture removal at day ten of post-surgery. 
Analgesia (buprenorphine 0.1 mg/kg s/c) was administered twice daily for two days. Antibiotics 
(enrofloxacin 30 mg/kg) were administered subcutaneously for two days and were added to drinking 
water for five days more. After two weeks of surgery, all sutures were removed.  
Animals were allocated to one of three groups randomly for culling at 6, 12 and 24 weeks post-
surgery. All animals were sacrificed by injection of a pentobarbitone overdose and subsequently 
cardiorespiratory arrest was confirmed. 
5.2.5 Mechanical Testing  
Within 6 hours of sacrificing the animals, tibias were harvested and push-out test was performed. All 
soft tissue was dissected from the bone. Specimens were kept moist throughout. The bone was 
carefully sectioned by saw perpendicular to the long axis of the implant so that the implanted end of 
the implant was flush with the cut surface (Figure 5.3). Bone and soft tissue overlying the cortical end 
of the implant was removed to ensure both ends of the implant were completely free of organic 
material. A thin layer of methyl-methacrylate (MMA) was laid around the periphery of the sample to 
aid stability. 
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In order to measure the push-out strength of the implant, a screw-driven Instron machine (Instron, 
High Wycombe, UK) with a head speed of 1 mm/minute was used. The sample was placed on a 
specimen-supporting plate with a 5 mm hole in the centre. A custom-made jig was used to align the 
implant longitudinally over a hole in the supporting plate (Figure 5.3 and Figure 5.4). The critical step 
in performing a successful push-out test is to align the implant with that of the hole in the supporting 
plate. The initial maximum positive deflection was taken as the maximal value. A value for maximal 
shear strength was calculated using Equation 5.1 : 
 
Equation 5.1: Equation for calculating maximal shear strength.
 
Where: σu is shear strength (MPa), Fmax is initial maximum positive deflection force (N), D is pre-
implantation implant diameter (mm), and H is implant length (mm). 
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Figure 5.3: Sample preparation for push-out test. (a) Cross section of tibia displaying the previously 
embedded end of the implant. (b) Jig for alignment of sample. 
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Figure 5.4: Schematic drawing of set-up for push-out test 
 
After the push-out test, implants were fixed in 10% v/v neutral buffered formalin for 24 hours 
followed by immersion in 70% ethanol. Selected implants were examined by scanning electron 
microscopy (SEM) and energy dispersive X-ray spectroscopy (EDS). 
5.2.6 Histological Studies 
5.2.6.1 Histological Section Preparation 
The rabbit distal femurs were cleared of soft tissue. Samples were immersed in 10% v/v neutral 
buffered formalin for seven days then transferred into 70% ethanol for transport to Radboud 
Universitat in Nijmegen, Netherlands. Specimens were dehydrated in graded ethanol using an 
automated tissue processor before embedding in methyl methacrylate (Technovit, Hatfield, PA, USA). 
Parallel sections to the long axis of the implant in a sagittal plane with 10-15 µm thickness were 
produced using a diamond-blade sawing microtome technique. The embedded samples were sectioned 
using a Leica SP1600 microtome with a 270 µm diamond-edged blade with a 1:1 v/v mixture of 
glycerine and water as a lubricant and coolant. An initial thick section was produced for SEM from 
the selected samples. A coverslip was glued to the tissue block with a UV-activated cyanoacrylate-
based cement (301 Industrial Permacol Contact Cement, Ede, Netherlands) before sectioning 
commenced. The next three sections were obtained after exposure to 0.1 M HCl for 15 seconds and 
were then stained with methylene blue for 60 seconds and acid fuchine for 30 seconds prior to gluing 
on a coverslip. 
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5.2.6.2 Histomorphometry Analysis 
Histomorphometry analysis is a way to quantitatively evaluate the amount of the tissue in contact with 
and surrounding the implant. Quantitative assessments was achieved using Osteomeasure software 
(Osteometrics Inc, Decatur, GA, USA) using a microscope at 20 magnification (Figure 5.5). The 
parameters calculated are as follows: 
Bone-implant contact (BIC): measurements of BIC area were made along the two long sides of the 
implant on each section. Bone contact with the implant was only counted for cancellous bone with a 
clear connection to the trabecular architecture. A value for total implant length was obtained by 
tracing using Osteomeasure software. Subsequently a ratio of bone contact to implant surface length 
was obtained. This procedure was repeated for each of the three stained sections from each specimen. 
A mean value from these three ratios was obtained and taken as the value for that particular specimen.  
Bone volume to total volume (BV/TV): two-dimensional measurements of bone surface area were 
expressed as a three-dimensional volume of the total bone volume (280). To calculate the BV/TV, 
first the volume of cancellous bone next to both long sides of the implant in each section was 
measured by tracing using Osteomeasure software in 20 magnification. Then this measured area 
was divided by the total area examined. Less than 100 µm of each implant was visible in each field 
and was subtracted from the total area examined. This procedure was repeated for each of the three 
stained sections from each specimen. A mean value from these three ratios was obtained and taken as 
the value for that particular specimen.  
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Figure 5.5: Example of a tracing of a region in which the area of bone was measured (black marked area) 
to calculate BIC and BV/TV. The yellow marked area corresponds to implant volume; the blue dotted 
line represents bone–implant contact surface. The region of interest is on both implant sides and 
illustrated on one side above. Acid fuchine and methylene blue stain for an HA-coated implant after 6 
weeks implantation in the distal femur, magnification 20.  
 
5.2.7 Scanning Electron Microscopy 
5.2.7.1 SEM-EDS analysis on Tibial Implants after Push-out Test 
The tibial implants which were kept in 70% ethanol after the push-out test were dehydrated with a 
graded series (increasing concentration) of ethanol. Then samples were incubated in 
hexamethylsilasane (HMDS) for 5 minutes following fresh HMDS for another 5 minutes. After the 
samples were dried, chromium sputter coating was applied on the samples at 1.2 atm pressure and 20 
mA voltage for 4 minutes, to improve SEM images. Samples were examined by SEM (LEO 1525) at 
15 or 20 kV with (EDS).  
5.2.7.2 SEM-EDS analysis on the Cross-section of Femur Implants  
To determine the elemental composition of the bone adjacent to the implant and to evaluate the alloy-
coating-bone interfaces on the cross-section of femur implants, SEM (LEO 1525) at 15 or 20 kV was 
used with EDS. Samples were dehydrated and embedded in resin followed by grinding the 
longitudinal sections with 1200 grit SiC paper and polishing them with a 1 µm diamond suspension. A 
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chromium sputter coating was applied to the samples, at 1.2 atm pressure and 20 mA voltage for 4 
minutes, to improve SEM images. 
5.2.8 Bioactive Glass Dissolution Studies  
Dissolution studies were carried out on the HP1 glass. 75 mg of < 38 µm glass powder was immersed 
in 50 ml of Tris buffer or simulated body fluid (SBF) at pH 7.25. The immersed powders in Tris 
buffer or SBF was placed in an orbital shaker incubator (New Brunswick Scientific C24 Incubator) at 
a constant temperature of 37°C for 0.5, 1, 2, 7, 14 and 28 days. After removing the samples from the 
shaker the pH value was measured using a pH meter (Oakton Instruments, NL). The glass powders 
were withdrawn from the solution then the solution was filtered through medium porosity filter paper 
(5 µm particle retention, VWR International). Acetone was sprayed on the collected powder to stop 
any further reaction. The solutions were filtered (0.2 µm cellulose acetate syringe filters, Anachem, 
UK) and kept at 4°C. Samples were diluted by a factor of 1:10 and quantitatively analysed by using 
inductively coupled plasma-optical emission spectroscopy (ICP-OES) (iCAP 6000, Thermo 
Scientific, Waltham, MA, USA) and each sample read in triplicate. The ICP-OES analysis measured 
amounts of the following ions: strontium, silicon, calcium, phosphate and magnesium. The method for 
preparation of Tris buffer and SBF solutions was explained in chapter 3, sections 3.2.5.1 and 3.2.5.2.  
The formation of hydroxycarbonated apatite (HCA) was measured by XRD on the collected powders 
from SBF at the mentioned different time points above; the details of the XRD machine were given in 
section 5.2.2.2. 
5.2.9 Statistical Analysis 
Statistical analysis for both mechanical testing and histology assessment was performed using the 
paired sample Wilcoxon-Sign Rank test to compare groups within time points. The Mann-Whitney U 
test was used to compare groups between time points. p-values below 0.05 and 0.01 were interpreted 
as statistically significant. All statistical analysis was performed using SPSS. 
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5.3 Results 
5.3.1 Particle Size Analysis 
Particle size distribution values of HP1 glass as determined by particle size analyser and Captal 30 
hydroxyapatite are shown in Table 5.2.  
 
Table 5.2: Particle size distribution values for HP1 glass as determined by particle size analyser (top 
table). The data for Captal 30 particles was provided by Plasma Biotal Ltd (bottom table).  
HP1 Test 1 Test 2 Test 3 Average SD
D 10 (µm) 2.33 2.41 2.37 2.37 0.04
D 50 (µm) 26 26.65 26.23 26.29 0.33
D 90 (µm) 44.54 44.9 44.69 44.71 0.18
Mean (µm) 24.77 25.23 24.97 24.99 0.23
Captal 30 
Hydroxyapatite Average SD 
D 10 (µm) 10 5
D 50 (µm) 30 5
D 90 (µm) 50 5
 
 
5.3.2 X-Ray Diffraction 
XRD patterns for HP1 glass powder, HA particles and their coatings on Ti substrate are shown in 
Figure 5.6. The XRD patterns revealed that both the glass powder and the coating of HP1 have an 
amorphous structure. The small diffraction peaks at 2θ=27º and 31º for the HP1 coating correspond to 
the diffraction line in the Ti alloy. The XRD patterns of the HA powder and its coating revealed 
peaks, which matched with the reference patterns of hydroxyapatite (JCPDS 09-432) (Figure 5.6b).  
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Figure 5.6: XRD patterns for (a) HP1 glass powder and coating, (b) HA powder and coating on Ti 
substrate; curves were smoothed by five-point adjacent average smoothing.  
 
5.3.3 Differential Scanning Calorimetry 
DSC was carried out on HP1 glass in order to obtain thermal data such as glass transition, onset of 
crystallisation and peak crystallisation temperatures. DSC traces for HP1 glass powder in different 
heating rates are shown in Figure 5.7. As can be seen from the graph the HP1 glass has two Tg values, 
which becomes clearer when using the 25°C/min heating rate. The optimum firing temperature for this 
glass is in the 700-800°C range.  
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Figure 5.7: DSC traces of HP1 glass as measured under different heating rates. 
 
5.3.4 Scanning Electron Microscopy  
Figure 5.8 demonstrates the surface morphology of HP1 and HA coatings after plasma-spraying as 
imaged by SEM. The surfaces of both samples exhibit some visible micron-scale topography and the 
shape of particles is apparent. The particle shapes of the glass for the HP1 coating are mostly 
spheroidised and flattened and coalesced on top of one another, whereas the particles of HA are less 
distinct and there are several cracks on the surface of the coating. There are no cracks visible on the 
surface of the HP1 coating. 
 
Figure 5.8: SEM micrographs of surface morphology of plasma-sprayed coatings (a) HP1 and (b) HA. 
Black arrows point to cracks in HA coating. SEM accelerating voltage=10 kV and magnification 500. 
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5.3.5 Animal Study 
Out of the 31 animals obtained for this study, two rabbits died during the settling-in period; one due to 
a gastrointestinal infection and the other was found to be lame due to the left knee effusion and was 
euthanased on veterinary advice. 
As described in section 5.2.4.2, surgery was performed and no death or complications occurred. 
Regarding post-operative complications, two animals required re-suturing under general anaesthetic 
due to wound dehiscence. One animal was euthanased due to a wound infection at day 10 after 
surgery and the other animal was euthanased at 9 days due to a second wound dehiscence. 
Two animals were excluded from the remaining 27 animals when assessing results. In the 6-week 
group, one animal was found to have a grossly hypertrophied and hyperaemic femur with a joint 
effusion in the femur containing BG-coated implant. These signs suggested an infection of the femur. 
The other excluded animal was in the 24-week group and had relatively small femurs which were 
found to have fractures bilaterally around the femoral implants. Therefore the groups for analysis 
included eight animals in the 6-week group, nine animals in the 12-week group and eight in the 24-
week group. Numbers of animals were assessed for the current study summarised in the flowchart 
below (Figure 5.9). 
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Figure 5.9: Flowchart showing the numbers of animals in the in vivo study. 
 
5.3.6 Mechanical Testing  
Figure 5.10 shows a boxplot for maximum shear strength of implants coated with HA and HP1 glass 
up to 24 weeks. Mean maximal shear strength values for HA-coated samples remained relatively 
constant with mean values of 3.5 MPa, 3.2 MPa and 3.9 MPa at 6, 12 and 24-weeks, respectively. On 
the contrary, the HP1-coated samples showed a trend of increasing maximal shear strength with mean 
values of 3.2 MPa, 4.1 MPa and 5.0 MPa during the study (data is shown in the appendix, Table A.2). 
There was a trend of increasing maximal shear strength in push-out tests of HP1 samples between 
weeks 6 and 24 (p<0.01) which was not seen for the HA group. No statistically significant increase 
was found in the HA group over the three time points. There was a trend of increasing maximal shear 
strength in the HP1 glass group compared to HA with a statistically significant difference between the 
two coatings at 24 weeks (p<0.05). 
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Figure 5.10: Boxplot showing the maximal shear strength, median, outliers, and 25% and 75% percentile 
for HA and HP1 glass 6, 12 and 24 weeks after implantation;  and  denote maximum and minimum 
outliers, respectively. Significant p-values are displayed.  
 
From visual inspection of the tibial implants following the push-out test, it was noted that HP1 
implants were darker than HA implants at 6 weeks. Qualitatively increasing quantities of adherent 
bone on the HA samples at 6, 12 and 24 weeks were visible (Figure 5.11). No adherent bone was seen 
on any of the HP1 implants at 6 weeks after push-out test, however adherent bone was observed at 12 
weeks and fragment of broken bone remained attached to the implant at 24 weeks after implantation.  
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Figure 5.11: Digital camera images of tibial implants after push-out test 6, 12 and 24 weeks after 
implantation. 
 
5.3.7 Histological Studies 
5.3.7.1 Light Microscopy Analysis 
At 6 weeks after implantation of the implants, a very thin layer of HP1 glass coating was occasionally 
visible, but was mostly absent when stained sections were analysed in higher magnification. HP1 
samples tended to have a thickened bone layer adjacent to the implant with a less well preserved 
trabecular structure at 6 weeks, whereas the HA samples showed extensions of existing trabeculae 
spreading over the coating surface but with less bone adjacent to the implant. Bone trabecular 
architecture was more preserved in HA samples. Also, HA samples displayed greater amounts of bone 
on the implant surface which was not linked to the trabecular network. This greater amount of bone 
could represent projections of bone from trabeculae not visible within the section or “in contact” bone 
formation. Larger areas of deep fuchine staining indicated greater new bone formation in the HP1 
glass group specimen compared to the HA group (Figure 5.12 a and b). 
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Figure 5.12: Light microscopy images of the bone-implant interface (distal femur with implants) in a 
single animal for each time points. (a) HA-coated at 6 weeks after implantation; (b) HP1-coated implants 
at 6 weeks after implantation. The HP1 coating has virtually dissolved by 6 weeks. (c and d) HA-coated 
and HP1-coated implants respectively at 12 weeks after implantation; (e and f ) HA-coated and HP1-
coated implants respectively at 24 weeks after implantation. Acid fuchine and methylene blue stain, 
magnification 4. 
 
It was noted that only one HP1 glass specimen contained a region of fibrous interposition along 
approximately 30% of one side of the bone-implant interface on all three sections in this time point 
(Figure 5.13). No other significant fibrous tissue was seen alongside any other implant. 
200 µm
Implant
Fibrous tissue interposition
Bone
 
Figure 5.13: Light microscopy shows formation of fibrous tissue interposition of bone-implant interface in 
the HP1-glass-coated specimen 6 weeks after implantation; acid fuchine and methylene blue stain, 
magnification 20. 
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There was no coating visible in HP1-coated implants at 12 weeks, whereas the HA coating was 
present in all animals. The structure of the bone between the two implant types differed less than at 6 
weeks, with an increasingly organised trabecular structure in the HP1 glass group (Figure 5.12 c and 
d). At 12 weeks, two HA samples and one HP1 glass specimen showed amounts of fibrous tissue, 
which covered less than 10% of the implant surface. 
At 24 weeks after implantation, there was no visible coating for HP1-coated implants and HA was 
uniformly present. A similar trabecular structure adjacent to the implant was observed for the two 
groups. In this time point, there was less bone alongside the implant in both groups compared with at 
6 weeks. The trabecular architecture was well developed and there was a little deep fuchine staining to 
suggest significant new bone formation (Figure 5.12 e and f). There was no significant fibrous 
interposition in any of the sections at 24 weeks. An overview of the representative implants with peri-
implant bone at 6, 12 and 24 weeks after implantation were shown in Figure 5.14. 
2.0 mm 2.0 mm
 
Figure 5.14: Zoomed out light microscopy images of the peri-implant trabecular bone (distal femur with 
implants) in a single animal for each time points. (a, c and e) HA-coated implant at 6, 12 and 24 weeks 
after implantation respectively; (b, d and f) HP1-coated implant at 6, 12 and 24 weeks after implantation 
respectively. The middle part of the implant has been omitted from the images (dashed line). Acid fuchine 
and methylene blue stain, magnification 2.   
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5.3.7.2 Histomorphometric Analysis  
Figure 5.15 shows the percentage of implant surface in contact with bone for HA- and HP1-coated 
implants 6, 12 and 24 weeks after implantation. There was no statistically significant difference in 
bone-implant contact between HP1 and HA coatings at any time point. There was a trend for 
increasing bone-implant contact in both groups with time. Statistically significant differences in the 
bone-implant contact ratio were only observed in the HA-coated group not only in 6 weeks but also in 
12 weeks. The HP1-coated group did not achieve a statistical significant difference in bone-implant 
contact at any time point. A broad spread of values in the 6 week data may explain this (appendix, 
Table A.3).  
 
Figure 5.15: Boxplot displaying bone-implant contact, median, 25% and 75% percentile for HA- and 
HP1-coated implants 6, 12 and 24 weeks after implantation. Significant p-values are displayed. 
 
With regard to the BV/TV ratio there was a statistically significant difference between the HA and 
HP1 coatings at 6 weeks (Figure 5.16 and appendix, Table A.4). The mean ratio of BV/TV in HP1-
coated implants was found to be 69.5% compared to 55.9% in the HA-coated group (p<0.05). New 
bone formation, which is detected by deeply stained bone, was greater for the HP1 coating in 6 weeks. 
At 12 weeks there was no significant difference between the two implant coatings. There was a clear 
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reduction in the BV/TV at 24 weeks which is likely associated with the remodelling of the peri-
implant woven bone into mature lamellar bone. 
 
Figure 5.16: Boxplot displaying the ratio of bone volume to total volume, median, 25% and 75% 
percentile for HA and HP1 glass 6, 12 and 24 weeks after implantation. Significant p-values are displayed. 
 
5.3.8 Scanning Electron Microscopy  
5.3.8.1 SEM of Tibial Implants 
SEM-EDS was carried out on HP1- and HA-coated implants before their implantation to study the 
chemical composition of the implants. The EDS spectra of both sets of implants confirmed the 
elements of which they were composed (Figure 5.17).  
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Figure 5.17: SEM micrographs of (a) HP1- and (b) HA-coated implants before implantation. Boxes 
indicate the area in which EDS analysis was carried out. EDS spectra of (c) HP1- and (d) HA-coated 
implants before implantation. Chromium was used to coat the implants. SEM accelerating voltage=15 kV 
and magnification 100. 
 
In order to determine both the change in the chemical composition of the implants after implantation 
and which interface failed during the push-out test, SEM-EDS analysis was performed on the selected 
implants. The EDS analysis of the HP1-coated implants at 6 weeks confirmed that the spectra were 
dominated by signals arising from titanium, aluminium and vanadium with no evidence of silicon 
(Figure 5.18a and c). The EDS spectra of the HA-coated implant showed the peaks corresponding to 
the carbon, calcium and phosphorus (Figure 5.18b,d). Tabulated data from the quantitative analysis of 
tibial implants following push-out test at 6 weeks is shown in the appendix (Table A.5). The EDS 
analysis of HP1-coated implants following the push-out test at 6 weeks revealed that they were 
composed mostly of titanium, vanadium and aluminium with no evidence of silicon or strontium, 
whereas HA-coated implants were composed mainly of calcium and phosphorus. 
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Figure 5.18 SEM micrographs of (a) HP1- and (b) HA-coated implants 6 weeks after implantation. Boxes 
indicate the area in which EDS analysis was carried out. EDS spectra of (c) HP1- and (d) HA-coated 
implants 6 weeks after implantation. SEM accelerating voltage=15 kV and magnification 100. 
 
Furthermore EDS analysis of the bone tunnel following push-out test for both HP1 and HA coated 
implants demonstrated the presence of major bone elements such as calcium and phosphorus (Figure 
5.19). However, quantitative EDS analysis of the HP1-coated implant did not show evidence of 
silicon or strontium at 6 weeks (Figure 5.19a and c). The EDS spectrum of the bone tunnel for the 
HA-coated implant demonstrated the presence of calcium and phosphorus (Figure 5.19b and d).  
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 Figure 5.19: SEM micrographs of bone tunnel of (a) HP1- and (b) HA-coated implants after push-out 
test at 6 weeks. Boxes indicate the area in which EDS analysis was carried out. EDS spectra of bone 
tunnel of (c) HP1- and (d) HA-coated implants after push-out test. Chromium was used to coat the 
implants. SEM accelerating voltage=15 kV and magnification 100. 
 
5.3.8.2 SEM of Femoral Implants 
Figure 5.20 shows SEM micrographs of a cross-section of HP1- and HA-coated implants 6 weeks 
after implantation in the distal femur. SEM analysis of the HP1-coated implant confirmed that the 
majority of the HP1 coating was absent by 6 weeks, whereas the HA coating was clearly visible at this 
time. From the backscattered images (Figure 5.21) it can be seen that in the HP1 specimen there was 
direct apposition of bone to the titanium implant surface and for the HA samples the coating was 
interlocked with the implant surface with bone conducted over the coating surface.  
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Figure 5.20: SEM micrographs of polished cross-sections of coated implants in femur bone 6 weeks after 
implantation in the same animal, (a) HP1-coated implant at lower magnification (40), (b) HA-coated 
implant at lower magnification (40), (c,e) bone-implant interface of HP1-coated implant at higher 
magnification (500), (d,f) bone-implant interface of HA-coated implant at higher magnification (500). 
SEM accelerating voltage=15 kV for all images.  
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Figure 5.21: Backscattered electron image of polished cross-sections of coated implants in femur bone 6 
weeks after implantation in the same animal, (a) HP1-coated implant (100), (b) HA-coated implant 
(100), (C) bone-implant interface of HP1-coated implant at higher magnification (500) and (d) bone-
implant interface of HA-coated implant at higher magnification (500). SEM accelerating voltage=20 kV 
for all images. 
 
In order to find out if the HP1 coating was present at the early time points, SEM-EDS analysis was 
carried out on a sample from an animal culled 10 days after implantation as a result of wound 
dehiscence. SEM micrographs showed that the coating was present at this time point (Figure 5.22a 
and b). Figure 5.22b illustrates a line scan performed across the bone-coating-implant interfaces. The 
results from line-scanning revealed that elements from glass such as strontium and silicon were still 
detectable over a distance of 20 to 80 µm which matches with the area in which coating is present 
(Figure 5.22c). 
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Figure 5.22: SEM micrographs of a polished cross-section of HP1-coated implants in femur bone from an 
animal culled 10 days after implantation (a). Box in (a) corresponds to the area of (b), line-scan profile 
across the bone-coating-alloy interfaces (b) and normalised element concentrations (c). SEM accelerating 
voltage=15 kV.  
 
Furthermore EDS dot-mapping on the cross-section of HP1-coated implants at day 10 of implantation 
confirmed that the signals arising from silicon correlated with the location of coating and those from 
aluminium and titanium with the location of the Ti alloy (Figure 5.23). The majority of calcium and 
phosphorus signals are associated with the position of the bone, however there were a few signals 
arising from calcium and phosphorus that originated from the coating. 
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Figure 5.23: Comparative elemental mapping on a cross-section of an HP1-coated implant 10 days after  
implantation. EDS dot-mapping on the representative area (a) showing the presence of silicon (Si), 
phosphorus (P), calcium (Ca), carbon (c), aluminium (Al) and titanium (Ti) (b-g). Representative area 
size: 280  220 µm, SEM accelerating voltage=15 kV and bars indicate magnification. 
 
SEM investigation was carried out on the cross-section of both HA- and HP1-coated implants in the 
femur bone at different time points after implantation (Figure 5.24). SEM micrographs revealed that 
the HA coating is present during all the time points after the implantation. However, a delimitation 
between HA coating and alloy at 24 weeks was noticed while the bone-HA coating contact seemed 
well preserved (Figure 5.24, left column and bottom row). SEM of the HP1-coated implant showed 
that the majority of the HP1 coating was absent during the three time points of the experiment; 6, 12 
and 24 weeks (Figure 5.24 right column).  
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Figure 5.24: SEM micrographs of polished cross-sections of implants in femur bone after 6, 12 and 24 
weeks of implantation; HA-coated implants (left column) and HP1-coated implants (right column). SEM 
micrograph for each time point comes from a single animal. The marked area corresponds to the area in 
which EDS analysis was carried out; EDS spectra are shown in Figure 5.25. SEM accelerating voltage=20 
kV and magnification 500.  
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With the aim of tracing the migration of strontium and silicon from the HP1 glass coating towards to 
the bone adjacent to the implant, EDS analysis was carried out. EDS allows us to evaluate the process 
of coating degradation at the observation time points. Areas of approximately 100 µm distal from the 
implant interface towards the bone (the marked area in Figure 5.24) were assessed. At all three time 
points, the EDS spectra taken of the marked area showed peaks consistent with bone elements such as 
calcium and phosphorus for the HA-coated implant (Figure 5.25, left column), while the EDS spectra 
acquired from the HP1 coating demonstrated the presence of bone, metallic elements from Ti alloy 
and occasional peaks arising from silicon (Figure 5.25, right column). Strontium was not detected in 
the bone adjacent to either HA- or HP1-coated implants. 
 
 
Figure 5.25: EDS spectra of the bone adjacent to the implants in femur bone (see marked area in Figure 
5.24) 6, 12 and 24 weeks after implantation; HA-coated implants (left column) and HP1-coated implants 
(right column).  
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5.3.9 Dissolution Ion Studies and Bioactivity Assessment of HP1 Glass Powder 
5.3.9.1 Ion Release in Tris Buffer and SBF Solutions 
The findings from histological evaluation and SEM-EDS analysis demonstrate the absence of the HP1 
glass at 6 weeks, however this coating was still present ten days after implantation. To investigate the 
dissolution behaviour of ions released from HP1 glass, a study was carried out in vitro in Tris buffer 
and SBF. The profiles of the ions released from HP1 glass powder (< 38 µm) in Tris buffer and SBF 
over 28 days of immersion are presented in Figure 5.26, left and right, respectively. 
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Figure 5.26: ICP results, ion-release profile after immersion of HP1 glass powder in Tris buffer (left) and 
SBF (right) over 28 days of interaction. 
 
During the first week of immersion slight variations were observed in the ionic concentration of the 
released ions from HP1 glass into Tris buffer. The ionic concentration of Sr2+, Ca2+ and soluble silica 
increases sharply up to day 14 of immersion and then slightly rises (Figure 5.26, left). HP1 glass 
releases more strontium ions into the Tris buffer during the immersion time than other ions. Sr2+, Ca2+, 
PO4-3 and Mg2+ ions all follow a similar trend; very faster at the start of immersion and then reaching 
a plateau after 24 hr. There is a rapid increase in ionic concentration of Si at early immersion times in 
SBF, which then decreases gradually (Figure 5.26, right). Additionally, the theoretical concentration 
values for the ions released from HP1 glass in Tris buffer, assuming that glass completely dissolves, 
were calculated (Table 5.3).  
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Table 5.3: Calculated theoretical values of ionic concentration of ions released from HP1 glass, assuming 
glass completely dissolves in Tris buffer.  
Sr2+ Soluble 
silica Ca
2+ PO4-3 Mg2+
Ionic concentration of ions released from 
HP1 glass in Tris buffer assuming glass 
completely dissolves (ppm) 307 270 96 60 39
 
 
5.3.1 Characterisation of the Surface Precipitated Layers by XRD  
Figure 5.27 presents XRD patterns of HP1 glass before and after soaking in SBF for 7, 14 and 28 
days. XRD patterns were compared to reference patterns of carbonated hydroxyapatite (JCPDS 19-
272). At day 28, a small peak was observed at 2θ = 28.12º which reflects the presence of carbonated 
hydroxyapatite.  
20 30 40 50
In
te
n
s
ity
 
(a.
u
.
)
2θ (°) 
28 days
14 days
7 days
no SBF
 
Figure 5.27: XRD patterns of unreacted HP1 glass (bottom) and after immersion in SBF for 7, 14 and 28 
days; curves were smoothed by five-point adjacent average smoothing.  
5.4 Discussion 
5.4.1 Structural Characterisation, Mechanical Testing and SEM-EDS Analysis of the Bone-
implant Interface 
During plasma-spraying the crystallinity percentage of HA decreases as a result of HA decomposition 
at the high temperature necessary for the plasma-spraying technique followed by the rapid cooling  
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rate (281;282). The degree of crystallinity can be varied from 50% to 90% (282). The plasma-sprayed 
HA coating may consist of a mixture of the non-molten core of HA particles and the new, 
recrystallised HA phase. Here, XRD measurement of the HA powder and the produced HA coating 
shows high crystallinity for both of these. However, XRD results for the HP1 glass sample 
demonstrated that both particles and coating were amorphous. It has been shown that in the biological 
environment, HA coatings with high crystallinity are more stable (23;283). There is also general 
agreement that when the coating contains more of amorphous phase the growth of the bone happens at 
a faster rate due to more rapid initial dissolution. 
Furthermore, XRD patterns for HA coating (Figure 5.6b) showed some hydroxyapatite related peaks 
in the same positions as HA powder with different intensities. This can be explained by the crystal 
orientation effect during the plasma spraying processing; for example if there was a temperature 
gradient and the crystals grow perpendicularly outwards from the metal substrate. 
In terms of thermal properties the HP1 glass has been designed to have a slightly higher TEC than a 
metal substrate; this ensures that in the coated substrate there are minimal thermal stresses. The 
calculated TEC of HP1 is 11.1 × 10-6 ºC which enables the glass to be coated on Ti alloy. TEC is also 
important factor to consider for HA coating and it has been reported that the TEC of HA (12 × 10-6ºC) 
is closer to that of Ti alloy (9.2 × 10-6ºC) than those of other metallic implants such as cobalt-
chromium alloy (282). The difference between the TEC of HA coating and substrate may explain the 
visible cracks on the surface of the HA coating (Figure 5.8). 
Glass transition and onset of crystallisation temperatures were determined for HP1 glass using DSC, 
to ensure that the glass transition temperature is sufficiently low and that the sintering window is big 
enough to result in sintering below the α → β phase transition of the Ti6Al4V which occurs in the 
range of between 955 and 1010°C (209). 
While the implant is in the bone, the surface of coating contacts with bone and body fluid directly. 
Therefore, surface morphology and roughness of the coating are important parameters which can 
effect dissolution of the coating and the bone-implant response (282;284;285). It is worth pointing out 
that coating roughness can be controlled by changing the spray parameters (284). Here, the the effect 
of spraying conditions on the coating surface cannot be discussed since Plasma Biotal Ltd did not 
provide the details of spraying parameters used for the specimens. However, we tried to produce the 
similar surface roughness for both samples by matching the particle size as this was our only point of 
control for the surface roughness that would reduce the differences between the properties of these 
samples. According to the particle size analysis, the average size distribution of HP1 glass matches 
well with that of the HA particles.   
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The long-term performance of the coated implants depends on the mechanical properties of the 
implants and the characteristics of the coatings. Thickness of the coating can affect the mechanical 
properties. Most manufacturers provide HA coatings of 50-75 µm thickness for commercially used 
orthopaedic implants (282). The thickness depends on the coating characteristics and the location of 
implantation. Implants with a coating thickness of 50-100 µm were used for the current study for both 
HA and HP1 coatings. 
Push-out test results of the HP1 coating showed that there was an increase in maximal shear strength, 
whereas there was a slight increase in this for the HA sample over the period of the experiment. 
Lopez-Sastre et al. compared the osteointegration of plasma-sprayed coatings of BG (Biovetro 
formula) with that of HA in sheep after 2, 4, 6, 8, 12, and 16 weeks of implantation (286). They found 
that the average shear-strength values for BG-coated implants were significantly lower (p<0.05) than 
those of HA-coated implants at different time points during the study. In another study it has been 
shown that the ultimate shear strength measured for the 10% strontium-substituted hydroxyapatite 
coating, prepared using sol-gel dip-coating, was increased over that of hydroxyapatite coating at 12 
weeks after implant insertion in ovariectomised rats (80). In the study carried out by Geesink et al., 
plasma-sprayed apatite coating on titanium implants was inserted into the femurs of dogs and the 
shear strength of the implant-bone interface increased during the follow-up period  from 6 weeks  to 
one year (277). Svehla et al. studied five different surfaces on titanium alloy implants in an ovine 
model and showed that shear-strength values for the HA coating on the grit-blasted surface increased 
from 4 to 8 and 12 weeks after implantation (287). 
In the present study the reason why the maximal shear strength of HA coating did not show an 
increase during the observation time points is unclear. It is likely that by 6 weeks the maximum shear 
strength may be present in the lapine model. However, based on the visual examination of the tibia 
implants after push-out test there was bone adherent to the HA samples at all time points of 
experiment (Figure 5.11). This observation indicates that the bond between HA coating and bone was 
stronger than the bone itself. Furthermore, quantitative EDS analysis data showed that the spectra 
were dominated by bone elements for HA coatings after push-out test at 6 week which specifies that 
the failure happened in the surrounding bone. Some discrepancies have been noted in the results from 
different laboratories regarding why the interface fails for plasma-sprayed HA-coated implants after 
push-out test. Some in vivo studies have reported that the metal-coating interface failed 
(277;288;289). The probability of the failure at this interface is higher for the implants with longer 
implantation period. In another study, Wang et al. reported that the failure site of plasma-sprayed HA 
coating at 12 weeks of implantation in a canine model was the bone-coating interface (290). The 
variation in these studies can be related to differences in coating thickness, surface roughness, implant 
size, push-out test condition and surgical techniques.  
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At 6 weeks after implantation almost no bone was seen on the HP1 coating and the implants were 
darker than HA implants (Figure 5.11). Moreover, quantitative analysis of EDS data of the tibia 
implants after the push-out test at 6 weeks showed that the spectra dominated by Ti alloy species. 
Therefore, the speculation is that the failure occurred within the coating-alloy interface of HP1-coated 
implants. This finding was in disagreement with a study which has shown that in BG-coated implants 
failure always occurred at the bone-coating interface (286), but the authors did not provide 
information regarding the matching of TEC of the BG coatings with Ti alloy cylinders. In order to 
confirm the above assumption, quantitative EDS analysis was carried out on the bone tunnel 
following push-out test of the HP1 implant and this revealed that there was no glass coating attached 
to the bone (Figure 5.19). Therefore, we may instead postulate that the HP1 glass coating had 
dissolved by 6 weeks and the grit-blasted surface of Ti alloy which has the capability of 
osseointegration, was exposed to the bone. Taken together, the push-out test and SEM-EDS results 
may suggest that the HP1 glass stimulates more bone formation adjacent to the implant (peri-implant 
bone formation), which consequently results in higher mechanical fixation of the implants. This 
hypothesis agrees with the broken bone fragments on the HP1 implants at 24 weeks which are visible 
to the naked eye and which indicate a noteworthy capacity of osseointegration either of HP1 glass 
composition or of grit-blasted Ti alloy.  
SEM observation plus EDS analysis revealed that the majority of the HP1 coating was dissolved by 6 
weeks, whereas a thick layer of HA coating was present during the three time points of the study. 
Resorption of the HA coating is an important matter for the implant fixation. Moroni et al. compared 
the external fixation pin with and without HA coating in an ovine model and found good contact and 
slight resorption of HA after 6 weeks of operation (291). Cimerman et al. and Hemmerle et al., in 
separate ovine studies, showed that the HA coating had disappeared 6 months after implantation 
(292). Complete loss of an HA-coated implant of 60 µm thickness was reported after 4 years of 
implantation by Buma et al (293).  
The lack of the presence of the HP1 coating after 6 weeks implantation was unexpected. The HP1 
glass is a potentially commercial formulation from RepRegen Ltd and the choice of this glass for a 
coating application was based on its thermal properties which were discussed earlier and the results of 
cell culture study which showed that HP1 glass dissolution products enhanced the ALP activity of 
Saos-2 cells. There are two hypotheses which could describe the disappearance of the HP1 coating by 
6 weeks: first, the coating detached during the insertion procedure and second, the HP1 coating 
dissolved more swiftly than was expected. The following part will discuss the results of the 
experiments that were carried out to investigate the mentioned hypotheses.  
Light microscopy and SEM observations of the bone-implant interface of femur implants revealed 
that the majority of the HP1 coating dissolved by 6 weeks after insertion of the implant, whereas a 
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thick layer of HA coating was visible at all the three time points. Furthermore, EDS analysis on tibial 
implants after push-out test did not show any spectral components related to the composition of the 
HP1 coatings, e.g., strontium or silicon. However, quantitative analysis of EDS on the cross section of 
femur bone adjacent to the HP1 implant showed a silicon peak at 6 and 12 weeks despite the absence 
of a coating. Merolli et al. evaluated the gradual process of plasma-sprayed BG coating implants using 
EDS at 4, 8 and 12 weeks after implantation in a lapine model (294). They considered silicon to be the 
indicator for the presence of the glass and reported that silicon has a maximum peak in a sample after 
4 weeks and, despite the absence of coating, a small signal due to silicon was present 12 weeks after 
implantation. They concluded that the silicon signal is likely related to glass components which are 
incorporated inside the newly formed bone (294). Line-scanning throughout the alloy-coating-bone 
interfaces and dot-mapping on the cross-section of the HP1-coated implant after 10 days of 
implantation in the femur showed that the glass elements present in the area match with the location 
of the HP1 glass coating. Therefore, this finding negates the proposition that the HP1 coating 
detached during the insertion procedure and leaves the second hypothesis as possible. 
To understand the reason for the rapid dissolution of the HP1 glass, the dissolution behaviour and 
bioactivity of this glass were assessed in vitro. It is worth pointing out that there are discrepancies in 
the findings of different studies on the dissolution rate of the BG since there are various factors which 
could affect the dissolution of the BG. For example, in a study designed to investigate the bone 
apposition between bone and 45S5 BG coating in the rabbit femur, it was shown that the BG coating 
was still present after 24 weeks (295). In another in vivo comparison, in the sheep femur, the BG 
coating disappeared more rapidly than an HA coating from 4 weeks onward (286). As previously 
described in the literature review chapter, the general mechanism by which BG dissolves and forms 
an HCA layer on the surface of the glass is understood (154) but the effect of glass composition on the 
degradation process and formation of HA remains unclear. In general, immersing the glass disc or a 
scaffold in SBF solution at 37ºC and measuring the weight loss of the glass as a function of time is 
used to study the dissolution rate of the BG (25;296). However, there might be some precipitation 
which would make this weight loss measurement inaccurate. Therefore, studying the behaviour of 
ions which are released in a simple solution such as Tris buffer should be useful to investigate the 
basic aspects of the dissolution process (297). The theoretical calculated values for the concentration 
of ions released from HP1 glass in Tris buffer can predict the dissolution behaviour for the released 
ions (Table 5.3). From the SBF data it can be seen that the release of phosphate reaches a plateau in 
the early stage of immersion which means that it does not precipitate. There is in general agreement 
that the concentration of phosphate ions in BG decreases in SBF due to the precipitation and 
formation of an HCA layer. The rate of development of the HCA layer on the surface of glass exposed 
to SBF provides an in vitro index of bioactivity. XRD measurements on the HP1 glass particles after 
the SBF study showed that this glass formed a small amount of HCA after 14 days. This failure to 
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rapidly form HCA on the surface of the glass particles in vivo may stimulate a foreign-body reaction 
(298). This reaction could be followed by a reduction in local pH due to the release of cytokines and 
prostaglandins from the cells (282) which would cause rapid dissolution of the glass. It has been 
shown that at lower pH values the breakdown of the glassy network of the Bioglass® 45S5 occurred 
and no precipitation of calcium or phosphate salts was reported (299). The local biological 
environment may be affected by degradation of BGs and other biodegradable materials. As a result of 
fast degradation in the early stages, release of ions such as sodium and calcium increases which leads 
to pH changes (25;300;301). A furthers challenge in elucidates the situation is that the biological 
outcomes of these changes are difficult to predict from in vitro studies such as SBF (8). The 
comparative study of in vitro and in vivo bioactivity of BG grafts by Towler et al. showed that the 
ability to form HCA in SBF cannot predict the ability to bond to the bone and the use of SBF for 
screening orthopaedic biomaterials should be considered with caution (302). On the contrary, the 
studies by Fujibayashi et al. and Kokubo et al. indicated that study in SBF is important for in vitro 
evaluation of apatite formation and a good screening test for in vivo bioactivity of materials 
(222;303). 
Accordingly, the failure to produce an HCA layer of HP1 glass may explain the rapid dissolution of 
this glass. As discussed in chapter 3, zinc can delay the HCA formation on the surface of the glasses. 
However, light microscopy of the area with a remnant of HP1 coating which was seen occasionally in 
some slides showed good bone-coating contact without fibrous tissue formation. This result confirms 
that although HP1 glass did not form an apatite layer in SBF it did demonstrate good bone contact. 
5.4.2 Histomorphometric Analysis 
One of the chief goals in orthopaedics is to achieve good and fast bone implant osseointegration 
(304). Measurement of the percentage of bone-implant contact and the amount of peri-implant bone 
volume can be used as an assessment of osseointegration. Here, histomorphometric analysis showed a 
significant peri-implant bone-volume increase in HP1-coated implants compared with the HA-coated 
implants 6 weeks. However, there was an overall reduction in the amount of peri-implant bone in both 
groups by 24 weeks. The process of remodeling of woven bone into mature lamellar bone may 
explain the decrease in bone volume which occurred in both groups between 12 and 24 weeks. 
Primary and secondary stability are important to achieve and maintain osseointegration and both are 
related to peri-implant bone volume (116). Primary implant stability and secondary implant stability 
refer to the initial mechanical fixation and long term stability of the implant, respectively, and both 
correlate to the bone mineral density (305). Regarding the correlation between bone mineral density 
and osseointegration, there is a dental study which suggested that low bone density, which is common 
in osteoporotic bones, may affect the healing time of bone tissue after implantation, but that implant 
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osseointegration may be obtained in osteoporotic patients (306). However, there is trong evidence for 
a link between osteoporosis and an increased risk of peri-prosthetic fracture (307). Therefore, an 
implant with the ability to increase the amount of peri-implant bone volume and bone mineral density 
is expected to prevent peri-prosthetic fracture. 
Studies on HA-coated implants have showed that regardless of loaded or unloaded experimental 
conditions and substrate material, these implants demonstrate a better bone-implant contact than do 
uncoated implants at all observed time points (283;291;308). In the current study, histomorphometric 
analysis of the bone-implant contact demonstrated little difference between the HA and HP1 coatings 
over the course of the experiment. There was a significant increase in bone-implant contact between 
the 6 and 12 week time points for HA-coated implants while the wide spread of the 6 week data for 
HP1-coated implants meant that results from this group were not statistically significant. However, 
there was an increase in the mean maximal shear strength in the HP1-coated group at the same time 
points. The amount of bone-implant contact between the 12 and 24 week samples remained similar in 
both groups, which suggests that although significant remodeling occurs in the peri-implant region 
after 12 weeks, as shown by the reduction in bone volume, the amount of bone-implant contact is 
preserved.  
In a study that compared BG- with HA-coated implants, the histological analysis showed less bone-
implant contact for BG-coated implant with interposition of fibrous tissue in the bone-implant 
interface (286). Here, light microscopy did not reveal significant fibrous tissue in the bone-implant 
interface of the HP1-coated group. As discussed earlier, exposing a rough grit-blasted Ti alloy surface 
to the bone after the HP1 coating had dissolved resulted in gradual bonding of bone to the Ti alloy and 
may have enhanced the fixation of implant and caused true osseointegration. Taken together, these 
findings suggest that the HP1 coating performed more in the fashion of an osteoinductive agent rather 
than a true coating acting as an interface between organic and inorganic phases. 
It is worth emphasising the direct relation between surface roughness and bone-implant contact which 
was also reported in a systematic review from 1953 to 2003 and which leads to a significant increase 
in bone-implant contact with a higher surface roughness (285). Therefore, an unexpected observation 
of the current study would be that the rapid dissolution of the glass has exposed the roughened 
implant surface and has provided mechanical improvement. The study design was such that the HA 
coating cannot be applied on a smooth surface (309) and the preparation method for both coatings 
must be consistent. Considering the knowledge gained from the dissolution behaviour of the HP1 
glass, it may be have been desirable to include a group of uncoated grit-blasted Ti alloy implants as a 
control in parallel with the coatings that were used.      
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Finally, it is worth to point out that the type/specious of the animal model, the material is used as 
substrate to coat the glass on its surface and surgery techniques are all important factors which may 
affect the results. The choice of the rabbit for this study was because this animal is easy to handle, 
takes up relatively little space, is cheap to maintain, has bone with a similar strength and density to 
human bone and reach skeletal maturity rapidly at 6 months (310). However, the lapine model has 
relatively small volume of bone available for implantation of devices and there are some differences 
in macro and micro architecture of bone compared to human bones. Although, dogs or sheep are more 
useful when considering the use of a particular material or implant surface modification in humans, 
rabbits provide a convenient model for the initial investigation of osseointegration before progression 
onto more expensive weight-bearing models in larger species (311). Furthermore, there is no clear 
agreement on the morphology of the implants that can be used for assessment of osseointegration in 
the rabbits. The size of the implants is also important matter to be considered. According to the ISO 
guidelines (312), no more than 3 implants of 2 mm diameter and 6 mm length should be used in the 
rabbit femur or tibia due to the risk of fracture.  
                                                                                             
5.5 Conclusion 
This study for the first time demonstrated the potential application of high-phosphate strontium-
substituted glass coatings for implant fixation. Improving implant fixation, principally in osteoporotic 
patients, has great clinical importance and this study approached this issue using a strontium-
substituted glass coating by exploiting the beneficial effect of strontium on bone mineral density. 
When identical Ti alloy implants were used, HP1 encouraged greater implant fixation than HA in two 
of the three evaluation which, be specific parameters of osseointegration, superior mechanical fixation 
and increased peri-implant bone formation. The rapid dissolution rate of the strontium-substituted 
glass caused a failure at the bone-implant interface in this group compared to the HA group at 6 
weeks, which suggests that the rate of true osseointegration was superior in the HA group. However, 
higher implant fixation was seen for strontium-substituted glass through increased bone formation 
adjacent to the roughened Ti alloy implant. These results suggest that in the future strontium-
substituted bioactive glass coatings could provide a viable alternative to hydroxyapatite, particularly 
in patients with reduced bone mineral density.  
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The challenge of repairing and regenerating bone tissue damaged by injury or disease should not be 
underestimated in orthopaedics. With the increasingly aging population, osteoporosis and bone 
fractures have become more frequent and have given rise to the requirements for prosthetic metallic 
implants. For successful skeletal reconstructive surgery it is essential to promote the fastest and most 
reliable osseo-integration of an implant device. The main cause of implant failure and revision surgery 
is non-bonding of bone to biomedical implants. Improving the interface between implant and bone 
tissue is important and notably a great advance has been made using different approaches. The 
success of stabilization of this interface relies on our ability to study and understand the structure of 
the material used and the biological interactions between bone tissue and material, and then we can 
produce effective and long-lasting materials with tissue mimicking abilities. In this thesis the 
development of such a material to provide a strong bond in the implant-bone interface was studied.   
A multidisciplinary approach was applied to develop novel strontium-substituted high-phosphate 
containing BGs that combine the bioactivity and biocompatibility of BG with the beneficial effect of 
bone stimulation due to strontium release, that can be used as bioactive coatings for metal implants. 
Additionally, to address the importance of matching the TEC of the coatings to the alloy used for 
prosthesis, which has been neglected in most of the published studies, the coatings were designed in 
such a way that the TEC of the coatings were close to that of the metal to achieve satisfactory 
adhesion between the BG coatings and the Ti alloy. This research has been the first work to study the 
structural, physical and biological effects of the addition of strontium into the multicomponent BG 
compositions designed for coating applications.    
Strontium was substituted for calcium on a molar basis into multicomponent silica-based glass 
compositions. Since these compositions were designed for coating applications the chemical 
compositions were designed in such a way that the thermal expansion coefficient of the glass was 
close to that of the metal. Zinc and magnesium were the main components needed to achieve this. 
Structural changes in the glass were characterised and it was found that these glasses contain two 
separate phases including phosphate and silicate phases and substituting strontium did not change 
both the silicon and phosphorus speciation. However, as a result of the larger ionic size of strontium 
compared with calcium the glass network expanded. This significant finding confirmed that 
substituting strontium for calcium in the glass network changed the physical properties of a BG 
without changing its structure. The sintering behaviour of the glasses has been characterised and it 
was found that the mixed calcium/strontium glasses exhibited a larger processing window, which 
favours sintering without crystallisation occurring and obtaining amorphous well sintered coatings. 
SEM and XRD characterisations of the coatings produced by enamelling technique confirmed a 
coherent well bonded interface between the Ti alloy and the glass, with no obvious crystallisation at 
the interface, and no Al, Ti or V was detected in the glass away from the interfacial region. 
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Following the characterisation of the strontium-substituted glasses, their ability to form HCA was 
studied in SBF solution and it was found that HCA formation was retarded. This cannot be the direct 
effect from strontium since the non-strontium containing glass also did not show HCA formation but 
it may explained by the effect of other components that were added to the glass composition, such as 
zinc or magnesium.  
In vitro cell culture studies were performed to determine the effect of strontium-substituted glasses on 
cell viability. Human osteosarcoma cell lines (Saos-2) were treated in the media containing ions from 
glasses to measure metabolic activity, total DNA and ALP. Also, Saos-2 cells were seeded on the 
glass coatings to study the cell viability on the coatings and the interaction of the cells with the 
coatings. The initial difficulty caused by washing out the Saos-2 cells after seeding on the coatings 
was overcome by allowing the cells to attach for 30 minutes before standard cell-culture media was 
added. It was found that strontium-substituted glasses do not have a toxic effect on the cells and the 
coatings support cellular attachment and growth. Even if no quantitative experiments were performed, 
it was clear that the cells were more visible on the 10% strontium-substituted glass coating and total 
DNA and ALP activity of this composition were higher than the non-strontium containing and 50% 
Sr-substituting glass. According to the in vivo and in vitro data from the literature (71;226;264) and 
and considering this alongside the current study, 10% strontium-substituted glass fits within the range 
of strontium which can enhance bone mineralisation. 
In order to get the ideal biological effect from the glasses produced and designed them in such a way 
to exhibit an increased apatite deposition a series of 10% Sr-substituted BG with varying P2O5 content 
was designed with TEC that matched that of Ti alloy. Sufficient cations were added to ensure charge 
neutrality in the PO43- complex formed. It was found that the glasses have phase separated structure, 
with silicate rich and phosphate rich domains. And as P2O5 is added through the series no changes 
were observed in the ratio of Q2 and Q3 silicate species. An increase in P2O5 content of the Sr-
substituted glasses aids formation of the HCA layer in SBF and allowed for apatite formation at a 
lower pH. The finding that addition of P2O5 aids bioactivity has also been shown in simple four 
component soda-lime-phosphosilicate glasses previously (215), however the effect of increasing P2O5 
content in Sr-substituted BG on cultured osteoblasts had remained unexplored. Therefore, cellular 
response (metabolic activity, proliferation, differentiation and cell attachment) of Saos-2 cells to the 
10% Sr-substituted BG with varying P2O5 content was studied. It was found that higher phosphate-
content Sr-substituted bioactive glass can enhance Saos-2 cells metabolic activity and it does not 
unduly affect osteoblast viability. Cell death was not observed on the Saos-2 cells seeded on the 
surface of the glass coating suggesting that addition of P2O5, within the range of 1.07 to 6.42 mol%, 
has no toxic effect resulting in cell death.    
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In a research project performed in collaboration with the Department of Surgery and Cancer and 
Department of Mechanical Engineering, I investigated the degree of osseointegration of the 
potentially commercial BG composition termed HP1. This formulation was provided by RepRegen 
Ltd. HP1 is 50% strontium-substituted BG with high phosphate content that can be used as a coating 
for Ti alloy implants as its TEC is designed to match with Ti alloy. This plasma sprayed coating was 
compared with HA-coated implants in a lapin model and provided increased peri-implant bone 
formation and superior mechanical fixation. The choice of the rabbit for this study was because this 
animal is easy to handle, takes up relatively little space, is cheap to maintain, has bone with a similar 
strength and density to human bone and reach skeletal maturity rapidly at 6 months (310).  
After synthesising HP1 glass by melt-derived technique in order to reduce the differences in the 
surface roughness between HP1 and HA samples, the particle size of the HP1 glass was matched with 
the particle size of HA powders by changing the parameters related to milling and sieving of the glass 
powder to obtain an approximate particle size match. The same coating thickness as that for HA was 
also used for the implantation studies. 
Thermal characterisation of the HP1 glass showed that the sintering window is large enough to result 
in sintering below the α → β phase transition of the Ti alloy and XRD data revealed amorphous 
coatings after plasma-spraying.  Although, it was found that the HP1 glass coating dissolved by 6 
weeks, this coating encouraged greater implant fixation than HA in two of the three specific 
evaluation parameters including; osseointegration, superior mechanical fixation and increased peri-
implant bone formation. Higher implant fixation was seen for strontium-substituted glass through 
increased bone formation adjacent to the roughened Ti alloy implant. The results obtained from the in 
vivo animal study suggested that the strontium-substituted BG coating with high phosphate content 
has a great potential to use as a viable alternative to plasma sprayed hydroxyapatite coatings, 
particularly in patients with reduced bone mineral density. Further optimisation of the glass 
composition needs to be done with regard to the dissolution rate of the produced coating. 
It is hoped that the results presented in this thesis will help researchers to develop the coatings for 
clinical orthopaedic applications, principally in osteoporotic patients. The use of BG coatings 
to deliver therapeutic concentrations of strontium ions to the surrounding bone can be exploited in 
tissue engineering and regenerative medicine applications.  
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Future Research Avenues 
Many interesting questions have been raised during this study with respect to understanding the 
structure of the glasses and their behaviour in the biological environment. Future work on the 
following points detailed below, may help to bring the BG coating into the clinical use to meet the 
growing requirements for the long-lasting prosthetic metallic implants for our aging population, 
particularly with osteoporotic bones. 
• The produced glasses clearly illustrated the existence of two separate silicate and phosphate 
phases. It would be interesting to study the phase size and dimensions on physical properties 
such as the glass transition temperatures and TEC of the glasses. Numbers of potential 
techniques are available for the investigation of phase separation. Transmission Electron 
Microscopy is useful to providing an idea of the phase distribution and dimensions. 
Specifically, Small Angle Neutron Diffraction study on phase separated structures of BGs 
can provide beneficial information with respect to the dimensions of phase separation.       
•  A deeper understanding of the role of zinc and magnesium in the structure and bioactivity 
behaviour of the multicomponent BGs would be very interesting e.g. designing high-
phosphate non-zinc containing glasses to find out how much the HCA formation ability 
would be affected by increasing phosphate content.  
• With the knowledge that has been gained regarding the dissolution of the glass used for in 
vivo animal study, a group of uncoated implants in parallel with the BG and HA groups 
would enhance the study. 
  
  
Appendix 
 
Table A.1: Appen factors for components in the glasses studied, adapted from (220).  
Component                                  SiO2 P2O5 CaCO3 SrCO3 Na2CO3 K2CO3 ZnO MgO
Appen factor 3.8 14 13 16 39.5 46.5 5 6
 
 
 
 
Figure A.1: Plots of ln(heating rate) vs. (a)Tg, (b)To and (c) Tc for 75% Sr glass. 
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Table A.2: Push-out test results. Maximal shear strength with mean values (MPa) for HA- and HP1-
coated implants 6, 12 and 24 weeks after implantation.  
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Table A.3: Histology results. Bone-implant contact ratio values (%) for HA-and HP1-coated implants 6, 
12 and 24 weeks after implantation.  
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Table A.4: Histology results. Bone volume to total volume ratio values (%) for HA- and HP1-coated 
implants 6, 12 and 24 weeks after implantation.  
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Table A.5: Quantitative analysis of EDS spectra of tibial implants following push-out test at 6 weeks. All 
results are in atomic percent and all are normalised. For consistency the middle sections of the implants 
were selected for EDS analysis as shown in Figure 5.18 a and b. 
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